Qiagen (QGEN) 20-F2 Mar 202019 FY Annual report (foreign)Financial data

Company Profile

Document and Entity Information

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2019shares
Entity Addresses [Line Items]
Document Registration Statement	false
Document Accounting Standard	U.S. GAAP
Document Type	20-F
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-38332
Entity Registrant Name	QIAGEN N.V.
Entity Incorporation, State or Country Code	P7
Entity Address, Address Line One	Hulsterweg 82
Entity Address, Postal Zip Code	5912 PL
Entity Address, City or Town	Venlo
Entity Address, Country	NL
Title of 12(b) Security	Common Shares, par value EUR 0.01 per share
Trading Symbol	QGEN
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding	227,752,280
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001015820
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Business Contact
Entity Addresses [Line Items]
Entity Address, Address Line One	Hulsterweg 82
Entity Address, Postal Zip Code	5912 PL
Entity Address, City or Town	Venlo
Entity Address, Country	NL
Contact Personnel Name	Roland Sackers
Contact Personnel Fax Number	011-31-77-355-6658

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 623,647	$ 1,159,079
Restricted cash	5,743	0
Short-term investments	129,586	234,606
Accounts receivable, net of allowance for doubtful accounts of $12,115 and $9,270 in 2019 and 2018, respectively	385,117	351,612
Income taxes receivable	42,119	34,936
Inventories, net	170,704	162,912
Fair value of derivative instruments - current	107,868	102,754
Prepaid expenses and other current assets (of which $13,697 and $3,873 in 2019 and 2018 due from related parties, respectively)	105,464	109,161
Total current assets	1,570,248	2,155,060
Long-term assets:
Property, plant and equipment, net of accumulated depreciation of $699,130 and $603,430 in 2019 and 2018, respectively	455,243	511,659
Goodwill	2,140,503	2,108,536
Intangible assets, net of accumulated amortization of $776,520 and $1,194,679 in 2019 and 2018, respectively	632,434	475,043
Deferred income tax assets	56,542	42,896
Fair value of derivative instruments - long-term	192,266	295,363
Other long-term assets (of which $16,830 and $24,300 in 2019 and 2018 due from related parties, respectively)	188,380	159,775
Total long-term assets	3,665,368	3,593,272
Total assets	5,235,616	5,748,332
Current liabilities:
Current portion of long-term debt	285,244	503,116
Accounts payable	84,767	69,415
Fair value of derivative instruments - current	103,175	106,594
Accrued and other current liabilities (of which $15,404 and $5,488 due to related parties in 2019 and 2018, respectively)	444,303	263,017
Income taxes payable	33,856	30,047
Total current liabilities	951,345	972,189
Long-term liabilities:
Long-term debt, net of current portion	1,421,108	1,671,090
Deferred income tax liabilities	23,442	63,411
Fair value of derivative instruments - long-term	196,929	317,393
Other long-term liabilities	106,201	89,279
Total long-term liabilities	1,747,680	2,141,173
Commitments and contingencies
Equity:
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no shares issued and outstanding	0	0
Financing preference shares, 0.01 EUR par value, authorized—40,000 shares, no shares issued and outstanding	0	0
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued — 230,829 shares in 2019 and 2018, respectively	2,702	2,702
Additional paid-in capital	1,777,017	1,742,191
Retained earnings	1,178,457	1,379,624
Accumulated other comprehensive loss	(309,619)	(310,644)
Less treasury shares, at cost— 3,077 and 5,320 shares in 2019 and 2018, respectively	(111,966)	(178,903)
Total equity	2,536,591	2,634,970
Total liabilities and equity	$ 5,235,616	$ 5,748,332

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Thousands	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares
Current assets:
Accounts receivable - allowance for doubtful accounts \| $	$ 12,115	$ 9,270
Prepaid expenses and other current assets - due from related parties \| $	13,697	3,873
Long-term assets:
Property, plant and equipment - accumulated depreciation \| $	699,130	603,430
Intangible assets - accumulated amortization \| $	776,520	1,194,679
Other long-term assets - due from related parties \| $	16,830	24,300
Current liabilities:
Accrued and other current liabilities - due to related parties \| $	$ 15,404	$ 5,488
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no shares issued and outstanding
Preference shares, shares authorized (in shares)	450,000,000	450,000,000
Preference shares, shares issued (in shares)	0	0
Preference shares, shares outstanding (in shares)	0	0
Financing preference shares, 0.01 EUR par value, authorized—40,000 shares, no shares issued and outstanding
Financing preference shares, shares authorized (in shares)	40,000,000	40,000,000
Financing preference shares, shares issued (in shares)	0	0
Financing preference shares, shares outstanding (in shares)	0	0
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued — 230,829 shares in 2019 and 2018, respectively
Common Shares, shares authorized (in shares)	410,000,000	410,000,000
Common Shares, shares issued (in shares)	230,829,000	230,829,000
Less treasury shares, at cost— 3,077 and 5,320 shares in 2019 and 2018, respectively
Treasury shares (in shares)	3,077,000	5,320,000

Consolidated Statements of (Los

Consolidated Statements of (Loss) Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Net sales	$ 1,526,424	$ 1,501,848	$ 1,417,536
Cost of sales:
Cost of sales	449,651	444,165	422,226
Acquisition-related intangible amortization	71,511	56,723	72,749
Total cost of sales	521,162	500,888	494,975
Gross profit	1,005,262	1,000,960	922,561
Operating expenses:
Research and development	157,448	161,852	154,084
Sales and marketing	391,906	392,281	375,562
General and administrative	112,262	104,568	102,080
Acquisition-related intangible amortization	29,973	39,032	39,398
Restructuring, acquisition, integration and other, net	199,778	28,659	98,018
Long-lived asset impairments	140,031	7,987	0
Total operating expenses	1,031,398	734,379	769,142
(Loss) income from operations	(26,136)	266,581	153,419
Other income (expense):
Interest income	22,113	20,851	10,645
Interest expense	(74,185)	(67,293)	(49,685)
Other income (expense), net	432	5,598	(4)
Total other expense, net	(51,640)	(40,844)	(39,044)
(Loss) income before income tax (benefit) expense	(77,776)	225,737	114,375
Income tax (benefit) expense	(36,321)	35,357	73,981
Net (loss) income	$ (41,455)	$ 190,380	$ 40,394
Basic (loss) earnings per common share (in USD per share)	$ (0.18)	$ 0.84	$ 0.18
Diluted (loss) earnings per common share (in USD per share)	$ (0.18)	$ 0.82	$ 0.17
Weighted-average common shares outstanding
Basic (in shares)	226,777	226,640	228,074
Diluted (in shares)	226,777	233,456	233,009

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (41,455)	$ 190,380	$ 40,394
Other comprehensive income (loss) to be reclassified to profit or loss in subsequent periods:
Gains (losses) on cash flow hedges, before tax	17,052	25,207	(50,067)
Reclassification adjustments on cash flow hedges, before tax	(3,888)	(9,774)	26,136
Cash flow hedges, before tax	13,164	15,433	(23,931)
Losses on marketable securities, before tax	0	0	(854)
Gains on pensions, before tax	(796)	1,325	886
Foreign currency translation adjustments, before tax	(12,156)	(108,045)	135,945
Other comprehensive income (loss), before tax	212	(91,287)	112,046
Income tax relating to components of other comprehensive income (loss)	813	460	1,034
Total other comprehensive income (loss), after tax	1,025	(90,827)	113,080
Comprehensive (loss) income	$ (40,430)	$ 99,553	$ 153,474

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Shares
Balance (in shares) at Dec. 31, 2016		239,707,000				5,147,000
Balance at Dec. 31, 2016	$ 2,607,096	$ 2,812	$ 1,794,665	$ 1,263,464	$ (333,839)	$ (120,006)
Increase (Decrease) in Stockholders' Equity
Capital repayment (in shares)		(8,878,000)
Capital repayment	(244,429)	$ (110)	(244,319)			$ 191
Issuance of warrants	45,307		45,307
Net income (loss)	40,394			40,394
Unrealized gain (loss), net on pension	620				620
Unrealized gain (loss), net on hedging contracts	(42,489)				(42,489)
Realized (gain) loss, net on hedging contracts	19,602				19,602
Unrealized loss, net on marketable securities	(786)				(786)
Translation adjustment, net	136,133				136,133
Purchase of treasury shares (in shares)						(1,909,000)
Purchase of treasury shares	(60,970)					$ (60,970)
Issuance of common shares in connection with stock plan (in shares)						2,593,000
Issuance of common shares in connection with stock plan	6,076			(55,913)		$ 61,989
Share-based compensation	34,442		34,442
Balance (in shares) at Dec. 31, 2017		230,829,000				4,272,000
Balance at Dec. 31, 2017	2,540,996	$ 2,702	1,630,095	1,247,945	(220,759)	$ (118,987)
Increase (Decrease) in Stockholders' Equity
Issuance of warrants	71,983		71,983
Net income (loss)	190,380			190,380
Unrealized gain (loss), net on pension	754				754
Unrealized gain (loss), net on hedging contracts	22,365				22,365
Realized (gain) loss, net on hedging contracts	(7,331)				(7,331)
Translation adjustment, net	(106,615)				(106,615)
Purchase of treasury shares (in shares)						(2,871,000)
Purchase of treasury shares	(104,685)					$ (104,685)
Issuance of common shares in connection with stock plan (in shares)						1,823,000
Issuance of common shares in connection with stock plan	4,412			(40,357)		$ 44,769
Share-based compensation	$ 40,113		40,113
Balance (in shares) at Dec. 31, 2018	230,829,000	230,829,000				5,320,000
Balance at Dec. 31, 2018	$ 2,634,970	$ 2,702	1,742,191	1,379,624	(310,644)	$ (178,903)
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(41,455)			(41,455)
Conversion of warrants (in shares)						2,056,000
Conversion of warrants	(4)		(31,067)	(37,698)		$ 68,761
Unrealized gain (loss), net on pension	(437)				(437)
Unrealized gain (loss), net on hedging contracts	17,052				17,052
Realized (gain) loss, net on hedging contracts	(3,888)				(3,888)
Translation adjustment, net	(11,702)				(11,702)
Purchase of treasury shares (in shares)						(1,987,000)
Purchase of treasury shares	(74,450)					$ (74,450)
Issuance of common shares in connection with stock plan (in shares)						3,622,000
Issuance of common shares in connection with stock plan	2,075			(121,698)		$ 123,773
Tax withholding related to vesting of stock awards (in shares)						(1,448,000)
Tax withholding related to vesting of stock awards	(51,147)					$ (51,147)
Share-based compensation	$ 65,893		65,893
Balance (in shares) at Dec. 31, 2019	230,829,000	230,829,000				3,077,000
Balance at Dec. 31, 2019	$ 2,536,591	$ 2,702	$ 1,777,017	$ 1,178,457	$ (309,619)	$ (111,966)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (41,455)	$ 190,380	$ 40,394
Adjustments to reconcile net (loss) income to net cash provided by operating activities, net of effects of businesses acquired:
Depreciation and amortization	231,458	206,436	216,448
Non-cash impairments	144,830	17,020	5,137
Amortization of debt discount and issuance costs	40,763	35,537	24,773
Share-based compensation expense	65,893	40,113	34,442
Deferred income tax (benefit) expense	(55,362)	(23,272)	60,176
Loss (gain) on marketable securities	2,867	(2,725)	1,055
Reversals of contingent consideration	(10,433)	0	(3,269)
Other items, net including fair value changes in derivatives	(3,394)	(8,834)	(4,521)
Net changes in operating assets and liabilities:
Accounts receivable	(39,578)	(41,813)	(34,165)
Inventories	(30,028)	(36,918)	(21,633)
Prepaid expenses and other current assets	18,626	(9,942)	(5,245)
Other long-term assets	(1,406)	(30,312)	(16,786)
Accounts payable	9,252	6,993	4,321
Accrued and other current liabilities	19,913	(13,317)	2,828
Income taxes	(6,782)	14,239	(41,266)
Other long-term liabilities	(14,321)	15,911	24,090
Net cash provided by operating activities	330,843	359,496	286,779
Cash flows from investing activities:
Purchases of property, plant and equipment	(117,950)	(109,773)	(90,081)
Proceeds from sale of equipment	0	0	42
Purchases of intangible assets	(156,934)	(40,990)	(34,324)
Purchases of investments, net	(5,170)	(9,398)	(4,777)
Cash paid for acquisitions, net of cash acquired	(68,058)	(172,832)	(50,549)
Purchases of short-term investments	(293,959)	(568,002)	(450,564)
Proceeds from redemptions of short-term investments	396,098	691,765	189,006
Proceeds from divestiture	1,000	16,394	0
Cash received (paid) for collateral asset	22,685	(3,461)	(20,707)
Other investing activities	10	(15,059)	(2,310)
Net cash used in investing activities	(222,278)	(211,356)	(464,264)
Cash flows from financing activities:
Proceeds from long-term debt, net of issuance costs	0	0	329,875
Proceeds from issuance of cash convertible notes, net of issuance costs	0	494,879	394,391
Purchase of call option related to cash convertible notes	0	(97,277)	(73,646)
Proceeds from issuance of warrants, net of issuance costs	0	72,406	45,396
Capital repayment	0	0	(243,945)
Proceeds from exercise of call option related to cash convertible notes	134,737	0	0
Payment of intrinsic value of cash convertible notes	(133,763)	0	0
Repayment of long-term debt	(506,400)	0	0
Principal payments on capital leases	0	(1,308)	(1,402)
Proceeds from issuance of common shares	2,075	4,412	6,075
Tax withholding related to vesting of stock awards	(49,998)	0	0
Purchase of treasury shares	(74,450)	(104,685)	(60,970)
Other financing activities	(11,281)	(8,019)	(8,587)
Net cash (used in) provided by financing activities	(639,080)	360,408	387,187
Effect of exchange rate changes on cash, cash equivalents and restricted cash	826	(7,183)	8,832
Net (decrease) increase in cash, cash equivalents and restricted cash	(529,689)	501,365	218,534
Cash and cash equivalents, beginning of period	1,159,079	657,714	439,180
Cash, cash equivalents and restricted cash, end of period	629,390	1,159,079	657,714
Supplemental cash flow disclosures:
Cash paid for interest	29,721	25,902	20,252
Cash paid for income taxes	41,474	29,317	40,499
Supplemental disclosure of non-cash investing activities:
Equipment purchased through capital lease	$ 0	$ 0	$ 88

Corporate Information and Basis

Corporate Information and Basis of Presentation	12 Months Ended
Corporate Information and Basis of Presentation	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Corporate Information and Basis of Presentation	Corporate Information and Basis of Presentation Corporate Information QIAGEN N.V. is a public limited liability company ('naamloze vennootschap') under Dutch law with registered office at Hulsterweg 82, 5912 PL Venlo, The Netherlands. QIAGEN N.V., a Netherlands holding company, and subsidiaries (we, our or the Company) is the leading global provider of Sample to Insight solutions that are used by over 500,000 customers worldwide to transform biological samples into valuable molecular insights. Our sample technologies are used to isolate and process DNA, RNA and proteins - the building blocks of life - from blood, tissue and other materials. Assay technologies are used to make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases are used to analyze and interpret complex genomic data to report relevant, actionable insights. Automation solutions are used to tie these technologies together in seamless and cost-effective workflows. We provide this portfolio to two major customer classes: Molecular Diagnostics (human healthcare) and Life Sciences comprised of Academia / Applied Testing (life sciences research, forensics and food safety) and Pharma. With approximately 5,100 employees in over 35 locations worldwide, we market our products in more than 130 countries. Basis of Presentation The accompanying consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and all amounts are presented in U.S. dollars rounded to the nearest thousand, unless otherwise indicated. The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments, contingent consideration and available-for-sale financial instruments that have been measured at fair value. We undertake acquisitions to complement our own internal product development activities. In 2019, we completed three immaterial acquisitions, including the January 2019 acquisition of N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data located in Concord, Massachusetts. On April 27, 2018, we acquired all shares in STAT-Dx Life, S.L. (STAT-Dx), a privately-held company located in Barcelona, Spain and on April 19, 2018, we acquired all remaining shares of a privately held entity in which we held a minority interest. On January 6, 2017, we acquired OmicSoft Corporation, located in Cary, North Carolina (U.S.). Accordingly, at their respective acquisition dates, all the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include the operating results from the acquired companies from the acquisition dates. Certain prior year amounts have been reclassified to conform to the current year presentation. Beginning in 2019 in the Consolidated Statements of (Loss) Income, the line item "Acquisition-related intangible amortization" in cost of sales is presented separately. Previously, these amounts were presented together in one line in cost of sales. Additionally beginning in 2019, "Restructuring, acquisition, integration and other, net" and "Long-lived asset impairments" within operating expenses are presented separately. Previously, these amounts were presented together with general and administrative expenses in one line as "General and administrative, restructuring, integration and other, net." These reclassifications had no effect on (loss) income from operations.

Effects of New Accounting Prono

Effects of New Accounting Pronouncements	12 Months Ended
Effects of New Accounting Pronouncements	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Effects of New Accounting Pronouncements	Effects of New Accounting Pronouncements The following new Financial Accounting Standards Board (FASB) Accounting Standards Updates (ASU) were adopted in 2019, 2018 and 2017: Adoption of New Accounting Standards in 2019 The FASB issued guidance codified in Accounting Standards Codification (ASC) Topic 842, Leases (Topic 842), which supersedes the lease requirements in ASC Topic 840 and aims to increase transparency and comparability among organizations and requires disclosure of key information about leasing arrangements. The main principle of ASC 842 requires lessees to recognize the assets and liabilities that arise from nearly all leases on the consolidated balance sheet. Lessor accounting remains mainly consistent with the former guidance, with the majority of changes allowing for better alignment with the new lessee model and ASC Topic 606. We adopted these standards as per the effective date of January 1, 2019, using the modified retrospective approach and did not restate comparative periods. Under this approach, the cumulative effect of initially applying the standard was recognized as an adjustment to the opening balance of retained earnings on the date of initial application. As a lessee, the classification of our leases did not change, but we recognized a lease liability and corresponding right-of-use asset on our consolidated balance sheets for all our operating leases. We have elected the package of practical expedients which allows us to not reassess (1) whether existing contracts contain leases, (2) the lease classification for existing leases, and (3) whether existing initial direct costs meet the new definition. We also elected the hindsight practical expedient which permits entities to use hindsight in determining the lease term when transitioning to ASC 842. Our initial lease liabilities and right-of-use assets totaled $57.7 million and $57.4 million , respectively, as recorded in our consolidated balance sheet as of January 1, 2019, primarily relating to leased office space. The difference between the additional lease assets and lease liabilities was recorded as a $0.3 million adjustment to retained earnings. Further disclosure is found in Note 12 "Leases" . ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new guidance became effective for public entities beginning on January 1, 2019 by applying a modified retrospective approach to existing hedging relationships as of the adoption date. Under the modified retrospective approach, entities with cash flow or net investment hedges will make (1) a cumulative-effect adjustment to accumulated other comprehensive income so that the adjusted amount represents the cumulative change in the hedging instruments’ fair value since hedge inception (less any amounts that should have been recognized in earnings under the new accounting model) and (2) a corresponding adjustment to opening retained earnings as of the most recent period presented on the date of adoption. We adopted ASU 2017-12 on January 1, 2019 without any cumulative effect. ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , removes Step 2 of the goodwill impairment test. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for public entities for annual periods beginning January 1, 2020 and early adoption is permitted. The new guidance is required to be applied on a prospective basis. We adopted ASU 2017-04 on January 1, 2019 and applied the new guidance prospectively as required. ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework, provides guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements . ASU 2018-13 is effective for public entities for annual periods beginning January 1, 2020. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We adopted ASU 2018-13 on January 1, 2019 and applied the entire standard to disclosures as required beginning in 2019. ASU 2018-15, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, provides guidance on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor, i.e. a service contract. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for public entities for annual periods beginning January 1, 2020, and early adoption is permitted and should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted ASU 2018-15 on January 1, 2019 and applied the guidance to all implementation costs prospectively. ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities, amends how a decision maker or service provider determines whether its fee is a variable interest entity (VIE) when a related party under common control also has an interest in the VIE. We adopted ASU 2018-17 on January 1, 2019, on a prospective basis. Adoption of New Accounting Standards in 2018 ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and additional related accounting standard updates to clarify and provide implementation guidance were adopted with a date of initial application of January 1, 2018. The comparative information for 2017 has not been adjusted and continues to be reported under ASC Topic 605 Revenue Recognition. As a result, we changed our accounting policy for revenue recognition as further discussed in the Notes below. We applied the Topic 606 using the "modified retrospective method" by recognizing the effect of initially applying Topic 606 as an $1.3 million decrease to the opening balance of retained earnings at January 1, 2018, for all contracts not completed at January 1, 2018. ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities as well as an additional clarifying accounting standard update became effective for our financial statements beginning in the first quarter of 2018. This ASU makes targeted improvements to existing U.S. GAAP for both the recognition and measurement of financial assets and financial liabilities. Changes in accounting to our equity investments as a result of this standard are further discussed in Notes below. As required, we adopted using a cumulative-effect adjustment to the balance sheet as of the beginning of 2018 and recorded an adjustment to decrease opening retained earnings at January 1, 2018 by $0.9 million as required for our equity investments recorded at fair value. ASU 2016-05, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments and ASU 2016-18, Statement of Cash Flows (Topic 320): Restricted Cash, addresses classification issues and presentation related to the statement of cash flows and was adopted on January 1, 2018 without any impact from the adoption. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, aims to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. This standard was adopted on a modified retrospective basis resulting in a decrease to opening retained earnings of $16.1 million at January 1, 2018. ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , clarifies and provides a more robust framework to use in determining when a set of assets and activities is a business. We adopted this update beginning January 1, 2018, without impact. ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , clarifies when to account for a change to the terms and conditions of a share-based payment award as a modification. This guidance is effective prospectively and was adopted as of January 1, 2018. ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, permits reclassification of stranded tax effects of the U.S. Tax Cuts and Jobs Act (Tax Act). We adopted this standard as of April 1, 2018 with no impact as we had no stranded tax effects. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, we reclassify the tax effects to the consolidated statement of income (loss) on an item-by-item basis when the pre-tax item in accumulated other comprehensive income (loss) is reclassified to income. ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , aligns most of the accounting for share-based payment awards issued to employees and non-employees. We early adopted this standard as of July 1, 2018, without material impact. Adoption of New Accounting Standards in 2017 ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory , requires in scope inventory to be measured at the lower of cost and net realizable value. We adopted this standard without material impact. ASU 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting , eliminates the requirement to retroactively adopt the equity method of accounting when an investment qualifies for use of the equity method as a result of an increase in the level of ownership or degree of influence. We adopted this standard without impact. ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , simplifies several aspects of accounting for share-based payment transactions, including income tax consequences. We adopted this standard on January 1, 2017 on a prospective basis. New Accounting Standards Not Yet Adopted The following new FASB Accounting Standards Updates, which are not yet adopted as of December 31, 2019 , have been grouped by their required effective dates: First Quarter of 2020 ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in ASU 2016-13 replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The measurement of expected credit losses under Topic 326 is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted for as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with Topic 842 on leases. In addition, Topic 326 made changes to the accounting for available-for-sale debt securities. One such change is to require credit losses to be presented as an allowance rather than as a write-down on available-for-sale debt securities management does not intend to sell or believes is more likely than not they will be required to sell. Topic 326 is effective for us for annual periods beginning on January 1, 2020 and we will adopt using the modified retrospective approach. Under this approach, the cumulative effect of initially applying the standard is recognized as adjustment to the opening balance of retained earnings on the date of initial application. We currently expect a transition adjustment of approximately $14.0 million due primarily to expected credit losses on loans, notes and accounts receivable. ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer of that transaction. The guidance amends ASC 808 to refer to unit-of-account guidance in ASC 606 and requires it to be used only when assessing whether a transaction is in the scope of ASC 606. ASU 2018-18 is effective for us for annual periods beginning on January 1, 2020. Entities are required to apply the amendments retrospectively to the date they initially applied ASC 606. We adopted ASU 2018-18 on January 1, 2020 without any cumulative effect. First Quarter of 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod tax allocations and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating income taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods beginning on January 1, 2021, with earlier adoption permitted. We intend to adopt the ASU on the effective date of January 1, 2021 and are evaluating the potential impact ASU 2019-12 may have on our consolidated financial statements. ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. We intend to adopt the ASU on the effective date of January 1, 2021 and are evaluating the potential impact ASU 2020-01 may have on our consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of QIAGEN N.V. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Investments in either common stock or in-substance common stock of companies where we exercise significant influence over the operations but do not have control, and where we are not the primary beneficiary, are accounted for using the equity method. All other investments are accounted for as discussed under "Non-marketable Investments" below. When there is a portion of equity in an acquired subsidiary not attributable, directly or indirectly, to the Company, we record the fair value of the noncontrolling interests at the acquisition date and classify the amounts attributable to noncontrolling interests separately in equity in the consolidated financial statements. Any subsequent changes in the Company's ownership interest while the Company retains its controlling financial interest in its subsidiary are accounted for as equity transactions. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Concentrations of Risk We buy materials for products from many suppliers, and are not dependent on any one supplier or group of suppliers for the business as a whole. However, key components of certain products, including certain instrumentation components and chemicals, are available only from a single source. If supplies from these vendors were delayed or interrupted for any reason, we may not be able to obtain these materials timely or in sufficient quantities in order to produce certain products and sales levels could be negatively affected. Additionally, our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories. Fluctuations in the research and development budgets of these researchers and their organizations for applications in which our products are used could have a significant effect on the demand for our products. The financial instruments used in managing our foreign currency, equity and interest rate exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated international financial institutions. The carrying values of our financial instruments incorporate the non-performance risk by using market pricing for credit risk. However, we have no reason to believe that any counterparties will default on their obligations. In order to minimize our exposure with any single counterparty, we have entered into master agreements which allow us to manage the exposure with the respective counterparty on a net basis. Other financial instruments that potentially subject us to concentrations of credit risk are cash and cash equivalents, short-term investments, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and short-term investments by dealing with highly-rated financial institutions and investing in a broad and diverse range of financial instruments. We have established guidelines related to credit quality and maturities of investments intended to maintain safety and liquidity. Concentration of credit risk with respect to accounts receivable is limited due to a large and diverse customer base, which is dispersed over different geographic areas. Allowances are maintained for potential credit losses and such losses have historically been within expected ranges. Foreign Currency Translation Our reporting currency is the U.S. dollar and the functional currencies of our subsidiaries are generally the local currency of the respective countries in which they are headquartered. All amounts in the financial statements of entities whose functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows: (1) assets and liabilities at period-end rates, (2) income statement accounts at average exchange rates for the period, and (3) components of equity at historical rates. Translation gains or losses are recorded in equity, and transaction gains and losses are reflected in net income as a component of other expense, net. Realized gains or losses on the value of derivative contracts entered into to hedge the exchange rate exposure of receivables and payables are also included in net (loss) income as a component of other expense, net. The net loss on foreign currency transactions was $5.7 million , $12.3 million , and $3.3 million in 2019 , 2018 and 2017 , respectively, and is included in other income (expense), net. The exchange rates of key currencies were as follows: Closing rate at December 31, Annual average rate (US$ equivalent for one) 2019 2018 2019 2018 2017 Euro (EUR) 1.1234 1.1450 1.1196 1.1813 1.1292 Pound Sterling (GBP) 1.3204 1.2800 1.2768 1.3356 1.2882 Swiss Franc (CHF) 1.0350 1.0161 1.0062 1.0228 1.0156 Australian Dollar (AUD) 0.7023 0.7059 0.6954 0.7478 0.7666 Canadian Dollar (CAD) 0.7696 0.7337 0.7535 0.7719 0.7710 Japanese Yen (JPY) 0.0092 0.0091 0.0092 0.0091 0.0089 Chinese Yuan (CNY) 0.1437 0.1454 0.1448 0.1514 0.1480 Segment Information We determined that we operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting . Our chief operating decision maker (CODM) makes decisions based on the Company as a whole. In addition, we have a common basis of organization and types of products and services which derive revenues and consistent product margins. Accordingly, we operate and make decisions as one reporting unit. Revenue Recognition Beginning January 1, 2018, we recognize revenues when control of promised goods or services transfers to our customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services. The majority of our sales revenue continues to be recognized when products are shipped to the customers at which point control transfers. Prior to January 1, 2018, payments for milestones, generally based on the achievement of substantive and at-risk performance criteria, were recognized in full at such time as the specified milestone had been achieved according to the terms of the agreement. See Note 4 "Revenue" for further discussion of accounting for milestone payments after adoption of ASC 606 Revenue from Contracts with Customers . Warranty We provide warranties on our products against defects in materials and workmanship for a period of 1 year. A provision for estimated future warranty costs is recorded in cost of sales at the time product revenue is recognized. Product warranty obligations are included in accrued and other current liabilities in the accompanying consolidated balance sheets. Research and Development Research and product development costs are expensed as incurred. Research and development expenses consist primarily of salaries and related expenses, facility costs, and amounts paid to contract research organizations and laboratories for the provision of services and materials as well as costs for internal use or clinical trials. Government Grants We recognize government grants when there is reasonable assurance that all conditions will be complied with and the grant will be received. Our government grants generally represent subsidies for specified activities and are therefore recognized when earned as a reduction of the expenses recorded for the activity that the grants are intended to compensate. Thus, when the grant relates to research and development expense, the grant is recognized over the same period that the related costs are incurred. Otherwise, amounts received under government grants are recorded as liabilities in the balance sheet. When the grant relates to an asset, the nominal amount of the grant is deducted from the carrying amount of the asset and recognized over the same period that the related asset is depreciated. Borrowing Costs Borrowing costs directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets (qualifying asset) when such borrowing costs are significant. All other borrowing costs are expensed in the period they occur. Shipping and Handling Income and Costs Shipping and handling costs charged to customers are recorded as revenue in the period that the related product sale revenue is recorded. Associated costs of shipping and handling are included in sales and marketing expenses. For the years ended December 31, 2019 , 2018 and 2017 , shipping and handling costs totaled $27.9 million , $28.4 million and $28.6 million , respectively. Advertising Costs The costs of advertising are expensed as incurred and are included as a component of sales and marketing expense. Advertising costs for the years ended December 31, 2019 , 2018 and 2017 were $8.1 million , $8.1 million and $7.2 million , respectively. General and Administrative General and administrative expenses primarily represent the costs required to support administrative infrastructure. These costs include licensing costs in connection with continued investments information technology improvements, including cyber security, across the organization as well as personnel in administrative functions. Restructuring, Acquisition, Integration and Other We incur indirect acquisition and business integration costs in connection with business combinations. These costs represent incremental costs that we believe would not have been incurred absent the business combinations. Major components of these costs include consulting and related fees incurred to integrate or restructure the acquired operations, payroll and related costs for employees remaining with the Company on a transitional basis and public relations, advertising and media costs for re-branding of the combined organization. Restructuring costs include personnel costs (principally termination benefits) as well as contract and other costs, primarily contract termination costs. Termination benefits are accounted for in accordance with FASB ASC Topic 712, Compensation - Nonretirement Postemployment Benefits, and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits, the similarity of benefits under the current plan and prior plans, and the existence of statutory required minimum benefits. Contract and other costs are accounted for in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations and are recorded when the liability is incurred. The specific restructuring measures and associated estimated costs are based on management's best business judgment under the existing circumstances at the time the estimates are made. If future events require changes to these estimates, such adjustments will be reflected in the period of the revised estimate. Income Taxes We account for income taxes under the liability method. Under this method, total income tax expense is the amount of income taxes expected to be payable for the current year plus the change from the beginning of the year for deferred income tax assets and liabilities established for the expected further tax consequences resulting from differences in the financial statement carrying amount and the tax basis of assets and liabilities. Deferred tax assets and/or liabilities are determined by multiplying the differences between the financial statement carrying amount and the tax reporting bases for assets and liabilities by the enacted tax rates expected to be in effect when such differences are recovered or settled. Deferred tax assets are reduced by a valuation allowance to the amount more likely than not to be realized. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Tax benefits are initially recognized in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement with the taxing authority using the cumulative probability method, assuming the tax authority has full knowledge of the position and all relevant facts. Our policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties within the income tax expense. Derivative Instruments We enter into derivative financial instrument contracts to minimize the variability of cash flows or income statement impact associated with the anticipated transactions being hedged or to hedge fluctuating interest rates. As changes in foreign currency or interest rate impact the value of anticipated transactions, the fair value of the forward or swap contracts also changes, offsetting foreign currency or interest rate fluctuations. Derivative instruments are recorded on the balance sheet at fair value. Changes in fair value of derivatives are recorded in current earnings or other comprehensive income, depending on whether a derivative is designated as part of a hedge transaction. Share-Based Payments Compensation cost for all share-based payments is recorded based on the grant date fair value, less an estimate for pre-vesting forfeitures, recognized in expense over the service period using an accelerated method. Forfeiture Rate— This is the estimated percentage of grants that are expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimated the forfeiture rate based on historical forfeiture experience. Restricted Stock Units and Performance Stock Units: Restricted stock units and performance stock units represent rights to receive Common Shares at a future date. The fair market value of restricted and performance stock units is determined based on the number of stock units granted and the fair market value of our shares on the grant date. The fair market value at the time of the grant, less an estimate for pre-vesting forfeitures, is recognized in expense over the vesting period. At each reporting period, the estimated performance achievement of the performance stock units is assessed and any change in the estimated achievement is recorded on a cumulative basis in the period of adjustment. Cash and Cash Equivalents Cash and cash equivalents consist of cash on deposit in banks and other cash invested temporarily in various instruments that are short-term and highly liquid, and having an original maturity of less than 90 days at the date of purchase. (in thousands) 2019 2018 Cash at bank and on hand $ 189,569 $ 208,083 Short-term bank deposits 434,078 950,996 Cash and Cash Equivalents $ 623,647 $ 1,159,079 Restricted Cash Restricted cash includes cash that is subject to legal restriction in connection with a tender offer and not available for general operating purposes. As of December 31, 2019, we have $5.7 million of restricted cash. Short-Term Investments Short-term investments are classified as “available for sale” and stated at fair value, which is equivalent to the amortized cost, in the accompanying balance sheet. Interest income is accrued when earned and changes in fair market values are reflected in other income (expense), net. The amortization of premiums and accretion of discounts to maturity arising from acquisition is included in interest income. A decline in fair value that is judged to be other-than-temporary is accounted for as a realized loss and the write-down is included in the consolidated statements of income. Realized gains and losses, determined on a specific identification basis on the sale of short-term investments, are included in income. Fair Value of Financial Instruments The carrying amount of cash and cash equivalents, notes receivable, accounts receivable, accounts payable and accrued liabilities approximate their fair values because of the short maturities of those instruments. The carrying value of our variable rate debt and capital leases approximates their fair values because of the short maturities and/or interest rates which are comparable to those available to us on similar terms. The fair values of the Cash Convertible Notes are based on an estimation using available over-the-counter market information. The fair values of the Private Placement Senior Notes were estimated using the changes in the U.S. Treasury rates and the fair value of the German Private Placement is based on an estimation using changes in the euro swap rates Accounts Receivable and Allowance for Doubtful Accounts Our accounts receivable are unsecured and we are at risk to the extent such amounts become uncollectible. We continually monitor accounts receivable balances, and provide for an allowance for doubtful accounts at the time collection becomes questionable based on payment history or age of the receivable. Amounts determined to be uncollectible are written off against the allowance. For the years ended December 31, 2019 , 2018 and 2017 , write-offs of accounts receivable totaled $5.8 million , $2.8 million and $3.2 million , respectively, while provisions for doubtful accounts which were charged to expense totaled $8.7 million , $4.4 million and $3.1 million , respectively. For all years presented, no single customer represented more than ten percent of accounts receivable or consolidated net sales. Inventories Inventories are stated at the lower of cost or net realizable value, determined on either a weighted average cost basis or a standard cost basis which is regularly adjusted to actual. Inventories include material, direct labor and overhead costs and are reduced for estimated obsolescence. Inventories consisted of the following as of December 31, 2019 and 2018 : (in thousands) 2019 2018 Raw materials $ 26,077 $ 25,819 Work in process 45,729 38,659 Finished goods 98,898 98,434 Total inventories, net $ 170,704 $ 162,912 Property, Plant and Equipment Property, plant and equipment, including equipment acquired under capital lease obligations, are stated at cost less accumulated amortization. Capitalized internal-use software costs include only those direct costs associated with the actual development or acquisition of computer software solely to meet internal needs and cloud-based applications to deliver our service and comprise costs associated with the design, coding, installation and testing of the system. Costs associated with preliminary development, such as the evaluation and selection of alternatives, as well as training, maintenance and support are expensed as incurred. Costs for software to be sold, leased or otherwise marketed that are related to the conceptual formulation and design are expensed as incurred. Costs incurred to produce software products and the software components of products to be sold, leased or marketed after technological feasibility is established are capitalized and amortized in accordance with the accounting standards for the costs of software to be sold, leased, or otherwise marketed. All other depreciation is computed using the straight-line method over the estimated useful lives of the assets ( 3 to 40 years). Amortization of leasehold improvements is computed on a straight-line basis over the lesser of the remaining life of the lease or the estimated useful life of the improvement asset. We have a policy of capitalizing expenditures that materially increase assets’ useful lives and charging ordinary maintenance and repairs to operations as incurred. When property or equipment is disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in earnings. Business Combinations We include the results of operations of the businesses that we acquire as of the acquisition date. The purchase price of an acquired business is allocated to the individual assets acquired and liabilities assumed based on their fair values at the date of acquisition. Those fair values are determined using income, cost and market approaches, most of which depend upon significant inputs that are not observable in the market, or level 3 measurements. The excess of purchase price over the fair value of identifiable assets acquired and liabilities assumed is recorded as goodwill. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. The purchase price for some business combinations includes consideration that is contingent on the achievement of net sales or earnings targets by the acquired business. Contingent consideration is measured initially and on a recurring basis at fair value. Payments to settle the acquisition-date fair value of contingent consideration are presented as financing activities on the statement of cash flows; any payments in excess of the acquisition-date fair value are presented as operating activities. Acquired Intangibles and Goodwill Acquired intangibles with alternative future uses are carried at cost less accumulated amortization and consist of licenses to technology held by third parties and other acquired intangible assets. Amortization is computed over the estimated useful life of the underlying patents, which has historically ranged from 1 to 20 years. Purchased intangible assets acquired in business combinations, other than goodwill, are amortized over their estimated useful lives unless these lives are determined to be indefinite. Intangibles are assessed for recoverability considering the contract life and the period of time over which the intangible will contribute to future cash flow. The unamortized cost of intangible assets, where cash flows are independent and identifiable from other assets, is evaluated periodically and adjusted, if necessary, if events and circumstances indicate that a decline in value below the carrying amount has occurred. Intangible asset impairments recorded during the year ended December 31, 2019 are further discussed in Note 6 "Restructuring" . Amortization expense related to developed technology and patent and license rights which have been acquired in a business combination is included in cost of sales. Amortization of trademarks, customer base and non-compete agreements which have been acquired in a business combination is recorded in operating expense under the caption 'acquisition-related intangible amortization'. Amortization expenses of intangible assets not acquired in a business combination are recorded within either the cost of sales, research and development or sales and marketing line items based on the use of the asset. We dispose the gross carrying amount and accumulated amortization of fully amortized intangible assets from historic business combinations once they are considered fully integrated into our business. The fair value of in-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until completion or abandonment of the related research and development activities. IPR&D is tested for impairment annually or when any event or circumstance indicates that the fair value may be below the carrying value. If and when research and development is complete, the associated asset is amortized over the estimated useful life. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired arising from business combinations. Goodwill is subject to impairment tests annually or earlier if indicators of potential impairment exist, using a fair-value-based approach. We have elected to perform our annual test for indications of impairment as of October 1 st of each year. Following the annual impairment tests for the years ended December 31, 2019 , 2018 and 2017 , goodwill has not been impaired. Non-Marketable Investments We have investments in non-marketable equity securities issued by privately held companies. These investments are included in other long-term assets in the accompanying consolidated balance sheets. Non-marketable investments through which we exercise significant influence but do not have control are accounted for using the equity method. We monitor for changes in circumstances that may require a reassessment of the level of influence. Following the adoption of ASU 2016-01 on January 1, 2018, our non-marketable equity securities not accounted for under the equity method are either carried at fair value or under the measurement alternative. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. Investments are evaluated periodically, or when impairment indicators are noted, to determine if declines in value are other-than-temporary. In making that determination, we consider all available evidence relating to the realizable value of a security. This evidence includes, but is not limited to, the following: • adverse financial conditions of a specific issuer, segment, industry, region or other variables; • the length of time and the extent to which the fair value has been less than cost; and • the financial condition and near-term prospects of the issuer. We consider whether the fair values of any of our non-marketable investments have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If any such decline is considered to be other than temporary (based on various factors, including historical financial results, product development activities and the overall health of the affiliate’s industry), then a write-down of the investment would be recorded in operating expense to its estimated fair value. Variable Interest Entities We evaluate at the inception of each arrangement whether we have made an investment in an entity that is considered a variable interest entity (VIE) or if we hold other variable interests in an arrangement that is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE as an investment in a non-marketable investment or in accordance with other applicable GAAP. Impairment of Long-Lived Assets We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. We consider, amongst other indicators, a history of operating losses or a change in expected sales levels to be indicators of potential impairment. Assets are grouped and evaluated for impairment at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying amount of the asset exceeds fair value which is determined by applicable market prices, when available. When market prices are not available, we generally measure fair value by discounting projected future cash flows of the asset. Considerable judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could differ from such estimates.

Revenue

Revenue	12 Months Ended
Revenue	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Nature of Goods and Services Our revenues are reported net of sales and value added taxes and accruals for estimated rebates and returns and are derived primarily from the sale of consumable and instrumentation products, and to a much lesser extent, from the sale of services, intellectual property and technology. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to performance obligations based on their relative stand-alone selling prices. We offer warranties on our products. Certain of our warranties are assurance-type in nature and do not cover anything beyond ensuring that the product is functioning as intended. Based on the guidance in Topic 606, assurance-type warranties do not represent separate performance obligations. The Company also sells separately-priced service contracts which qualify as service-type warranties and represent separate performance obligations. We sell our products and services both directly to customers and through distributors generally under agreements with payment terms typically less than 90 days and in most cases not exceeding one year and therefore contracts do not contain a significant financing component. Consumable and Related Revenue Consumable Products: In the last three years, revenue from consumable product sales has accounted for approximately 78 - 80% of our net sales and revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of our contracts have a single performance obligation to transfer a product or multiple performance obligations to transfer multiple products concurrently. Accordingly, we recognize revenue when control of the products has transferred to the customer, which is generally at the time of shipment of products as this is when title and risk of loss have been transferred. In addition, invoicing typically occurs at this time so this is when we have a present right to payment. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products and is generally based upon a negotiated formula, list or fixed price. Related Revenue: Revenues from related products include software-as-a-service (SaaS), licenses, intellectual property and patent sales, royalties and milestone payments and over the last three years has accounted for approximately 8 - 10% of our net sales. SaaS arrangements: Revenue from SaaS arrangements, which allow customers to use hosted software over the contract period without taking possession of the software, is recognized over the duration of the agreement unless the terms of the agreement indicate that revenue should be recognized in a different pattern, for example based on usage. Licenses : Licenses for on-site software, which allow customers to use the software as it exists when made available, are sold as perpetual licenses or term licenses. Revenue from on-site licenses are recognized upfront at the point in time at the later of when the software is made available to the customer and the beginning of the license term. When a portion of the transaction price is allocated to a performance obligation to provide support and/or updates, revenue is recognized as the updates/support are provided, generally over the life of the license. Fees from research collaborations include payments for technology transfer and access rights. Royalties from licensees of intellectual property are based on sales of licensed products and revenues are recognized at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Milestone Payments: At the inception of each companion diagnostic co-development arrangement that includes development milestone payments, which represent variable consideration, we evaluate whether the milestones are probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control, such as milestones which are achieved through regulatory approvals, are considered to be constrained and excluded from the transaction price until those approvals are received. Revenue is recognized following the input method as this is considered to best depict the timing of the transfer of control. This involves measuring actual hours incurred to date as a proportion of the total budgeted hours of the project. At the end of each subsequent reporting period, the proportion of completion is trued-up. We also re-evaluate the probability of achievement of development milestones and any related constraint on a periodic basis, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Instruments Revenue from instrumentation includes the instrumentation equipment, installation, training and other instrumentation services, such as extended warranty services or product maintenance contracts and over the last three years has accounted for approximately 11 - 12% of net sales. Revenue from instrumentation equipment is recognized when the customer obtains control of the instrument which is predominantly at the time of delivery or when title has transferred to the customer. Service revenue is recognized over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. Contract Estimates The majority of our revenue is derived from contracts (i) with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount in which we have the right to invoice as product is delivered. We have elected the practical expedient not to disclose the value of remaining performance obligations associated with these types of contracts. However, we have certain companion diagnostic co-development contracts in which our performance obligations extend over multiple years. As of December 31, 2019 , we had $20.4 million of remaining performance obligations for which the transaction price is not constrained related to these contracts of which we expect to recognize over the next 12 to 18 months . Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. Contract Balances The timing of revenue recognition, billings and cash collections can result in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) in the consolidated balance sheet. Contract assets as of December 31, 2019 and 2018 totaled $5.5 million and $6.9 million , respectively, and are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets and relate to the companion diagnostic co-development contracts discussed above. Contract liabilities primarily relate to advances or deposits received from customers before revenue is recognized and is primarily related to instrument service and software subscription revenue. As of December 31, 2019 and 2018 , contract liabilities totaled $56.2 million and $54.3 million , respectively, of which $48.5 million and $45.3 million is included in accrued and other current liabilities, respectively, and $7.7 million and $9.0 million in included in other long-term liabilities, respectively. During the twelve months ended December 31, 2019 and 2018 , we satisfied the associated performance obligations and recognized revenue of $48.3 million and $44.5 million , respectively, related to advance customer payments previously received. Disaggregation of Revenue We disaggregate our revenue based on product categories and customer class as shown in the tables below for the years ended December 31, 2019 , 2018 and 2017 : 2019 (in thousands) Consumables and related Instruments Total Molecular Diagnostics $ 665,866 $ 71,266 $ 737,132 Life Sciences 688,281 101,011 789,292 Academia / Applied Testing 418,518 69,114 487,632 Pharma 269,763 31,897 301,660 Total $ 1,354,147 $ 172,277 $ 1,526,424 2018 (in thousands) Consumables and related Instruments Total Molecular Diagnostics $ 649,602 $ 82,197 $ 731,799 Life Sciences 665,857 104,192 770,049 Academia / Applied Testing 407,370 72,131 479,501 Pharma 258,487 32,061 290,548 Total $ 1,315,459 $ 186,389 $ 1,501,848 2017 (in thousands) Consumables and related Instruments Total Molecular Diagnostics $ 605,462 $ 77,702 $ 683,164 Life Sciences 637,253 97,119 734,372 Academia / Applied Testing 392,066 67,477 459,543 Pharma 245,187 29,642 274,829 Total $ 1,242,715 $ 174,821 $ 1,417,536 Refer to Note 21 "Segment Information" for disclosure of revenue by geographic region.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
Acquisitions and Divestitures	Dec. 31, 2019
Asset Acquisitions, Business Combinations And Divestitures [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestitures Business Combinations and Asset Acquisitions For acquisitions which have been accounted for as business combinations, the acquired companies’ results have been included in the accompanying consolidated statements of income from their respective dates of acquisition. Our acquisitions have historically been made at prices above the fair value of the acquired net assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing infrastructure, such as sales force, shared service centers, distribution channels and customer relations, to expand sales of an acquired business' products; use of the infrastructure of the acquired businesses to cost-effectively expand sales of our products; and elimination of duplicative facilities, functions and staffing. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. 2019 Business Combinations In January 2019, we completed the acquisition of N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data located in Concord, Massachusetts. The cash consideration, net of cash acquired, was $24.5 million . This acquisition was not significant to the overall consolidated financial statements and as of December 31, 2019 , the allocation of the purchase price was final. The acquisition did not have a material impact to net sales, net income or earnings per share and therefore no pro forma information has been provided herein. In the third quarter of 2019, we acquired two additional companies for total cash consideration, net of cash acquired, of $43.5 million . The purchase price allocations for these acquisitions are preliminary and are based upon preliminary estimates which used information that was available to management at the time the financial statements were prepared and these estimates and assumptions are subject to change within the measurement period, up to one year from the acquisition date. Accordingly, the allocation may change. We continue to gather information about the assets and liabilities acquired, including the acquired tax balance. These acquisitions were not significant to the overall consolidated financial statements and the acquisitions did not have a material impact to net sales, net income or earnings per share. Thus, no pro forma information has been provided herein. 2018 Business Combination In April 2018, we acquired all shares in STAT-Dx Life, S.L. (STAT-Dx), a privately-held company located in Barcelona, Spain, which is developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries. The cash consideration totaled $148.8 million . The acquisition included contingent consideration which is recorded as part of the purchase price based on the acquisition date fair value. Potential contingent payments through 2024 under the purchase agreement total $44.3 million , of which the fair value of $37.4 million was recorded as purchase price using a probability-weighted analysis of the future milestones applying discount rates between 6.5% and 6.9% . Direct acquisition costs totaled $2.0 million . The final purchase price allocation differed from the initial preliminary purchase price allocation as follows: (in thousands) Final Preliminary As of April 27, 2018 Difference Purchase Price: Cash consideration $ 148,780 $ 148,780 $ — Fair value of contingent consideration 37,377 36,751 626 $ 186,157 $ 185,531 $ 626 Final Allocation: Cash and cash equivalents $ 7,357 $ 7,357 $ — Prepaid expenses and other current assets 1,432 1,432 — Inventories 1,868 1,868 — Income tax receivables 2,213 2,213 — Accounts payable (1,412 ) (1,412 ) — Accruals and other current liabilities (1,785 ) (560 ) (1,225 ) Fixed and other long-term assets 6,306 6,434 (128 ) Developed technology 31,300 80,100 (48,800 ) In-process research and development 24,300 — 24,300 Goodwill 117,621 97,268 20,353 Deferred tax liability on fair value of identifiable intangible assets acquired (3,043 ) (9,169 ) 6,126 Total $ 186,157 $ 185,531 $ 626 The changes in the values of in-process research and development assets and developed technology relate to new information obtained, that existed at the acquisition date, regarding key assumptions in the valuation model since the initial purchase price allocation. The weighted average amortization period for the developed technology is 10 years. The goodwill acquired is not deductible for tax purposes. In-process research and development relates to technologies that remain in development at the time of acquisition and which had not yet obtained regulatory approval. During 2019, one development project was completed and a portion of in-process research and development costs were reclassified into developed technology as further discussed in Note 11 "Goodwill and Intangible Assets" . The remaining technologies within in-process research and development are expected to be completed within the next two years . Revenue and earnings in the reporting periods since the acquisition date have not been significant. No pro forma financial information has been provided herein as the acquisition of STAT-Dx did not have a material impact to our net sales, net income or earnings per share on a pro forma basis. Other 2018 Business Combination In April 2018, we acquired all remaining shares of a privately held entity in which we held a minority interest. The value of the minority interest investment was revalued in connection with the acquisition by $4.8 million and a corresponding gain was recorded in general and administrative, restructuring, integration and other, net in the accompanying consolidated statement of income for the year ended December 31, 2018. This acquisition was not significant to the overall consolidated financial statements. The acquisition did not have a material impact to net sales, net income or earnings per share and therefore no pro forma information has been provided herein. 2019 Asset Acquisition On January 31, 2019, we acquired the digital PCR asset of Formulatrix, Inc., a developer of laboratory automation solutions. We paid Formulatrix $125.0 million in cash upon closing and will pay future milestone payments of $135.9 million in 2020. As of December 31, 2019 , $134.3 million is included in accrued and other current liabilities in the accompanying consolidated balance sheet for the present value of the future expected payments. Divestitures In 2019, we sold a portfolio of protein catalysation products for $1.0 million . An immaterial gain was recorded on the sale. In 2018, we sold a portfolio of veterinary testing products for a total of €15.1 million ( $18.5 million ), of which $16.4 million was received in cash and the balance due in April 2020 . An $8.0 million gain was recorded on the sale to other income (expense), net in the accompanying consolidated statements of income for the year-ended December 31, 2018.

Restructuring and Impairments

Restructuring and Impairments	12 Months Ended
Restructuring and Impairments	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Impairments	Restructuring and Impairments As part of our restructuring activities, we incur expenses that qualify as exit and disposal costs under U.S. GAAP including severance and employee costs as well as contract and other costs, primarily contract termination costs, as well as inventory write-offs and other implementation costs primarily related to consulting fees. Personnel related costs primarily relate to cash severance and other termination benefits including accelerated share-based compensation. We also incur expenses that are an integral component of, and are directly attributable to, our restructuring activities which do not qualify as exit and disposal costs under U.S. GAAP, which consist of asset-related costs such as intangible asset impairments and other asset related write-offs. Personnel costs are primarily determined based on established benefit arrangements, local statutory requirements, or historical benefit practices. We recognize these benefits when payment is probable and estimable. Other benefits which require future service and are associated to non-recurring benefits are recognized ratably over the future service period. Other assets, including inventory, are impaired or written-off if the carrying value exceeds the fair value. All other costs are recognized as incurred. 2019 Restructuring In the second half of 2019, we decided to suspend development of NGS-related instrument systems and entered into a new strategic partnership with Illumina to commercialize IVD kits worldwide on Illumina's diagnostic sequencers. In order to align our business with this new strategy, we began restructuring initiatives to target resource allocation to growth opportunities in our Sample to Insight portfolio. Impairments to property, plant and equipment primarily impacted computer software and machinery and equipment. Costs incurred to either purchase software or produce software products and the software components of products to be sold, leased or marketed after technological feasibility is established were previously capitalized during the development of certain NGS-related instrument systems. These long-lived assets were fully impaired due to the decision to suspend further development. In addition to computer software, certain machinery and equipment assets were fully impaired given that these assets had no alternative use following the changes announced for this program and it was estimated that no value was recoverable in a market disposal. Due to the suspended development, intangible assets were also assessed for recoverability. The abandoned assets include developed technology related to the suspended projects as well as the termination of licenses which were used exclusively in connection with this program. As a result, we recorded intangible asset impairment charges due to the conclusion that the identified assets have no alternative use outside of the suspended program and thus are fully impaired. We also conducted an impairment review of inventory and prepaid and other assets and recorded the charges noted in the table below. As these charges, including inventory, are a direct result of the decision to suspend further development of NGS-related instrument systems and are not related to external market factors, the impairment charges were recorded in the line item restructuring, acquisition, integration and other, net in the consolidated statements of (loss) income due to the assets being deemed excess and no longer utilized due to the discontinued development and related actions discussed above. In addition, we have initiated measures to: • shift Commercial Operations activities into Business Areas; • transition manufacturing activities into a regional structure; and • expand the scope of activities at QIAGEN Business Services (QBS) centers in Wroclaw, Poland and Manila, Philippines The following is a summary of the charges recorded during the year ended December 31, 2019 . Year ended December 31, 2019 Consolidated Statement of (Loss) Income Classification and Type of Charge (in thousands) Note Total Restructuring, acquisition, integration and other, net Personnel related (of which $2,956 due to related parties) (22) $ 70,578 Contract termination costs (of which $15,676 due to related parties) 42,099 Consulting fees 10,150 Accounts receivable (of which $5,984 due from related parties) 10,825 Inventories 12,336 Prepaid expenses and other assets (of which $12,915 was long-term and $2,270 due from related parties) 17,012 163,000 Long-lived asset impairments Property, plant and equipment (9) 98,472 Intangible assets (11) 40,301 138,773 Other (expense) income, net Equity method investment impairment (10) 4,799 Total $ 306,572 Of the total costs incurred, $60.2 million are accrued as of December 31, 2019 in accrued and other current liabilities in the accompanying consolidated balance sheet as summarized in the following table that includes the cash components of the restructuring activity. (in thousands) Personnel Related Contract Termination Consulting Fees Total Costs incurred in 2019 $ 44,640 $ 42,099 $ 10,150 $ 96,889 Payments (17,272 ) (18,294 ) (2,162 ) (37,728 ) Foreign currency translation adjustment 631 493 (53 ) 1,071 Liability at December 31, 2019 $ 27,999 $ 24,298 $ 7,935 $ 60,232 Future pre-tax costs between $15 - $23 million are expected to be incurred primarily related to personnel, consulting and contract termination costs before completion of the program in 2020. 2017 Restructuring We initiated restructuring initiatives in 2017 to mitigate the negative impacts stemming from the U.S. tax reform. Total pre-tax costs for the initiatives, which were concluded in 2018, were $24 million and no additional costs will be incurred related to this program. Cumulative costs for this program were as follows: (in thousands) Personnel Related Contract and Other Costs Inventory Write-offs & Asset Impairments Total Cost of sales $ — $ — $ 3,039 $ 3,039 Restructuring, acquisition, integration and other, net 6,174 4,583 — 10,757 Total 2017 costs 6,174 4,583 3,039 13,796 Cost of sales 424 1,193 — 1,617 Restructuring, acquisition, integration and other, net 4,207 4,232 1,610 10,049 Total 2018 costs 4,631 5,425 1,610 11,666 Restructuring, acquisition, integration and other, net (1,100 ) — — (1,100 ) Total 2019 releases (1,100 ) — — (1,100 ) Total cumulative costs $ 9,705 $ 10,008 $ 4,649 $ 24,362 The following table summarizes the cash components of the restructuring activity. (in thousands) Personnel Related Consulting Costs Total Liability at December 31, 2017 $ 6,222 $ 4,585 $ 10,807 Additional costs in 2018 6,468 5,554 12,022 Release of excess accrual (1,837 ) (129 ) (1,966 ) Payments (6,892 ) (7,149 ) (14,041 ) Foreign currency translation adjustment (141 ) (17 ) (158 ) Liability at December 31, 2018 $ 3,820 $ 2,844 $ 6,664 Release of excess accrual (1,100 ) — (1,100 ) Payments (2,269 ) (2,828 ) (5,097 ) Foreign currency translation adjustment (49 ) (16 ) (65 ) Liability at December 31, 2019 $ 402 $ — $ 402 During 2018 , fixed asset impairments of $1.6 million were recorded in connection with this initiative and are included within restructuring, acquisition, integration and other, net in the accompanying consolidated statements of income. As of December 31, 2019 and 2018 , liabilities of $0.4 million and $6.7 million , respectively, are included in accrued and other current liabilities in the accompanying consolidated balance sheets. 2016 Restructuring During 2016, we initiated a series of targeted actions to support faster sales momentum and improve efficiency and accountability. The objective with these actions is to ensure that we grow sustainably and consistently. Measures included simplifying our geographic presence with site reductions, focusing resources to shared service centers, and streamlining selected organizational structures. The cumulative cost for this program was $97.1 million and no additional costs will be incurred related to this program. During the year ended December 31, 2017, we incurred $19.7 million of costs, of which $1.4 million was included in cost of sales and $18.3 million was included in restructuring, acquisition, integration and other, net. During the years ended December 31, 2019 and 2018 , releases of excess accruals as included in the table below were included in restructuring, acquisition, integration and other, net. The following table summarizes the cash components of the restructuring activity. (in thousands) Personnel Related Facility Related Contract and Other Costs Total Liability at December 31, 2017 $ 4,294 $ 1,052 $ 1,066 $ 6,412 Release of excess accrual (343 ) (838 ) (546 ) (1,727 ) Payments (3,648 ) (214 ) (494 ) (4,356 ) Foreign currency translation adjustment (48 ) — (26 ) (74 ) Liability at December 31, 2018 $ 255 $ — $ — $ 255 Release of excess accrual (31 ) — — (31 ) Payments (225 ) — — (225 ) Foreign currency translation adjustment 1 — — 1 Liability at December 31, 2019 $ — $ — $ — $ —

Short-Term Investments

Short-Term Investments	12 Months Ended
Short-Term Investments	Dec. 31, 2019
Short-term Investments [Abstract]
Short-Term Investments	Short-Term Investments At December 31, 2019 and 2018 , we had $129.6 million ( $65.0 million and €57.5 million ) and $234.3 million ( $134.1 million and €87.5 million ), respectively, of money market deposits, commercial paper and loan receivables due from financial and nonfinancial institutions as summarized below. These instruments are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are carried at fair market value, which is equal to the cost. All instruments are classified as current assets in the accompanying balance sheets as they either have a maturity of less than one year or are redeemable at our discretion. Interest income is determined using the effective interest rate method. (in thousands) December 31, 2019 December 31, 2018 Money market deposits $ 87,468 $ 20,000 Commercial paper 22,459 179,219 Loans receivable 19,659 35,037 Total $ 129,586 $ 234,256

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2019
Prepaid Expense and Other Assets [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are summarized as follows as of December 31, 2019 and 2018 : (in thousands) Note 2019 2018 Prepaid expenses $ 45,409 $ 48,250 Other receivables 37,025 11,127 Value added tax 20,347 24,416 Cash collateral (14) 2,683 25,368 Total prepaid expenses and other current assets $ 105,464 $ 109,161

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment, including equipment acquired under capital lease obligations, are summarized as follows as of December 31, 2019 and 2018 : (in thousands) Estimated useful life 2019 2018 Land — $ 17,684 $ 17,938 Buildings and improvements 5-40 341,032 322,751 Machinery and equipment 3-10 292,294 306,750 Computer software 3-7 301,604 277,006 Furniture and office equipment 3-10 102,901 109,770 Construction in progress — 98,858 80,874 1,154,373 1,115,089 Less: Accumulated depreciation and amortization (699,130 ) (603,430 ) Property, plant and equipment, net $ 455,243 $ 511,659 Amortization of assets acquired under capital lease obligations is included within accumulated depreciation and amortization above for the years ended December 31, 2019 and 2018 , respectively. We recorded asset impairment charges as follows below for the years ended December 31, 2019 and 2018 . Year ended December 31, (in thousands) 2019 2018 Machinery and equipment $ 9,177 $ — Computer software 44,649 2,911 Furniture and office equipment 4,030 — Construction in progress 41,870 4,979 Total impairment in property, plant and equipment $ 99,726 $ 7,890 During the year ended December 31, 2019 , $98.5 million of impairments were related to the 2019 Restructuring program discussed in Note 6 "Restructuring" while the remaining $1.2 million were related to other identified impairments during the year. In 2018, we recorded asset impairment charges of $7.9 million of internal-use software of which $1.6 million related to the 2017 Restructuring program discussed in Note 6 "Restructuring" and $6.3 million related to strategic shifts in our business. No impairments to property, plant and equipment were recognized during the year ended December 31, 2017 . For the years ended December 31, 2019 , 2018 and 2017 depreciation and amortization expense totaled $86.0 million , $87.9 million and $82.5 million , respectively. For the years ended December 31, 2019 , 2018 and 2017 amortization related to computer software to be sold, leased or marketed totaled $18.3 million , $17.2 million and $13.9 million , respectively. Impairment charges related to computer software to be sold, leased or marketed are included in computer software and construction in progress in the table above and totaled $65.9 million for the year ended December 31, 2019 . As of December 31, 2019 and 2018 , the unamortized balance of computer software to be sold, leased or marketed was $36.6 million and $100.5 million , respectively. Repairs and maintenance expense was $10.7 million , $12.1 million and $12.7 million in 2019 , 2018 and 2017 , respectively. For the year ended December 31, 2019 and 2018 , construction in progress primarily includes amounts related to ongoing software development projects. For the years ended December 31, 2019 , 2018 and 2017 , interest capitalized in connection with construction projects was not significant.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2019
Investments [Abstract]
Investments	Investments The following discusses our marketable investments, non-marketable investments and the realized and unrealized gains and losses on these investments. Marketable Equity Securities A summary of our investments in marketable equity securities that have readily determinable fair values that are classified as available-for-sale follows below. These investments are reported at fair value with gains and losses recorded in earnings beginning in January 2018 upon adoption of ASU 2016-01. Prior to adoption, these investments were reported at fair value with unrealized gains and losses recognized in accumulated other comprehensive income on the balance sheet. Accordingly, upon adoption, we recorded a cumulative effect adjustment to decrease opening retained earnings at January 1, 2018 by a net of tax amount of $0.9 million (pre-tax $1.1 million ) for unrealized losses as of the adoption date. (in thousands, except shares held) As of December 31, 2019 HTG Molecular Diagnostics, Inc (HTGM) Oncimmune Holdings plc (Oncimmune) Shares held 833,333 560,416 Cost basis $ 2,000 $ — Fair value $ 585 $ 285 Total cumulative unrealized (loss) gain $ (1,415 ) $ 285 (in thousands, except shares held) As of December 31, 2018 HTGM Curetis N.V. (Curetis) Shares held 833,333 204,000 Cost basis $ 2,000 $ 1,444 Fair value $ 2,117 $ 350 Total cumulative unrealized gain (loss) $ 117 $ (1,094 ) During 2019, we received 560,416 shares in Oncimmune in settlement of a zero-book value financial instrument held with a third party. On the date of receipt, these shares held a fair value of $0.7 million which was recorded as a gain in other income (expense), net in the accompanying statements of (loss) income. Also during 2019, we sold the remaining 204,000 Curetis shares and recognized an immaterial loss in other income (expense), net. During the year ended December 31, 2018 , we sold 116,424 shares of Curetis and recognized a gain of $0.3 million in other income (expense), net in the accompanying statements of (loss) income. During the years ended December 31, 2019 and 2018 , losses recognized for the change in fair market value of all marketable equity securities totaled $2.1 million and $0.1 million , respectively. As of December 31, 2019 and 2018 , these marketable securities are included in other long-term assets in the accompanying consolidated balance sheets. Non-Marketable Investments We have made strategic investments in certain privately-held companies without readily determinable market values. Non-Marketable Investments Accounted for Under the Equity Method A summary of our non-marketable investments accounted for as equity method investments is as follows: Equity investments as of December 31, Share of income (loss) for the years ended December 31, ($ in thousands) Ownership Percentage 2019 2018 2019 2018 2017 PreAnalytiX GmbH 50.00 % $ 5,452 $ 5,405 $ 3,971 $ 4,062 $ 3,818 Suzhou Fuda Business Management and Consulting Partnership 33.67 % 3,100 3,138 — — — TVM Life Science Ventures III 4.80 % 1,219 — (330 ) — — Apis Assay Technologies Ltd 19.00 % 719 770 (51 ) — — Hombrechtikon Systems Engineering AG 19.00 % (761 ) 378 (1,124 ) (668 ) (346 ) MAQGEN Biotechnology Co., Ltd 40.00 % — 5,154 (383 ) (579 ) (542 ) Biotype Innovation GmbH 0.00 % — — — (123 ) 39 Pyrobett 19.00 % — — — (100 ) 195 $ 9,729 $ 14,845 $ 2,083 $ 2,592 $ 3,164 Of the $9.7 million of non-marketable investments accounted for as equity method investments, $10.5 million is included in other long-term assets and $0.8 million , where we are committed to fund losses, is included in other long-ter m liabilities in the accompanying consolidated balance sheets as of December 31, 2019 . During 2019 , we made an investment in TVM Life Science Ventures III and as of December 31, 2019 we hold a 4.8% ownership stake in this limited partnership that is accounted for under the equity method as we have the ability to exercise significant influence over the limited partnership. Also during the year ended December 31, 2019 , we recorded an impairment of $4.8 million in other income (expense), net in the accompanying consolidated statements of income, following changes in circumstances of MAQGEN Biotechnology Co., Ltd that indicated the carrying value was no longer recoverable. Accordingly, the investment was fully impaired. In 2018, we recorded impairments totaling $6.1 million in other (expense) income, net in the accompanying consolidated statements of income, following changes in the investees' circumstances that indicated the carrying value was no longer recoverable. During 2017, we sold our interest in QIAGEN (Suzhou) Institute of Translation Research Co., Ltd., which had no book value at the time of sale, for $3.5 million and recorded a corresponding gain in other income (expense), net in the accompanying statements of income. Three of our equity method investments are variable interest entities and we are not the primary beneficiary as we do not hold the power to direct the activities that most significantly impact the economic performance. Therefore, these investments are not consolidated. As of December 31, 2019 and 2018 , these investments had a total net carrying value of $1.2 million , of which $1.9 million is included in other long-term assets and $0.8 million is included in other long-term liabilities in the accompanying consolidated balance sheet. As of December 31, 2018 , these investments held a balance of $1.1 million which is included in other long-term assets in the consolidated balance sheet. These balances represent our maximum exposure to loss. Non-Marketable Investments Not Accounted for Under the Equity Method At December 31, 2019 and 2018 , we had investments in non-publicly traded companies that do not have readily determinable fair values with carrying amounts that totaled $70.8 million and $59.5 million , respectively. The changes in these investments which are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 59,484 $ 33,605 Cash investments in equity securities, net 3,619 9,633 Net increases due to observable price changes 7,760 13,104 Conversion of note receivable to equity securities — 11,369 Sale of equity securities — (5,400 ) Full acquisition of equity securities — (2,710 ) Foreign currency translation adjustments (14 ) (117 ) Balance at end of year $ 70,849 $ 59,484 During 2019 , we made additional investments of $3.6 million in non-marketable investments not accounted for under the equity method. As of December 31, 2019 and December 31, 2018 , investments in variable interest entities had a total carrying value of $41.0 million which is included in other long-term assets in the consolidated balance sheets, representing our maximum exposure to loss. Since adoption of ASU 2016-01, upward adjustments in the carrying value of these investments have been recognized for observable price changes totaling $20.9 million , of which $7.8 million occurred in 2019 and $13.1 million was recognized in 2018 in other income (expense), net in the accompanying consolidated statements of income. These adjustments were due to equity offerings at a higher price from the issuer in orderly transactions for identical or similar investments as those we hold. During 2018 , we made investments of $9.6 million in equity securities, of which $9.3 million was an additional investment in NeuMoDx Molecular, Inc. (NeuMoDx). The investment is part of a strategic partnership with NeuMoDx to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing. Under the agreement, we will initially distribute the NeuMoDx™ 288 (high-throughput version) and NeuMoDx™ 96 (mid-throughput version) in Europe and other major markets worldwide outside of the United States. NeuMoDx will distribute these instruments within the United States directly. The two companies have also entered into an agreement under which we can acquire all NeuMoDx shares not currently owned by QIAGEN at a predetermined price of approximately $234 million , subject to the achievement of certain regulatory and operational milestones. During 2018, we converted a note receivable from a non-publicly traded company, considered a related party, into an equity interest in that company. This note held a balance of $11.4 million including principal balance and accrued interest at conversion which was a non-cash investing activity and is therefore not included in the consolidated statement of cash flows. Also during 2018, we sold our interest in a non-publicly traded company which had a book value of $5.4 million . Proceeds from the sale totaled $10.5 million in cash resulting in a corresponding gain of $5.1 million recorded in other income (expense), net in the accompanying consolidated statement of income. Additionally during 2018, we acquired all remaining shares of a privately held entity in which we held a minority interest as discussed in Note 5 "Acquisitions and Divestitures". In 2017, we recorded total impairments to non-marketable investments not accounted for under the equity method of $5.1 million

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
Goodwill and Intangible Assets	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The following sets forth the intangible assets by major asset class as of December 31, 2019 and 2018 : 2019 2018 (in thousands) Weighted Average Life (in years) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized Intangible Assets: Patent and license rights 10.19 $ 320,406 $ (216,554 ) $ 448,220 $ (310,040 ) Developed technology 10.96 766,966 (346,085 ) 770,955 (561,615 ) Customer base, trademarks, and non-compete agreements 11.68 314,638 (213,881 ) 427,512 (323,024 ) 10.95 $ 1,402,010 $ (776,520 ) $ 1,646,687 $ (1,194,679 ) Unamortized Intangible Assets: In-process research and development $ 6,944 $ 23,035 Goodwill 2,140,503 2,108,536 $ 2,147,447 $ 2,131,571 The in-process research and development is associated to the acquisition of STAT-Dx as further discussed in Note 5 "Acquisitions and Divestitures" . The estimated fair value of acquired in-process research and development projects which have not reached technological feasibility at the date of acquisition are capitalized and subsequently tested for impairment through completion of the development process, at which point the capitalized amounts are amortized over their estimated useful life. If a project is abandoned rather than completed, all capitalized amounts are written-off immediately. During 2019 , one development project was completed and, after testing for impairment, $15.9 million of in-process research and development costs were reclassified into developed technology. Developed technology includes the digital PCR asset from Formulatrix as discussed in Note 5 "Acquisitions and Divestitures" which is being amortized over 10 years . The changes in intangible assets for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 475,043 $ 499,318 Additions 286,159 32,159 Additions from acquisitions 36,458 81,200 Amortization (122,560 ) (118,576 ) Disposals — (4,426 ) Impairments (40,301 ) — Foreign currency translation adjustments (2,365 ) (14,632 ) Balance at end of year $ 632,434 $ 475,043 During the year ended December 31, 2019 , we recorded an impairment charge of $40.3 million related to the restructuring activities discussed further in Note 6 "Restructuring and Impairments" of which $28.1 million is related to patent and license rights and $12.1 million is related to developed technology. Amortization expense on intangible assets totaled approximately $122.6 million , $ 118.6 million and $ 133.8 million , respectively, for the years ended December 31, 2019 , 2018 and 2017 . Cash paid for purchases of intangible assets during the year ended December 31, 2019 totaled $156.9 million , of which $11.5 million is related to current year payments for licenses that were accrued as of December 31, 2018 and $0.5 million is related to prepayments recorded in other long-term assets in the accompanying consolidated balance sheet. Intangible asset additions of $286.2 million includes $144.9 million of cash paid during the year ended December 31, 2019 , together with $137.8 million of additions that were accrued as of December 31, 2019 and $3.5 million of additions which were previously recorded as prepayments. Cash paid for intangible assets during the year ended December 31, 2018 totaled $41.0 million of which $11.9 million is related to current year payments for licenses that were accrued as of December 31, 2017 and $3.3 million is related to prepayments recorded in other long-term assets in accompanying consolidated balance sheet. Intangible asset additions of $32.2 million includes $25.8 million of cash paid during the year ended December 31, 2018 , together with $4.2 million of additions that were accrued as of December 31, 2018 and $2.2 million of additions which were previously recorded as prepayments. Amortization of intangibles for the next five years is expected to be approximately: (in thousands) Amortization Years ended December 31: 2020 $ 100,891 2021 $ 92,512 2022 $ 78,454 2023 $ 76,239 2024 $ 71,910 The changes in goodwill for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 2,108,536 $ 2,012,904 Business combinations 34,807 142,287 Purchase adjustments (236 ) — Disposals (225 ) (5,682 ) Foreign currency translation adjustments (2,379 ) (40,973 ) Balance at end of year $ 2,140,503 $ 2,108,536 The changes in the carrying amount of goodwill during the year ended December 31, 2019 resulted primarily from the acquisition of N-of-One, Inc. and other acquisitions and divestitures discussed in Note 5 "Acquisitions and Divestitures" and changes in foreign currency translation. The changes in goodwill during the year ended December 31, 2018 resulted primarily from the acquisition of STAT-Dx and other acquisitions and divestitures also discussed in Note 5 "Acquisitions and Divestitures"

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2019
Leases [Abstract]
Leases	Leases In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and additionally in July 2018, the ASU 2018-11, Leases (Topic 842) Targeted Improvements , which superseded ASC Topic 840, Leases . The new standard increases transparency and comparability by requiring the recognition by lessees of right-of-use (“ROU”) assets and lease liabilities on the balance sheet for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Accounting Policies We adopted Topic 842 Leases on its effective date on January 1, 2019 and the comparative information has not been adjusted and continues to be reported under ASC Topic 840 Leases . As a result, we changed our accounting policy for leases as detailed below. We implemented the standard using the required modified retrospective approach and have also elected to utilize the package of practical expedients, which permitted us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We also elected the practical expedient to use hindsight in determining the appropriate lease term and in assessing impairment of its right-of-use assets. In using the modified retrospective approach, we were required to recognize and measure leases existing at, or entered into after, the beginning of the earliest comparative period presented. Adoption of the new standard resulted in the recording of additional net lease assets and lease liabilities of approximately $57.4 million and $57.7 million , respectively as of January 1, 2019. The difference between the additional lease assets and lease liabilities was recorded as a $0.3 million adjustment to retained earnings. The standard did not materially impact our consolidated income statements and had no impact on cash flows. Nature of Existing Leases We have operating and finance leases for equipment, cars, machinery, other equipment, office and buildings. Our leases have remaining lease terms of 1 year to 9 years , some of which include options to extend or early renew the leases, and some of which include options to early terminate the leases. As of December 31, 2019 , no such options have been recognized as part of the right-of-use assets and lease liabilities. Operating leases can contain variable lease charges based on an index like consumer prices or rates. During 2019 , amounts recorded as variable lease payments not included in the operating lease liability were not material. When we cannot readily determine the interest rate implicit in the operating lease contracts, we apply our incremental borrowing rate based on information available at the commencement date in determining the present value of lease payments. We use the implicit rate when it is readily determinable. Supplemental balance sheet and other information related to leases was as follows: (in thousands, except lease term and discount rate) Location in balance sheet December 31, 2019 Operating lease right-of-use assets Other long-term assets $ 57,305 Current operating lease liabilities Accrued and other current liabilities $ 18,739 Long-term operating lease liabilities Other long-term liabilities $ 39,631 Weighted average remaining lease term - operating leases (in years) 3.71 Weighted average discount rate - operating leases 2.39 % The components of lease expense were as follows: Year Ended (in thousands) 2019 Operating lease cost $ 24,378 Supplemental cash flow information related to leases was as follows: Year Ended (in thousands) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ (26,113 ) Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 24,670 Maturities of lease liabilities were as follows: (in thousands) Operating Leases 2020 $ 19,914 2021 16,009 2022 11,885 2023 7,119 2024 3,391 Thereafter 3,202 Total lease payments (1) 61,520 Less imputed interest (3,150 ) Total $ 58,370 (1) Total lease payments exclude payments associated to the lease agreement discussed below that has not yet commenced. As of December 31, 2019 , we had an additional operating lease for a facility related primarily to research and development that has not yet commenced but will create significant rights and obligations for the Company. The agreement commences in 2020 with future undiscounted aggregate lease payments of $44.5 million to be paid over a lease term of 15 years . We did not hold any material finance leases as of December 31, 2019

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	12 Months Ended
Accrued and Other Current Liabilities	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
Accrued and Other Current Liabilities	Accrued and Other Current Liabilities Accrued and other current liabilities at December 31, 2019 and 2018 consist of the following: (in thousands) Note 2019 2018 Accrued contingent consideration and milestone payments (15) $ 142,604 $ 27,820 Accrued expenses and other liabilities 93,204 103,449 Payroll and related accruals 66,866 66,871 Restructuring (6) 62,227 6,850 Deferred revenue (4) 48,525 45,358 Operating lease liabilities (12) 18,739 — Accrued royalties (22) 5,481 5,469 Accrued interest on long-term debt (16) 5,257 6,200 Cash collateral (14) 1,400 1,000 Total accrued and other current liabilities $ 444,303 $ 263,017

Derivatives and Hedging

Derivatives and Hedging	12 Months Ended
Derivatives and Hedging	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging	Derivatives and Hedging Objective and Strategy In the ordinary course of business, we use derivative instruments, including swaps, forwards and/or options, to manage potential losses from foreign currency exposures and interest bearing assets or liabilities. The principal objective of such derivative instruments is to minimize the risks and/or costs associated with our global financial and operating activities. We do not utilize derivative or other financial instruments for trading or other speculative purposes. We recognize all derivatives as either assets or liabilities on the balance sheet on a gross basis, measure those instruments at fair value and recognize the change in fair value in earnings in the period of change, unless the derivative qualifies as an effective hedge that offsets certain exposures. We have agreed with almost all of our counterparties with whom we had entered into cross-currency swaps, interest rate swaps or foreign exchange contracts, to enter into bilateral collateralization contracts under which we will receive or provide cash collateral, as the case may be, for the net position with each of these counterparties . As of December 31, 2019 , cash collateral positions consisted of $1.4 million recorded in accrued and other current liabilities and $2.7 million recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet. As of December 31, 2018 , we had a liability position of $1.0 million recorded in accrued and other current liabilities and $25.4 million recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet. Non-Derivative Hedging Instrument Net Investment Hedge In 2017, we entered into a foreign currency non-derivative hedging instrument that is designated and qualifies as net investment hedge. The objective of the hedge is to protect part of the net investment in foreign operations against adverse changes in the exchange rate between the Euro and the functional currency of the U.S. dollar. The non-derivative hedging instrument is the German private corporate bond ("Schuldschein") which was issued in the total amount of $331.1 million as described in Note 16 "Lines of Credit and Debt" . Of the $331.1 million , which is held in both U.S. dollars and Euro, €255.0 million is designated as the hedging instrument against a portion of our Euro net investments in our foreign operations. The relative changes in both the hedged item and hedging instrument are calculated by applying the change in spot rate between two assessment dates against the respective notional amount. The effective portion of the hedge is recorded in the cumulative translation adjustment account within other accumulated comprehensive income (loss). Based on the spot rate method, the unrealized loss recorded in equity as of December 31, 2019 and 2018 is $0.4 million and $5.9 million , respectively. Since we are using the debt as the hedging instrument, which is also remeasured based on the spot rate method, there is no hedge ineffectiveness related to the net investment hedge as of December 31, 2019 and 2018 . Derivatives Designated as Hedging Instruments Cash Flow Hedges As of December 31, 2019 and 2018 , we held derivative instruments that are designated and qualify as cash flow hedges where the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive (loss) income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. In 2019 and in 2018 , we did not record any hedge ineffectiveness related to any cash-flow hedges in earnings. Based on their valuation as of December 31, 2019 , we expect approximately $1.9 million of derivative losses included in accumulated other comprehensive loss will be reclassified into income during the next 12 months. The cash flows derived from derivatives are classified in the consolidated statements of cash flows in the same category as the consolidated balance sheet account of the underlying item. We use interest rate derivative contracts to align our portfolio of interest bearing assets and liabilities with our risk management objectives. During 2015, we entered into five cross currency interest rate swaps through 2025 for a total notional amount of €180.0 million which qualify for hedge accounting as cash flow hedges. We determined that no ineffectiveness exists related to these swaps. As of December 31, 2019 and 2018 , interest receivables of $1.5 million and $1.4 million , respectively are recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet. Fair Value Hedges As of December 31, 2019 and 2018 , we held derivative instruments that qualify for hedge accounting as fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the effective portion of the gain or loss on the derivative is reflected in earnings. This effect on earnings is offset by the change in the fair value of the hedged item attributable to the risk being hedged that is also recorded in earnings. In 2019 and 2018 , we concluded there was no ineffectiveness. The cash flows derived from derivatives are classified in the consolidated statements of cash flows in the same category as the consolidated balance sheet account of the underlying item. We hold interest rate swaps which effectively fixed the fair value of a portion of our fixed rate private placement debt and qualify for hedge accounting as fair value hedges. We determined that no ineffectiveness exists related to these swaps. As of December 31, 2019 , an interest receivable of $0.1 million is recorded in prepaid and other current assets, and as of December 31, 2018 , accrued and unpaid interest of $0.1 million is recorded in accrued and other current liabilities, respectively, in the accompanying balance sheet. Derivatives Not Designated as Hedging Instruments Call Options We entered into Call Options which, along with the sale of the Warrants, represent the Call Spread Overlay entered into in connection with the Cash Convertible Notes and which are more fully described in Note 16 "Lines of Credit and Debt" . In these transactions, the Call Options are intended to address the equity price risk inherent in the cash conversion feature of each instrument by offsetting cash payments in excess of the principal amount due upon any conversion of the Cash Convertible Notes. Aside from the initial payment of premiums for the Call Options, we will not be required to make any cash payments under the Call Options. We will, however, be entitled to receive under the terms of the Call Options, an amount of cash generally equal to the amount by which the market price per share of our common stock exceeds the exercise price of the Call Options during the relevant valuation period. The exercise price under the Call Options is equal to the conversion price of the Cash Convertible Notes. The Call Options, for which our common stock is the underlying security, are derivative assets that requires mark-to-market accounting treatment due to the cash settlement features until the Call Options settle or expire. The Call Options are measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the Call Options, refer to Note 15 "Financial Instruments and Fair Value Measurements" . The Call Options do not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of income in other income (expense), net. Because the terms of the Call Options are substantially similar to those of the Cash Convertible Notes' embedded cash conversion option, discussed below, we expect the effect on earnings from the two derivative instruments to mostly offset each other. Cash Convertible Notes Embedded Cash Conversion Option The embedded cash conversion option within the Cash Convertible Notes discussed in Note 16 "Lines of Credit and Debt" is required to be separated from the Cash Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of income in other income (expense), net until the cash conversion option settles or expires. The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 15 "Financial Instruments and Fair Value Measurements" . Embedded Conversion Option During 2017, we purchased a convertible note for $3.0 million from a publicly listed company considered a related party. The embedded conversion option within the convertible note is required to be separated from the convertible note and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of income in other income (expense), net. The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 2 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 15 "Financial Instruments and Fair Value Measurements" . Foreign Exchange Contracts As a globally active enterprise, we are subject to risks associated with fluctuations in foreign currencies in our ordinary operations. This includes foreign currency-denominated receivables, payables, debt, and other balance sheet positions including intercompany items. We manage balance sheet exposure on a group-wide basis using foreign exchange forward contracts, foreign exchange options and cross-currency swaps. We are party to various foreign exchange forward, option and swap arrangements which had, at December 31, 2019 and December 31, 2018 , aggregate notional values of $701.4 million and $792.7 million which expire at various dates through March 2020 . The transactions have been entered into to offset the effects from short-term balance sheet exposure to foreign currency exchange risk. Changes in the fair value of these arrangements have been recognized in other income (expense), net. Fair Values of Derivative Instruments The following table summarizes the fair value amounts of derivative instruments reported in the consolidated balance sheets as of December 31, 2019 and 2018 : As of December 31, 2019 As of December 31, 2018 (in thousands) Current Asset Long-Term Asset Current Asset Long-Term Asset Assets: Derivative instruments designated as hedges Interest rate contracts - fair value hedge (1) $ — $ 2,474 $ — $ — Total derivative instruments designated as hedges $ — $ 2,474 $ — $ — Undesignated derivative instruments Embedded conversion option $ — $ — $ — $ 349 Call options 101,179 189,792 100,081 295,014 Foreign exchange contracts 6,689 — 2,673 — Total undesignated derivative instruments $ 107,868 $ 189,792 $ 102,754 $ 295,363 Total Derivative Assets $ 107,868 $ 192,266 $ 102,754 $ 295,363 As of December 31, 2019 As of December 31, 2018 (in thousands) Current Liability Long-Term Liability Current Liability Long-Term Liability Liabilities: Derivative instruments designated as hedges Interest rate contracts - cash flow hedge (1) $ — $ (6,027 ) $ — $ (17,574 ) Interest rate contracts - fair value hedge (1) — — (473 ) (721 ) Total derivative instruments designated as hedges $ — $ (6,027 ) $ (473 ) $ (18,295 ) Undesignated derivative instruments Cash convertible notes embedded conversion option $ (101,361 ) $ (190,902 ) $ (100,164 ) $ (299,098 ) Foreign exchange contracts (1,814 ) — (5,957 ) — Total undesignated derivative instruments $ (103,175 ) $ (190,902 ) $ (106,121 ) $ (299,098 ) Total Derivative Liabilities $ (103,175 ) $ (196,929 ) $ (106,594 ) $ (317,393 ) _________________ (1) The fair value amounts for the interest rate contracts do not include accrued interest. Gains and Losses on Derivative Instruments The following tables summarize the gains and losses on derivative instruments for the years ended December 31, 2019 , 2018 and 2017 : Year ended December 31, 2019 2018 2017 (in thousands) Other income (expense), net Other income (expense), net Other income (expense), net Total amounts presented in the Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded $ 432 $ 5,598 $ (4 ) Gains (Losses) on Derivatives in Cash Flow Hedges Interest rate contracts Amount of (loss) gain reclassified from accumulated other comprehensive income $ (3,888 ) $ (9,774 ) $ 26,136 Amounts excluded from effectiveness testing — — — Gains (Losses) on Derivatives in Fair Value Hedges Interest rate contracts Hedged item (3,668 ) 2,051 2,199 Derivatives designated as hedging instruments 3,668 (2,051 ) (2,199 ) Gains (Losses) Derivatives Not Designated as Hedging Instruments Embedded conversion option (349 ) 131 217 Call options (104,125 ) 74,682 37,414 Cash convertible notes embedded cash conversion option 106,998 (76,500 ) (36,741 ) Foreign exchange contracts 1,835 (19,857 ) 11,813 Total gains (losses) $ 471 $ (31,318 ) $ 38,839 Balance Sheet Line Items in which the Hedged Item is Included The following tables summarizes the balance sheet line items in which the hedged item is included as of December 31, 2019 and 2018 : Carrying Amount of the Hedged Assets (Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities) (in thousands) December 31, December 31, December 31, December 31, Current portion of long-term debt $ — $ (72,483 ) $ — $ (473 ) Long-term debt $ (129,290 ) $ (126,030 ) $ 2,474 $ (721 )

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
Financial Instruments and Fair Value Measurements	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements Assets and liabilities are measured at fair value according to a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1. Observable inputs, such as quoted prices in active markets; Level 2. Inputs, other than the quoted price in active markets, that are observable either directly or indirectly; and Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Our assets and liabilities measured at fair value on a recurring basis consist of short-term investments, which are classified in Level 1 and Level 2 of the fair value hierarchy, marketable securities discussed in Note 10 "Investments" , which are classified in Level 1, derivative contracts used to hedge currency and interest rate risk and derivative financial instruments entered into in connection with the Cash Convertible Notes discussed in Note 16 "Lines of Credit and Debt" , which are classified in Level 2 of the fair value hierarchy, and contingent consideration accruals which are classified in Level 3 of the fair value hierarchy, and are shown in the tables below. Non-marketable equity securities remeasured during the year ended December 31, 2019 and 2018 are classified within Level 3 in the fair value hierarchy following the adoption of ASU 2016-01. There were no transfers between levels for the year ended December 31, 2019 . In determining fair value for Level 2 instruments, we apply a market approach, using quoted active market prices relevant to the particular instrument under valuation, giving consideration to the credit risk of both the respective counterparty to the contract and the Company. To determine our credit risk, we estimated our credit rating by benchmarking the price of outstanding debt to publicly-available comparable data from rated companies. Using the estimated rating, our credit risk was quantified by reference to publicly-traded debt with a corresponding rating. The Level 2 derivative financial instruments include the Call Options asset and the embedded conversion option liability. See Note 16 "Lines of Credit and Debt" , and Note 14 "Derivatives and Hedging" , for further information. The derivatives are not actively traded and are valued based on an option pricing model that uses observable market data for inputs. Significant market data inputs used to determine fair values included our common stock price, the risk-free interest rate, and the implied volatility of our common stock. The Call Options asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated. Our Level 3 instruments include non-marketable equity security investments for which we estimate the value based on valuation methods using the observable transaction price at the transaction date and other unobservable inputs. These investments are carried at fair value or under the measurement alternative. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. Our Level 3 instruments also include contingent consideration liabilities. We value contingent consideration liabilities using unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. Contingent consideration arrangements obligate us to pay the sellers of an acquired entity if specified future events occur or conditions are met such as the achievement of technological or revenue milestones. We use various key assumptions, such as the probability of achievement of the milestones ( 0% to 100% ) and the discount rate (between 2.4% and 6.9% ), to represent the non-performing risk factors and time value when applying the income approach. We regularly review the fair value of the contingent consideration, and reflect any change in the accrual in the consolidated statements of income in the line items commensurate with the underlying nature of milestone arrangements. The following table presents our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis: As of December 31, 2019 As of December 31, 2018 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ 129,586 $ — $ 129,586 $ 350 $ 234,256 $ — $ 234,606 Marketable equity securities 870 — — 870 2,117 — — 2,117 Non-marketable equity securities — — 70,849 70,849 — — 59,484 59,484 Call option — 290,971 — 290,971 — 395,095 — 395,095 Foreign exchange contracts — 6,689 — 6,689 — 2,673 — 2,673 Embedded conversion option — — — — — 349 — 349 Interest rate contracts — 2,474 — 2,474 — — — — $ 870 $ 429,720 $ 70,849 $ 501,439 $ 2,467 $ 632,373 $ 59,484 $ 694,324 Liabilities: Foreign exchange contracts $ — $ (1,814 ) $ — $ (1,814 ) $ — $ (5,957 ) $ — $ (5,957 ) Interest rate contracts — (6,027 ) — (6,027 ) — (18,768 ) — (18,768 ) Cash conversion option — (292,263 ) — (292,263 ) — (399,262 ) — (399,262 ) Contingent consideration — — (162,160 ) (162,160 ) — — (48,971 ) (48,971 ) $ — $ (300,104 ) $ (162,160 ) $ (462,264 ) $ — $ (423,987 ) $ (48,971 ) $ (472,958 ) Refer to Note 10 "Investments" for the change in non-marketable equity securities with Level 3 inputs during the year ended December 31, 2019 . For contingent consideration liabilities with Level 3 inputs, the following table summarizes the activity for the years ended December 31, 2019 and 2018 : (in thousands) 2019 2018 Balance at beginning of year $ (48,971 ) $ (11,539 ) Additions from acquisitions (132,422 ) (53,962 ) Payments 11,800 16,530 Gain included in earnings 7,433 — Balance at end of year $ (162,160 ) $ (48,971 ) As of December 31, 2019 , of the total $162.2 million accrued for contingent consideration, $142.6 million is included in accrued and other current liabilities and $19.6 million is included in other long-term liabilities in the accompanying consolidated balance sheet. For the year ended December 31, 2019 the gain for the reduction in the fair value of contingent consideration related to unmet milestones of $7.4 million was recognized in restructuring, acquisition, integration and other, net in the accompanying consolidated statements of income. December 31, 2019 , the $132.4 million of additions is primarily related to the asset acquisition of Formulatrix discussed in Note 5 "Acquisitions and Divestitures" . The carrying values of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities, approximate their fair values due to their short-term maturities. The estimated fair value of long-term debt as disclosed in Note 16 "Lines of Credit and Debt" was based on current interest rates for similar types of borrowings. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. There were no fair value differences in the years ended December 31, 2019 and 2018 for nonfinancial assets or liabilities required to be measured at fair value on a nonrecurring basis other than the impairment of non-marketable investments not accounted for under the equity method as discussed in Note 10. The table below presents the carrying values and the estimated fair values of financial instruments not presented in the tables above. As of December 31, 2019 As of December 31, 2018 (in thousands) Carrying Amount Level 1 Level 2 Carrying Amount Level 1 Level 2 Long-term debt including current portion: Cash convertible notes $ 1,046,511 $ 1,296,334 $ — $ 1,439,931 $ 1,794,000 $ — U.S. Private placement 328,984 — 329,157 398,107 — 391,700 German private placement 330,857 — 334,371 336,168 — 337,768 $ 1,706,352 $ 1,296,334 $ 663,528 $ 2,174,206 $ 1,794,000 $ 729,468 The fair values of the financial instruments presented in the tables above were determined as follows: Cash Convertible Notes: Fair value is based on an estimation using available over-the-counter market information on the Cash Convertible Notes due in 2021, 2023 and 2024. U.S. Private Placement: Fair value of the outstanding bonds is based on an estimation using the changes in the U.S. Treasury rates. German Private Placement: Fair value is based on an estimation using changes in the euro swap rates. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. There were no adjustments in the twelve-month periods ended December 31, 2019 and 2018

Lines of Credit and Debt

Lines of Credit and Debt	12 Months Ended
Lines of Credit and Debt	Dec. 31, 2019
Debt Instruments [Abstract]
Lines of Credit and Debt	Lines of Credit and Debt Our credit facilities available and undrawn at December 31, 2019 total €426.6 million (approximately $479.2 million ). This includes a €400.0 million syndicated multi-currency revolving credit facility expiring December 2021 of which no amounts were utilized at December 31, 2019 or at December 31, 2018 , and three other lines of credit amounting to €26.6 million with no expiration date, none of which were utilized as of December 31, 2019 or as of December 31, 2018 . The €400.0 million facility can be utilized in Euro, British pounds sterling, Swiss franc or U.S. dollar and bears interest of 0.4% to 1.2% above three months EURIBOR, or LIBOR in relation to any loan not in euro, and is offered with interest periods of one , two , three or six months . The commitment fee is calculated based on 35% of the applicable margin. In 2019 and 2018 , $1.0 million of commitment fees were paid, respectively. The revolving facility agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on the encumbrance of assets and the maintenance of certain financial ratios. We were in compliance with these covenants at December 31, 2019 . The credit facilities are for general corporate purposes. During 2019, we repaid $506.4 million of long-term debt including $430.0 million for the amount due for the 2019 Cash Convertible Notes, $73.0 million for amounts due for the U.S. Private Placement and $3.4 million for a portion of the 2021 Cash Convertible Notes which was converted during the contingent conversion period as discussed further below. At December 31, 2019 and 2018 , total current long-term debt, net of debt issuance costs of $10.8 million and $14.2 million , respectively, consists of the following: (in thousands) 2019 2018 0.375% Senior Unsecured Cash Convertible Notes due 2019 $ — $ 427,445 0.875% Senior Unsecured Cash Convertible Notes due 2021 285,244 279,492 0.500% Senior Unsecured Cash Convertible Notes due 2023 347,995 335,201 1.000% Senior Unsecured Cash Convertible Notes due 2024 413,272 397,793 3.19% Series A Senior Notes due October 16, 2019 — 72,483 3.75% Series B Senior Notes due October 16, 2022 302,040 298,691 3.90% Series C Senior Notes due October 16, 2024 26,944 26,933 German Private Placement (Schuldschein) 330,857 336,168 Total long-term debt $ 1,706,352 $ 2,174,206 Less current portion 285,244 503,116 Long-term portion $ 1,421,108 $ 1,671,090 Beginning on January 1, 2020 and ending at the close of business on March 31, 2020, the 2021 Notes became convertible pursuant to the indenture as discussed below. The notes are all unsecured obligations that rank pari passu. Interest expense on long-term debt was $68.0 million , $ 61.2 million and $ 43.6 million for the years ended December 31, 2019 , 2018 and 2017 , respectively. Future maturities (stated at the carrying values) of long-term debt as of December 31, 2019 , are as follows: Year ending December 31, (in thousands) 2020 $ 285,244 2021 38,716 2022 471,432 2023 347,995 2024 546,716 thereafter 16,249 $ 1,706,352 Cash Convertible Notes due 2019, 2021, 2023 and 2024 On March 19, 2014 , we issued $730.0 million aggregate principal amount of Cash Convertible Senior Notes in two tranches consisting of $430.0 million due in 2019 ( 2019 Notes) and $300.0 million due in 2021 ( 2021 Notes). The aggregate net proceeds of the 2019 and 2021 Convertible Notes were $680.7 million , after payment of the net cost of the Call Spread Overlay described below and transaction costs. Additionally, we used $372.5 million of the net proceeds to repay other debt. During the first quarter of 2019, $430.0 million was paid at maturity ( 2019 Notes) and $3.4 million of the 2021 Notes was redeemed. On September 13, 2017, we issued $400.0 million aggregate principal amount of Cash Convertible Senior Notes which is due in 2023 ( 2023 Notes). The net proceeds of the 2023 Notes were $365.6 million , after payment of the net cost of the Call Spread Overlay described below and transaction costs paid . On November 13, 2018, we issued $500.0 million aggregate principal amount of Cash Convertible Senior Notes which is due in 2024 (2024 Notes). The net proceeds of the 2024 Notes were $468.9 million , after payment of the net cost of the Call Spread Overlay described below and transaction costs paid through December 31, 2019 . We refer to the 2019 Notes, 2021 Notes 2023 Notes and 2024 Notes, collectively as the “Cash Convertible Notes”. Interest on the Cash Convertible Notes is payable semi-annually in arrears and will mature on the maturity date unless repurchased or converted with their terms prior to such date. The interest rate and corresponding maturity of each Note are summarized in the table below. The Cash Convertible Notes are solely convertible into cash in whole, but not in part, at the option of noteholders under the circumstances described below and during the contingent conversion periods as shown in the table below. Cash Convertible Notes Annual Interest Rate Date of Interest Payments Maturity Date Contingent Conversion Period Conversion Rate per $200,000 Principal Amount 2021 Notes 0.875% March 19 and September 19 March 19, 2021 From April 29, 2014 to September 18, 2020 7,063.1647 2023 Notes 0.500% March 13 and September 13 September 13, 2023 From October 24, 2017 to March 13, 2023 4,829.7279 2024 Notes 1.000% May 13 and November 13 November 13, 2024 From December 24, 2018 to August 2, 2024 4,360.3098 Additionally, conversion may occur at any time following a Contingent Conversion Period through the fifth business day immediately preceding the applicable maturity date. Upon conversion, noteholders will receive an amount in cash equal to the Cash Settlement Amount, calculated as described below. The Cash Convertible Notes are not convertible into shares of our common stock or any other securities. Noteholders may convert of the Cash Convertible Notes into cash at their option at any time during the Contingent Conversion Periods described above only under the following circumstances (Contingent Conversion Conditions): • if the last reported sale price of our common stock for at least 20 -consecutive trading days during a period of 30 -consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • if we undergo certain fundamental changes as defined in the agreement; • during the five -business day period immediately after any 10 consecutive trading day period in which the quoted price for the 2021 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; • if parity event or trading price unavailability event, as the case maybe occurs for the 2023 Notes and 2024 Notes during the period of 10 days , including the first business day following the relevant trading price notification date. • if we elect to distribute assets or property to all or substantially all of the holders of our common stock and those assets or other property have a value of more than 25% of the average daily volume-weighted average trading price of our common stock for the prior 20 consecutive trading days; • if we elect to redeem the Cash Convertible Notes; or • if we experience certain customary events of default, including defaults under certain other indebtedness until such event has been cured or waived or the payment of the Notes have been accelerated. The Contingent Conversion Conditions in the 2021, 2023 and 2024 Notes noted above have been analyzed under ASC 815, Derivatives and Hedging , and, based on our analysis, we determined that each of the embedded features listed above are clearly and closely related to the 2021, 2023 and 2024 Notes (i.e., the host contracts). As a result, pursuant to the accounting provisions of ASC 815, Derivatives and Hedging , these features noted above are not required to be bifurcated as separate instruments. Beginning on January 1, 2020 and ending at the close of business on March 31, 2020, the 2021 Notes became convertible pursuant to the indenture. The 2021 Notes became convertible pursuant to Section 12.01(b)(iv) of the indenture because the arithmetic mean of the last reported sale prices of our common stock, in each trading day in at least one 20 -consecutive trading day period during the 30 -consecutive trading day period ending on the last trading day of the preceding fiscal quarter, was greater than 130% of the conversion price in effect on such last trading day. No Contingent Conversion Conditions were triggered for the 2023 Notes and 2024 Notes as of December 31, 2019 . Upon conversion, holders are entitled to a cash payment (Cash Settlement Amount) equal to the average of the conversion rate multiplied by the daily volume-weighted average trading price for our common stock over a 50 -day period. The conversion rate is subject to adjustment in certain instances but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of certain corporate events that may occur prior to the applicable maturity date, we may be required to pay a cash make-whole premium by increasing the conversion rate for any holder who elects to convert Cash Convertible Notes in connection with the occurrence of such a corporate event. We may redeem the Cash Convertible Notes in their entirety at a price equal to 100% of the principal amount of the applicable Cash Convertible Notes plus accrued interest at any time when 20% or less of the aggregate principal amount of the applicable Cash Convertible Notes originally issued remain outstanding. Because the Cash Convertible Notes contain an embedded cash conversion option, we have determined that the embedded cash conversion option is a derivative financial instrument, which is required to be separated from the Cash Convertible Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of income until the cash conversion option transaction settles or expires. The initial fair value liability of the embedded cash conversion option for the 2019 and 2021 Notes was $51.2 million and $54.0 million , respectively, $74.5 million for the 2023 Notes, and $98.5 million for the 2024 Notes, which simultaneously reduced the carrying value of the Cash Convertible Notes (effectively an original issuance discount). For further discussion of the derivative financial instruments relating to the Cash Convertible Notes, refer to Note 14 "Derivatives and Hedging" . As noted above, the reduced carrying value on the Cash Convertible Notes resulted in a debt discount that is amortized to the principal amount through the recognition of non-cash interest expense using the effective interest method over the expected life of the debt, which is five and seven for the 2019 Notes and 2021 Notes, and six years for the 2023 Notes and 2024 Notes, respectively. This resulted in our recognition of interest expense on the Cash Convertible Notes at an effective rate approximating what we would have incurred had nonconvertible debt with otherwise similar terms been issued. The effective interest rate of the 2019 Notes, 2021 Notes, 2023 Notes and 2024 Notes is 2.937% , 3.809% , 3.997% and 4.782% respectively, which is imputed based on the amortization of the fair value of the embedded cash conversion option over the remaining term of the Cash Convertible Notes. In connection with the issuance of the 2019 and 2021 Cash Convertible Notes, we incurred approximately $13.1 million in transaction costs. We incurred approximately $6.2 million in transaction costs for the 2023 Cash Convertible Notes. For 2024 Cash Convertible Notes, we incurred $5.7 million transaction costs of which $0.2 million was accrued as of December 31, 2019 . Such costs have been allocated to the Cash Convertible Notes and deferred and are being amortized to interest expense over the terms of the Cash Convertible Notes using the effective interest method. Interest expense related to the Cash Convertible Notes was comprised of the following: Year-Ended December 31 (in thousands) 2019 2018 Coupon interest $ 9,954 $ 6,890 Amortization of original issuance discount 36,966 32,114 Amortization of debt issuance costs 3,014 3,485 Total interest expense related to the Cash Convertible Notes $ 49,934 $ 42,489 Cash Convertible Notes Call Spread Overlay Concurrent with the issuance of the Cash Convertible Notes, we entered into privately negotiated hedge transactions (Call Options) with, and issued warrants to purchase shares of our common stock (Warrants) to, certain financial institutions. We refer to the Call Options and Warrants collectively as the “Call Spread Overlay”. The Call Options are intended to offset any cash payments payable by us in excess of the principal amount due upon any conversion of the Cash Convertible Notes. During 2014, we used $105.2 million of the proceeds from the issuance of the 2019 and 2021 Cash Convertible Notes to pay for the Call Options, and simultaneously received $69.4 million from the sale of the Warrants, for a net cash outlay of $35.8 million for the Call Spread Overlay. During 2017, we used $73.7 million of the proceeds from the from the issuance of the 2023 Cash Convertible Notes to pay for the premium for the Call Option, and simultaneously received $45.3 million from the sale of Warrants, for a net cash outlay of $28.3 million for the Call Spread Overlay. Issuance costs incurred in connection with the Warrant and the Call Option were $0.3 million and $0.1 million respectively. In November 2018, we used $97.3 million of the proceeds from the from the issuance of the 2024 Cash Convertible Notes to pay for the premium for the Call Option, and simultaneously received $72.4 million from the sale of Warrants, for a net cash outlay of $24.9 million for the Call Spread Overlay. Issuance costs incurred in connection with the Warrant and the Call Option were $0.5 million and $0.5 million respectively, of which $48.0 thousand was accrued as of December 31, 2019 . The Call Options are derivative financial instruments and are discussed further in Note 14 "Derivatives and Hedging" . The Warrants are equity instruments and are further discussed in Note 18 "Equity" . Aside from the initial payment of a premium of $105.2 million (2019 and 2021 Notes), $73.7 million (2023 Notes), and $97.3 million (2024 Notes) for the Call Option, we will not be required to make any cash payments under the Call Options, and will be entitled to receive an amount of cash, generally equal to the amount by which the market price per share of our common stock exceeds the exercise price of the Call Options during the relevant valuation period. The exercise price under the Call Options is initially equal to the conversion price of the Cash Convertible Notes. During the first quarter of 2019, we received $133.2 million in cash upon the exercise of the call options in connection with the repayment of the 2019 Notes. In the same transaction, we paid $132.7 million for the intrinsic value of the 2019 Notes' embedded cash conversion option. Not all of the 2019 Note holders tendered the required conversion notice, and as a result the net effect of the cash paid and received of $0.5 million was recognized as a gain in other income, net. In connection with the early conversion of a portion of the 2021 Notes during the first quarter of 2019, we received $0.4 million in cash and recorded an other receivable of $0.7 million upon the exercise of the related call options. In the same transaction, we paid $1.1 million for the intrinsic value of the 2021 Notes' embedded cash conversion option. During the second quarter of 2019, we collected the $0.7 million receivable balance and received $0.4 million in cash upon the exercise of additional call options. As a result of these early conversions, we have recognized a $0.4 million gain in other income, net. The Warrants that were issued with our Cash Convertible Notes, could have a dilutive effect to the extent that the price of our common stock exceeds the applicable strike price of the Warrants. For each Warrant that is exercised, we will deliver to the holder a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, plus cash in lieu of any fractional shares. We will not receive any proceeds if the Warrants are exercised. U.S. Private Placement In October 2012 , we completed a private placement through the issuance of new senior unsecured notes at a total amount of $400.0 million with a weighted average interest rate of 3.66% (settled on October 16, 2012 ). The notes were issued in three series: (1) $73.0 million 7 -year term due and paid in 2019 ( 3.19% ); (2) $300.0 million 10 -year term due in 2022 ( 3.75% ); and (3) $27.0 million 12 -year term due in 2024 ( 3.90% ). We paid $2.1 million in debt issuance costs which will be amortized through interest expense using the effective interest method over the lifetime of the notes. The note purchase agreement contains certain financial and non-financial covenants, including but not limited to, restrictions on priority indebtedness and the maintenance of certain financial ratios. We were in compliance with these covenants at December 31, 2019 . Based on an estimation using the changes in the U.S. Treasury rates, the Level 2 fair value of these senior notes as of December 31, 2019 and December 31, 2018 was approximately $329.2 million and $391.7 million , respectively. During 2014, we entered into interest rate swaps, which effectively fixed the fair value of $200.0 million of this debt, which was reduced to $127.0 million following the 2019 $73.0 million repayment. These interest rate swaps qualify for hedge accounting as fair value hedges as described in Note 14 "Derivatives and Hedging" . German Private Placement (Schuldschein) In 2017, we completed a German private placement bond ("Schuldschein") which was issued in several tranches totaling $331.1 million due in various periods through 2027. The Schuldschein consists of U.S. dollar and Euro denominated tranches. The Euro tranches are designated as a foreign currency non-derivative hedging instrument that qualifies as a net investment hedge as described in Note 14 "Derivatives and Hedging" . Based on the spot rate method, the change in the carrying value of the Euro denominated tranches attributed to the net investment hedge as of December 31, 2019 totaled $0.4 million of unrealized loss and is recorded in equity. We paid $1.2 million in debt issuance costs which are being amortized through interest expense over the lifetime of the notes. A summary of the tranches as of December 31, 2019 and December 31, 2018 is as follows: Carrying Value (in thousands) as of Currency Notional Amount Interest Rate Maturity December 31, 2019 December 31, 2018 EUR €11.5 million Fixed 0.4% March 2021 $ 12,905 $ 13,143 EUR €23.0 million Floating EURIBOR + 0.4% March 2021 25,811 26,286 EUR €21.5 million Fixed 0.68% October 2022 24,112 24,561 EUR €64.5 million Floating EURIBOR + 0.5% October 2022 72,335 73,684 USD $45.0 million Floating LIBOR + 1.2% October 2022 44,919 44,891 EUR €25.0 million Floating EURIBOR + 0.5% October 2022 28,026 28,543 EUR €64.0 million Fixed 1.09% June 2024 71,747 73,097 EUR €31.0 million Floating EURIBOR + 0.7% June 2024 34,753 35,406 EUR €14.5 million Fixed 1.61% June 2027 16,249 16,557 $ 330,857 $ 336,168

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes (Loss) income before income taxes for the years ended December 31, 2019 , 2018 and 2017 consisted of: (in thousands) 2019 2018 2017 Pretax income in The Netherlands $ 17,455 $ (1,675 ) $ 42,220 Pretax (loss) income from foreign operations (95,231 ) 227,412 72,155 $ (77,776 ) $ 225,737 $ 114,375 Income tax (benefit) expense for the years ended December 31, 2019 , 2018 and 2017 are as follows: (in thousands) 2019 2018 2017 Current—The Netherlands $ 5,670 $ 5,794 $ 3,430 —Foreign 13,371 52,835 10,375 19,041 58,629 13,805 Deferred—The Netherlands 4,177 2,551 151 —Foreign (59,539 ) (25,823 ) 60,025 (55,362 ) (23,272 ) 60,176 Total income tax (benefit) expense $ (36,321 ) $ 35,357 $ 73,981 The Netherlands statutory income tax rate was 25% for the years ended December 31, 2019 , 2018 and 2017 . Income from foreign subsidiaries is generally taxed at the statutory income tax rates applicable in the respective countries of domicile. The principal items comprising the differences between income taxes computed at The Netherlands statutory rate and our reported income taxes and effective tax rate for the years ended December 31, 2019 , 2018 and 2017 are as follows: 2019 2018 2017 (in thousands) Amount Percent Amount Percent Amount Percent Income taxes at The Netherlands statutory rate $ (19,444 ) 25.0 % $ 56,434 25.0 % $ 28,594 25.0 % Taxation of foreign operations, net (1) (25,720 ) 33.1 (33,994 ) (15.1 ) (38,635 ) (33.8 ) Tax impact from intangible property transfer (21,122 ) 27.2 — — — — Unrecognized tax benefits (2) 10,962 (14.1 ) 13,570 6.0 23,189 20.3 Tax impact from nondeductible items 7,986 (10.3 ) 2,949 1.3 2,645 2.3 Excess tax benefit related to share-based compensation (3,989 ) 5.1 (4,740 ) (2.1 ) (5,237 ) (4.6 ) Government incentives and other deductions (4) (7,516 ) 9.7 (2,892 ) (1.2 ) (6,519 ) (5.7 ) Changes in tax laws and rates (3) 331 (0.4 ) 1,907 0.8 12,958 11.3 Other items, net 1,306 (1.7 ) (1,170 ) (0.5 ) (5,658 ) (4.9 ) Valuation allowance (3) 20,885 (26.9 ) 3,293 1.5 62,644 54.8 Total income tax (benefit) expense $ (36,321 ) 46.7 % $ 35,357 15.7 % $ 73,981 64.7 % ____________________ (1) Our effective tax rate reflects the benefit of our global operations where certain income or loss is taxed at rates higher or lower than The Netherlands’ statutory rate of 25% as well as the benefit of some income being partially exempt from income taxes due to various intercompany operating and financing activities. The most significant tax benefits from these foreign operating and financing activities are attributable to subsidiaries in Germany, Singapore, Switzerland, Ireland, Dubai, and Luxembourg. These foreign tax benefits are due to a combination of favorable tax laws, regulations, rulings, and exemptions in these jurisdictions. (2) During 2019, we reassessed accruals for tax contingencies, primarily related to ongoing income tax audits. (3) The Netherlands' top statutory corporate income tax rate will be reduced to 21.7% from 25% beginning in 2021. Valuation allowance related to U.S. disallowed interest totaled $12.7 million in 2019 and $60.5 million in 2017. (4) Government incentives include favorable tax regulations in the U.S., Spain and the U.K. relating to research and development expense and other government incentives. We conduct business globally and, as a result, file numerous consolidated and separate income tax returns in The Netherlands, Germany, and the U.S. federal jurisdiction, as well as in various other state and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. Tax years in The Netherlands are potentially open back to 2007 for income tax examinations by tax authorities. The German group is open to audit for the tax years starting in 2014 and in 2019, the German tax authority commenced an audit for the 2014 - 2016 tax years. The U.S. consolidated group is subject to federal and most state income tax examinations by tax authorities beginning with the year ending December 31, 2016 through the current period. Our other subsidiaries, with few exceptions, are no longer subject to income tax examinations by tax authorities for years before 2015 . Changes in the amount of unrecognized tax benefits for the years ended December 31, 2019 , 2018 , and 2017 are as follows: (in thousands) 2019 2018 2017 Balance at beginning of year $ 55,780 $ 44,033 $ 18,294 Additions based on tax positions related to the current year 5,770 3,359 12,212 Additions for tax positions of prior years 14,532 11,984 9,933 Decrease for tax position of prior years (9,073 ) — — Decrease related to settlements (7,605 ) — — Decrease due to lapse of statute of limitations (409 ) (1,238 ) — (Decrease) increase from currency translation (993 ) (2,358 ) 3,594 Balance at end of year $ 58,002 $ 55,780 $ 44,033 At December 31, 2019 and 2018 , our net unrecognized tax benefits totaled approximately $58.0 million and $55.8 million , respectively, which, if recognized, would favorably affect our effective tax rate in any future period. It is reasonably possible that approximately $31.4 million of the unrecognized tax benefits may be released or utilized during the next 12 months due to lapse of statute of limitations or settlements with tax authorities; however, various events could cause our current expectations to change in the future. The above unrecognized tax benefits, if ever recognized in the financial statements, would be recorded in the statements of income as part of the income tax expense. Our policy is to recognize interest accrued related to an underpayment of income taxes in interest expense and penalties within income tax expense. For the years ended December 31, 2019 , 2018 and 2017 , we recognized a net expense for interest and penalties of $1.6 million , $1.1 million and $1.5 million , respectively. At December 31, 2019 and 2018 , we have accrued interest of $2.5 million and $4.1 million , respectively, which are not included in the table above. We have recorded net deferred tax assets of $33.1 million at December 31, 2019 and net deferred tax liabilities of $20.5 million at December 31, 2018 , respectively. The components of the net deferred tax asset and liability at December 31, 2019 and 2018 are as follows: 2019 2018 (in thousands) Deferred Tax Asset Deferred Tax Liability Deferred Tax Asset Deferred Tax Liability Net operating loss and tax credit carryforward $ 50,274 $ — $ 27,293 $ — Accrued and other liabilities 17,977 — 15,480 — Inventory 4,726 (1,439 ) 3,978 (1,725 ) Unrealized gain (loss) on investments — (4,973 ) 3,280 (4,855 ) Property, plant and equipment 5,297 (20,332 ) 3,604 (25,448 ) Intangible assets 1,078 (26,294 ) 1,721 (63,990 ) Share-based compensation 13,787 — 17,998 — Disallowed interest carryforwards 73,690 — 60,458 — Convertible notes 7,104 — 8,102 — Other 5,998 (6,174 ) 5,854 (3,614 ) 179,931 (59,212 ) 147,768 (99,632 ) Valuation allowance (87,619 ) — (68,651 ) — $ 92,312 $ (59,212 ) $ 79,117 $ (99,632 ) Net deferred tax assets (liabilities) $ 33,100 $ (20,515 ) At December 31, 2019 , we had $682.5 million in total net operating loss (NOL) carryforwards which included $394.0 million for Germany, $133.8 million for the U.S., $52.4 million for The Netherlands and $102.3 million for other foreign jurisdictions. Of the total $394.0 million NOL in Germany, there is no expiration and expect to be fully utilized in future years. The entire NOL in the U.S. is subject to limitations under Section 382 of the U.S. Internal Revenue Code. The NOLs in the U.S. will expire between 2024 through 2034 . At December 31, 2019 , we have $52.4 million of Netherlands net operating loss carryforwards before valuation allowance, which will expire in the year 2027. Of the total $102.3 million foreign NOL carryforwards, $25.4 million will expire between 2020 and 2028 while the rest of the NOLs can be carried forward indefinitely. At December 31, 2019 , we had $280.0 million of disallowed interest carryforwards which can be carried forward indefinitely. At December 31, 2019 , tax credits total $1.3 million which expire between 2030 and 2039 . For the years ended December 31, 2019 , 2018 and 2017 , the changes in the valuation allowance charged to income tax expense totaled $19.0 million , $0.8 million and $62.3 million , respectively. The valuation allowance relates to disallowed interest carryforwards and net operating loss carryforwards. The Company can only recognize a deferred tax asset to the extent it is "more likely than not" that these assets will be realized. Judgments around realizability depend on the availability and weight of both positive and negative evidence. As of December 31, 2019 , a deferred tax liability has not been recognized for residual income taxes in The Netherlands on the undistributed earnings of the majority of our foreign subsidiaries as these earnings are considered to be either indefinitely reinvested or can be repatriated tax free under the Dutch participation exemption. The indefinitely reinvested earnings retained of our subsidiaries that would be subject to tax if distributed amounted to $699.0 million at December 31, 2019 . Estimating the amount of the unrecognized deferred tax liability on indefinitely reinvested foreign earnings is not practicable. Should the earnings be remitted as dividends, we may be subject to taxes including withholding tax. We have $26.4 million of undistributed earnings that we do not consider indefinitely reinvested and have recorded a deferred tax liability at December 31, 2019 and December 31, 2018 , of $1.5 million and $0.9 million , respectively.

Equity

Equity	12 Months Ended
Equity	Dec. 31, 2019
Equity [Abstract]
Equity	Equity Shares The authorized classes of our shares consist of Common Shares ( 410 million authorized), Preference Shares ( 450 million authorized) and Financing Preference Shares ( 40 million authorized). All classes of shares have a par value of €0.01 . No Financing Preference Shares or Preference Shares have been issued. Like all shareholders' equity accounts, common shares are translated to U.S. dollars at the foreign exchange rates in effect when the shares are issued. Issuance and Conversion of Warrants In connection with the issuance of the Cash Convertible Notes as described in Note 16 "Lines of Credit and Debt" , we issued Warrants as summarized in the table below. The number of warrants and exercise prices are subject to customary adjustments under certain circumstances. The proceeds, net of issuance costs, from the sale of the Warrants are included as additional paid in capital in the accompanying consolidated balance sheets. Cash convertible notes Issued on Number of share warrants (in millions) Exercise price per share Proceeds from issuance of warrants, net of issuance costs (in millions) Warrants expire over a period of 50 trading days beginning on 2019 March 19, 2014 15.2 $32.0560 $40.6 December 27, 2018 2021 March 19, 2014 10.6 $32.0560 $28.3 December 29, 2020 2023 September 13, 2017 9.7 $50.9664 $45.3 June 26, 2023 2024 November 13, 2018 10.9 $52.1639 $72.4 August 27, 2024 The Warrants are exercisable only upon expiration. For each Warrant that is exercised, we will deliver to the holder a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus cash in lieu of any fractional shares. The Warrants could separately have a dilutive effect on shares of our common stock to the extent that the market value per share of our common stock exceeds the applicable exercise price of the Warrants (as measured under the terms of the Warrants). During 2019, 2.1 million common shares were issued in connection with the conversion of the 15.2 million warrants related to the 2019 Notes which resulted in a $31.1 million decrease to additional paid in capital, a $37.7 million decrease in retained earnings, a decrease of 68.8 million in treasury shares and an approximately $4 thousand cash payment for fractional shares. Share Repurchase Programs On May 6, 2019, we announced our sixth share repurchase program of up to $100 million of our common shares. During 2019, no shares were repurchased under this program. On January 31, 2018, we announced our fifth share repurchase program of up to $200 million of our common shares. During 2018, we repurchased 2.9 million QIAGEN shares for $104.7 million (including transaction costs). During 2019, we repurchased 2.0 million QIAGEN shares for $74.5 million (including transaction costs), bringing the total shares repurchased under this program to 4.9 million for $179.1 million (including transaction costs). On April 27, 2016, we announced the launch of our fourth $100 million share repurchase program. During 2017, 1.9 million QIAGEN shares were repurchased for $61.0 million (including transaction costs). The cost of repurchased shares is included in treasury stock and reported as a reduction in total equity when a repurchase occurs. Repurchased shares will be held in treasury in order to satisfy various obligations, which include exchangeable debt instruments, warrants and employee share-based remuneration plans. Synthetic Share Repurchase In August 2016, we announced our plan to return approximately $250.0 million to shareholders through a synthetic share repurchase program that combines a direct capital repayment with a reverse stock split. The synthetic share repurchase was implemented through a series of amendments to our Articles of Association which were approved by our shareholders at an Extraordinary General Meeting (EGM) held on October 26, 2016. The first amendment involved an increase in share capital by an increase in the nominal value per common share from EUR 0.01 to EUR 1.04 and a corresponding reduction in additional paid in capital. The second amendment involved a reduction in stock whereby 27 existing common shares with a nominal value of EUR 1.04 each were consolidated into 26 new common shares with a nominal value of EUR 1.08 each. The third amendment was a reduction of the nominal value per common share from EUR 1.08 to EUR 0.01 . As a result of these amendments, which in substance constitute a synthetic share buyback, $243.9 million was repaid to our shareholders and the outstanding number of common shares was reduced by 8.9 million , or 3.7% . The capital repayment program was completed in January 2017. Expenses incurred related to the capital repayment and share consolidation amounted to $0.5 million and were charged to equity. Accumulated Other Comprehensive Loss The following table is a summary of the components of accumulated other comprehensive loss as of December 31, 2019 and 2018 : (in thousands) 2019 2018 Net unrealized loss on hedging contracts, net of tax $ (2,289 ) $ (15,453 ) Net unrealized loss on pension, net of tax (561 ) (124 ) Foreign currency effects from intercompany long-term investment transactions, net of tax of $9.7 million and $9.3 million in 2019 and 2018, respectively (22,587 ) (21,662 ) Foreign currency translation adjustments (284,182 ) (273,405 ) Accumulated other comprehensive loss $ (309,619 ) $ (310,644 )

Earnings per Common Share

Earnings per Common Share	12 Months Ended
Earnings per Common Share	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings per Common Share We present basic and diluted earnings per share. Basic earnings per share is calculated by dividing the net (loss) income by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that would occur if all “in the money” securities to issue common shares were exercised. Due to the net loss for the year ended December 31, 2019 , stock options and restricted stock units representing approximately 3.9 million weighted-average shares of common stock and warrants representing 1.7 million shares of common stock were excluded from the computation of diluted net loss because the impact would have been antidilutive. The following schedule summarizes the information used to compute earnings per common share: Years ended December 31, (in thousands, except per share data) 2019 2018 2017 Net (loss) income $ (41,455 ) $ 190,380 $ 40,394 Weighted average number of common shares used to compute basic net income per common share 226,777 226,640 228,074 Dilutive effect of stock options and restrictive stock units — 4,613 4,760 Dilutive effect of outstanding warrants — 2,203 175 Weighted average number of common shares used to compute diluted net income per common share 226,777 233,456 233,009 Outstanding options and awards having no dilutive effect, not included in above calculation 107 272 52 Outstanding warrants having no dilutive effect, not included in above calculation 32,938 35,939 30,434 Basic (loss) earnings per common share $ (0.18 ) $ 0.84 $ 0.18 Diluted (loss) earnings per common share $ (0.18 ) $ 0.82 $ 0.17

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Licensing and Purchase Commitments We have licensing agreements with companies, universities and individuals, some of which require certain up-front payments. Royalty payments are required on net product sales ranging from 0.45 percent to 25 percent of covered products or based on quantities sold. Several of these agreements have minimum royalty requirements. The accompanying consolidated balance sheets include accrued royalties relating to these agreements in the amount of $5.5 million at December 31, 2019 and 2018 . Royalty expense relating to these agreements amounted to $13.5 million , $14.0 million , and $16.8 million for the years ended December 31, 2019 , 2018 and 2017 , respectively. Royalty expense is primarily recorded in cost of sales, with a small portion recorded as research and development expense depending on the use of the technology under license. Some of these agreements also have minimum raw material purchase requirements and requirements to perform specific types of research. At December 31, 2019 , we had commitments to purchase goods or services, and for future license and royalty payments. They are as follows: (in thousands) Purchase Commitments License & Royalty Commitments 2020 $ 126,121 $ 11,434 2021 35,915 9,012 2022 26,337 6,507 2023 3,223 4,382 2024 3,000 1,823 Thereafter — 4,297 $ 194,596 $ 37,455 As of December 31, 2019 , future license payments of $10.0 million and $14.5 million are included in accrued and other current liabilities and other long-term liabilities, respectively. Contingent Consideration Commitments Pursuant to the purchase agreements for certain acquisitions and other contractual arrangements, we could be required to make additional contingent cash payments totaling up to $179.4 million based on the achievement of certain revenue and operating results milestones as follows: (in thousands) Contingent Cash Payments 2020 $ 152,750 2021 11,800 2022 5,900 2024 5,900 Anytime 12-month period from now until 2028 3,000 $ 179,350 Of the $179.4 million total contingent obligation as discussed further in Note 15 "Financial Instruments and Fair Value Measurements" , we have assessed the fair value at December 31, 2019 to be $162.2 million , of which $142.6 million is included in accrued and other current liabilities and $19.6 million is included in other long-term liabilities in the accompanying consolidated balance sheet. Employment Agreements Certain of our employment contracts contain provisions which guarantee the payments of certain amounts in the event of a change in control, as defined in the agreements, or if the executive is terminated for reasons other than cause, as defined in the agreements. At December 31, 2019 , the commitment under these agreements totaled $6.2 million . Contingencies In the ordinary course of business, we provide a warranty to customers that our products are free of defects and will conform to published specifications. Generally, the applicable product warranty period is one year from the date of delivery of the product to the customer or of site acceptance, if required. Additionally, we typically provide limited warranties with respect to our services. From time to time, we also make other warranties to customers, including warranties that our products are manufactured in accordance with applicable laws and not in violation of third-party rights. We provide for estimated warranty costs at the time of the product sale. We believe our warranty reserves as of December 31, 2019 and 2018 appropriately reflect the estimated cost of such warranty obligations. The changes in the carrying amount of warranty obligations for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 2,848 $ 3,051 Provision charged to cost of sales 3,229 2,892 Usage (2,921 ) (2,760 ) Adjustments to previously provided warranties, net (1 ) (243 ) Currency translation (14 ) (92 ) Balance at end of year $ 3,141 $ 2,848 Litigation From time to time, we may be party to legal proceedings incidental to our business. As of December 31, 2019 , certain claims, suits or legal proceedings arising out of the normal course of business have been filed or were pending against QIAGEN or our subsidiaries. These matters have arisen in the ordinary course and conduct of business, as well as through acquisition. Although it is not possible to predict the outcome of such litigation, we assess the degree of probability and evaluate the reasonably possible losses that we could incur as a result of these matters. We accrue for any estimated loss when it is probable that a liability has been incurred and the amount of probable loss can be estimated. Litigation accruals recorded in accrued and other current liabilities totaled $0.8 million and $6.0 million as of December 31, 2019 and 2018 , respectively. The estimated amount of a range of possible losses is between $0.3 million and $2.2 million . During the year ended December 31, 2019 , payments of $5.4 million related to previous matters were made. Based on the facts known to QIAGEN and after consultation with legal counsel, management believes that such litigation will not have a material adverse effect on our financial position or results of operations above the amounts accrued. However, the outcome of these matters is ultimately uncertain, thus any settlements or judgments against us in excess of management's expectations could have a material adverse effect on our financial position, results of operations or cash flows. For the year ended December 31, 2017 , we had settlement amounts related to various acquisition-related litigation matters totaling $49.2 million , primarily related to PCR-based biomarker disputes and patent litigation, which were settled during 2017 of which $45.3 million was recorded to restructuring, acquisition, integration and other, net and $3.9 million was recorded as a license right. $44.8 million of the settlement amounts were paid during 2017 and as of December 31, 2017 , $4.4 million was accrued in accrued and other current liabilities.

Segment Information

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2019
Segment Reporting Information, Additional Information [Abstract]
Segment Information	Segment Information We operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting . We have a common basis of organization and our products and services are offered globally. Considering the acquisitions made during 2019 and our continued restructuring and streamlining of the growing organization, our chief operating decision maker (CODM) continues to make decisions with regards to business operations and resource allocation based on evaluations of QIAGEN as a whole. Accordingly, we operate and make decisions as one business segment. Product category and geographic information follows below. Product Category Information Net sales for the product categories are attributed based on those revenues related to sample and assay products and similarly related revenues including bioinformatics solutions, and revenues derived from instrumentation sales. Refer to Note 4 "Revenue" for disaggregation of revenue based on product categories and customer class. Geographical Information Net sales are attributed to countries based on the location of the customer. QIAGEN operates manufacturing facilities in Germany, China, and the United States that supply products to customers as well as QIAGEN subsidiaries in other countries. The intersegment portions of such net sales are excluded to derive consolidated net sales. No single customer represents more than ten percent of consolidated net sales. Our country of domicile is the Netherlands, which reported net sales of $15.8 million , $15.9 million and $15.0 million for the years ended 2019 , 2018 and 2017 , respectively, and these amounts are included in the line item Europe, Middle East and Africa as shown in the table below. (in thousands) 2019 2018 2017 Net Sales Americas: United States $ 663,869 $ 632,660 $ 579,906 Other Americas 58,121 60,359 73,478 Total Americas 721,990 693,019 653,384 Europe, Middle East and Africa 487,476 490,301 462,980 Asia Pacific, Japan and Rest of World 316,958 318,528 301,172 Total $ 1,526,424 $ 1,501,848 $ 1,417,536 Long-lived assets include property, plant and equipment. The Netherlands, which is included in the balances for Europe, reported long-lived assets of $1.3 million and $1.8 million as of December 31, 2019 and 2018 , respectively. (in thousands) 2019 2018 Long-lived assets Americas: United States $ 147,027 $ 152,381 Other Americas 3,507 3,748 Total Americas 150,534 156,129 Europe, Middle East and Africa: Germany 229,225 284,601 Other Europe, Middle East and Africa 49,004 50,051 Total Europe, Middle East and Africa 278,229 334,652 Asia Pacific and Japan 26,480 20,878 Total $ 455,243 $ 511,659

Share-Based Compensation

Share-Based Compensation	12 Months Ended
Share-Based Compensation	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Share-Based Compensation	Share-Based Compensation We adopted the QIAGEN N.V. Amended and Restated 2005 Stock Plan (the 2005 Plan) in 2005 and the QIAGEN N.V. 2014 Stock Plan (the 2014 Plan) in 2014. The 2005 Plan expired by its terms in April 2015 and no further awards will be granted under the 2005 Plan. The plans allow for the granting of stock rights and incentive stock options, as well as non-qualified options, stock grants and stock-based awards, generally with terms of up to 5 or 10 years, subject to earlier termination in certain situations. The vesting and exercisability of certain stock rights will be accelerated in the event of a Change of Control, as defined in the plans. All option grants have been at the market value on the grant date or at a premium above the closing market price on the grant date. We issue Treasury Shares to satisfy option exercises and award releases and had approximately 15.7 million Common Shares reserved and available for issuance under the 2005 and 2014 Plans at December 31, 2019 . Stock Options We have not granted stock options since 2013. A summary of the status of employee stock options as of December 31, 2019 and changes during the year then ended is presented below: All Employee Options Number of Shares (in thousands) Weighted Average Exercise Price Weighted Average Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2019 898 $ 20.04 Exercised (104 ) $ 19.95 Expired (2 ) $ 17.51 Outstanding at December 31, 2019 792 $ 20.06 1.78 $ 10,891 Vested at December 31, 2019 792 $ 20.06 1.78 $ 10,891 Vested and expected to vest at December 31, 2019 792 $ 20.06 1.78 $ 10,891 The total intrinsic value of options exercised during the years ended December 31, 2019 , 2018 and 2017 was $2.0 million , $5.0 million and $3.3 million , respectively. The actual tax benefit for the tax deductions from option exercises totaled $0.5 million , $0.8 million , and $0.7 million during the years ended December 31, 2019 , 2018 and 2017 , respectively. At December 31, 2019 , there was no unrecognized share-based compensation expense related to employee stock option awards. At December 31, 2019 , 2018 and 2017 , 0.8 million , 0.9 million and 1.1 million options were exercisable at a weighted average price of $20.06 , $20.04 and $19.54 per share, respectively. The options outstanding at December 31, 2019 expire in various years through 2023 . Stock Units Stock units represent rights to receive Common Shares at a future date and include restricted stock units which are subject to time-vesting only and performance stock units which include performance conditions in addition to time-vesting. The final number of performance stock units earned is based on the performance achievement which for some grants can reach up to 120% of the granted shares. There is no exercise price and the fair market value at the time of the grant is recognized over the requisite vesting period, generally up to 5 or 10 years. The fair market value is determined based on the number of stock units granted and the market value of our shares on the grant date. Pre-vesting forfeitures were estimated to be approximately 6.2% . At December 31, 2019 , there was $60.1 million remaining in unrecognized compensation cost including estimated forfeitures related to these awards, which is expected to be recognized over a weighted average period of 2.57 years. The weighted average grant date fair value of stock units granted during the years ended December 31, 2019 , 2018 and 2017 was $37.28 , $35.37 and $31.12 , respectively. The total fair value of stock units that vested during the years ended December 31, 2019 , 2018 and 2017 was $123.9 million , $54.3 million and $69.2 million , respectively. A summary of stock units as of December 31, 2019 and changes during the year are presented below: Stock Units Stock Units (in thousands) Weighted Average Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2019 8,343 Granted 1,618 Vested (3,517 ) Forfeited (1,261 ) Outstanding at December 31, 2019 5,183 2.57 $ 175,199 Vested and expected to vest at December 31, 2019 3,972 2.26 $ 134,254 Beginning in 2019, we began net share settlement for the tax withholding upon the vesting of awards. Shares are issued on the vesting dates net of the applicable statutory tax withholding to be paid by us on behalf of our employees. As a result, fewer shares are issued than the number of stock units outstanding. We record a liability for the tax withholding to be paid by us as a reduction to treasury shares. Compensation Expense Share-based compensation expense before taxes for the years ended December 31, 2019 , 2018 and 2017 totaled approximately $65.9 million , $40.1 million and $34.4 million , respectively, as shown in the table below. Compensation Expense (in thousands) 2019 2018 2017 Cost of sales $ 2,493 $ 2,879 $ 2,641 Research and development 5,810 6,457 6,102 Sales and marketing 7,947 9,372 6,820 General and administrative 23,706 21,405 19,614 Restructuring, acquisition, integration and other, net 25,938 — (735 ) Share-based compensation expense 65,894 40,113 34,442 Less: income tax benefit (1) 12,153 8,277 7,407 Net share-based compensation expense $ 53,741 $ 31,836 $ 27,035 (1) Does not include the excess tax benefit realized for the tax deductions of the share-based payment arrangements which totaled $4.0 million , $4.7 million and $5.2 million , respectively, for the years ended December 31, 2019 , 2018 and 2017 . Share-based compensation expense includes amounts related to the restructuring programs discussed in Note 6 "Restructuring and Impairments", including accelerated expense in 2019 and net forfeitures in 2017. No share-based compensation costs were capitalized for the years ended December 31, 2019 , 2018 or 2017 as the amounts were not material.

Employee Benefits

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2019
Retirement Benefits, Description [Abstract]
Employee Benefits	Employee Benefits We maintain various benefit plans, including defined contribution and defined benefit plans. Our U.S. defined contribution plan is qualified under Section 401(k) of the Internal Revenue Code, and covers substantially all U.S. employees. Participants may contribute a portion of their compensation not exceeding a limit set annually by the Internal Revenue Service. This plan includes a provision for us to match a portion of employee contributions. Total expense under the 401(k) plans, including the plans acquired via business acquisitions, was $4.0 million , $4.0 million and $3.6 million for the years ended December 31, 2019 , 2018 and 2017 , respectively. We also have a defined contribution plan which covers certain executives. We make matching contributions up to an established maximum. Matching contributions made to the plan, and expensed, totaled approximately $0.2 million , $0.2 million and $0.3 million in each year ended December 31, 2019 , 2018 and 2017 , respectively. We have five defined benefit, non-contributory retirement or termination plans that cover certain employees in Germany, France, Japan, Italy and the United Arab Emirates. These defined benefit plans provide benefits to covered individuals satisfying certain age and/or service requirements. For certain plans, we calculate the vested benefits to which employees are entitled if they separate immediately. The benefits accrued on a pro-rata basis during the employees’ employment period are based on the individuals’ salaries, adjusted for inflation. The liability under the defined benefit plans was $8.2 million at December 31, 2019 and $7.4 million at December 31, 2018 , and is included as a component of other long-term liabilities on the accompanying consolidated balance sheets.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions From time to time, we have transactions with other companies in which we hold an interest, all of which are individually and in the aggregate immaterial, as summarized in the table below. For the years ended December 31, (in thousands) 2019 2018 2017 Net sales $ 20,002 $ 23,358 $ 3,852 Net sales with related parties primarily reflects our ventures in China including our partnership to externalize the HPV test franchise for cervical cancer screening in China as well as our joint venture with Sichuan Maccura Biotechnology Co., Ltd which was terminated in conjunction with the 2019 restructuring activities discussed further in Note 6 "Restructuring and Impairments" which also details related party restructuring charges. As of December 31, (in thousands) 2019 2018 Accounts receivable $ 7,589 $ 10,109 Prepaid expenses and other current assets $ 13,697 $ 3,873 Other long-term assets $ 16,830 $ 24,300 Accounts payable $ 1,775 $ 4,888 Accrued and other current liabilities $ 15,404 $ 5,488 Prepaid expenses and other current assets include short-term loan receivables and supplier advances from companies with which we have an investment or partnership interest. In connection with the 2019 Restructuring further discussed in Note 6 "Restructuring and Impairments", we entered into a agreement with a non-publicly traded company considered a related party to reduce future purchase commitments to $25.2 million through 2022 . The commitment was reduced by $12.8 million which will be paid in 2020 and is included in accrued and other current liabilities as of December 31, 2019 in the accompanying consolidated balance sheet. During 2018, we purchased a convertible note for $15.0 million from a privately held company. The note is due in December 2021 and bears interest at 8% . In the event the company goes public, the note will convert into common shares in the company ranking pari-passu with existing common shares. As of December 31, 2019 , the principal and accrued interest of this note totals $16.3 million

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II QIAGEN N.V. AND SUBSIDIARIES SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017 (in thousands) Balance at Beginning of Year Provision Charged to Expense Write-Offs Foreign Exchange and Other Balance at End of Year Year Ended December 31, 2017: Allowance for doubtful accounts $ 7,614 $ 3,094 $ (3,233 ) $ 533 $ 8,008 Year Ended December 31, 2018: Allowance for doubtful accounts $ 8,008 $ 4,448 $ (2,827 ) $ (359 ) $ 9,270 Year Ended December 31, 2019: Allowance for doubtful accounts $ 9,270 $ 8,701 $ (5,777 ) $ (79 ) $ 12,115

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and all amounts are presented in U.S. dollars rounded to the nearest thousand, unless otherwise indicated. The consolidated financial statements have been prepared on a historical cost basis, except for derivative financial instruments, contingent consideration and available-for-sale financial instruments that have been measured at fair value. We undertake acquisitions to complement our own internal product development activities. In 2019, we completed three immaterial acquisitions, including the January 2019 acquisition of N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data located in Concord, Massachusetts. On April 27, 2018, we acquired all shares in STAT-Dx Life, S.L. (STAT-Dx), a privately-held company located in Barcelona, Spain and on April 19, 2018, we acquired all remaining shares of a privately held entity in which we held a minority interest. On January 6, 2017, we acquired OmicSoft Corporation, located in Cary, North Carolina (U.S.). Accordingly, at their respective acquisition dates, all the assets acquired and liabilities assumed were recorded at their respective fair values and our consolidated results of operations include the operating results from the acquired companies from the acquisition dates.
Reclassifications	Certain prior year amounts have been reclassified to conform to the current year presentation. Beginning in 2019 in the Consolidated Statements of (Loss) Income, the line item "Acquisition-related intangible amortization" in cost of sales is presented separately. Previously, these amounts were presented together in one line in cost of sales. Additionally beginning in 2019, "Restructuring, acquisition, integration and other, net" and "Long-lived asset impairments" within operating expenses are presented separately. Previously, these amounts were presented together with general and administrative expenses in one line as "General and administrative, restructuring, integration and other, net." These reclassifications had no effect on (loss) income from operations.
Adoption of New Accounting Standards and New Accounting Standards Not Yet Adopted	Adoption of New Accounting Standards in 2019 The FASB issued guidance codified in Accounting Standards Codification (ASC) Topic 842, Leases (Topic 842), which supersedes the lease requirements in ASC Topic 840 and aims to increase transparency and comparability among organizations and requires disclosure of key information about leasing arrangements. The main principle of ASC 842 requires lessees to recognize the assets and liabilities that arise from nearly all leases on the consolidated balance sheet. Lessor accounting remains mainly consistent with the former guidance, with the majority of changes allowing for better alignment with the new lessee model and ASC Topic 606. We adopted these standards as per the effective date of January 1, 2019, using the modified retrospective approach and did not restate comparative periods. Under this approach, the cumulative effect of initially applying the standard was recognized as an adjustment to the opening balance of retained earnings on the date of initial application. As a lessee, the classification of our leases did not change, but we recognized a lease liability and corresponding right-of-use asset on our consolidated balance sheets for all our operating leases. We have elected the package of practical expedients which allows us to not reassess (1) whether existing contracts contain leases, (2) the lease classification for existing leases, and (3) whether existing initial direct costs meet the new definition. We also elected the hindsight practical expedient which permits entities to use hindsight in determining the lease term when transitioning to ASC 842. Our initial lease liabilities and right-of-use assets totaled $57.7 million and $57.4 million , respectively, as recorded in our consolidated balance sheet as of January 1, 2019, primarily relating to leased office space. The difference between the additional lease assets and lease liabilities was recorded as a $0.3 million adjustment to retained earnings. Further disclosure is found in Note 12 "Leases" . ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new guidance became effective for public entities beginning on January 1, 2019 by applying a modified retrospective approach to existing hedging relationships as of the adoption date. Under the modified retrospective approach, entities with cash flow or net investment hedges will make (1) a cumulative-effect adjustment to accumulated other comprehensive income so that the adjusted amount represents the cumulative change in the hedging instruments’ fair value since hedge inception (less any amounts that should have been recognized in earnings under the new accounting model) and (2) a corresponding adjustment to opening retained earnings as of the most recent period presented on the date of adoption. We adopted ASU 2017-12 on January 1, 2019 without any cumulative effect. ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , removes Step 2 of the goodwill impairment test. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for public entities for annual periods beginning January 1, 2020 and early adoption is permitted. The new guidance is required to be applied on a prospective basis. We adopted ASU 2017-04 on January 1, 2019 and applied the new guidance prospectively as required. ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework, provides guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements . ASU 2018-13 is effective for public entities for annual periods beginning January 1, 2020. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We adopted ASU 2018-13 on January 1, 2019 and applied the entire standard to disclosures as required beginning in 2019. ASU 2018-15, Intangibles--Goodwill and Other--Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, provides guidance on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor, i.e. a service contract. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for public entities for annual periods beginning January 1, 2020, and early adoption is permitted and should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted ASU 2018-15 on January 1, 2019 and applied the guidance to all implementation costs prospectively. ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities, amends how a decision maker or service provider determines whether its fee is a variable interest entity (VIE) when a related party under common control also has an interest in the VIE. We adopted ASU 2018-17 on January 1, 2019, on a prospective basis. Adoption of New Accounting Standards in 2018 ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and additional related accounting standard updates to clarify and provide implementation guidance were adopted with a date of initial application of January 1, 2018. The comparative information for 2017 has not been adjusted and continues to be reported under ASC Topic 605 Revenue Recognition. As a result, we changed our accounting policy for revenue recognition as further discussed in the Notes below. We applied the Topic 606 using the "modified retrospective method" by recognizing the effect of initially applying Topic 606 as an $1.3 million decrease to the opening balance of retained earnings at January 1, 2018, for all contracts not completed at January 1, 2018. ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities as well as an additional clarifying accounting standard update became effective for our financial statements beginning in the first quarter of 2018. This ASU makes targeted improvements to existing U.S. GAAP for both the recognition and measurement of financial assets and financial liabilities. Changes in accounting to our equity investments as a result of this standard are further discussed in Notes below. As required, we adopted using a cumulative-effect adjustment to the balance sheet as of the beginning of 2018 and recorded an adjustment to decrease opening retained earnings at January 1, 2018 by $0.9 million as required for our equity investments recorded at fair value. ASU 2016-05, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments and ASU 2016-18, Statement of Cash Flows (Topic 320): Restricted Cash, addresses classification issues and presentation related to the statement of cash flows and was adopted on January 1, 2018 without any impact from the adoption. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, aims to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. This standard was adopted on a modified retrospective basis resulting in a decrease to opening retained earnings of $16.1 million at January 1, 2018. ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , clarifies and provides a more robust framework to use in determining when a set of assets and activities is a business. We adopted this update beginning January 1, 2018, without impact. ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , clarifies when to account for a change to the terms and conditions of a share-based payment award as a modification. This guidance is effective prospectively and was adopted as of January 1, 2018. ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, permits reclassification of stranded tax effects of the U.S. Tax Cuts and Jobs Act (Tax Act). We adopted this standard as of April 1, 2018 with no impact as we had no stranded tax effects. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, we reclassify the tax effects to the consolidated statement of income (loss) on an item-by-item basis when the pre-tax item in accumulated other comprehensive income (loss) is reclassified to income. ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , aligns most of the accounting for share-based payment awards issued to employees and non-employees. We early adopted this standard as of July 1, 2018, without material impact. Adoption of New Accounting Standards in 2017 ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory , requires in scope inventory to be measured at the lower of cost and net realizable value. We adopted this standard without material impact. ASU 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting , eliminates the requirement to retroactively adopt the equity method of accounting when an investment qualifies for use of the equity method as a result of an increase in the level of ownership or degree of influence. We adopted this standard without impact. ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , simplifies several aspects of accounting for share-based payment transactions, including income tax consequences. We adopted this standard on January 1, 2017 on a prospective basis. New Accounting Standards Not Yet Adopted The following new FASB Accounting Standards Updates, which are not yet adopted as of December 31, 2019 , have been grouped by their required effective dates: First Quarter of 2020 ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in ASU 2016-13 replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The measurement of expected credit losses under Topic 326 is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted for as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with Topic 842 on leases. In addition, Topic 326 made changes to the accounting for available-for-sale debt securities. One such change is to require credit losses to be presented as an allowance rather than as a write-down on available-for-sale debt securities management does not intend to sell or believes is more likely than not they will be required to sell. Topic 326 is effective for us for annual periods beginning on January 1, 2020 and we will adopt using the modified retrospective approach. Under this approach, the cumulative effect of initially applying the standard is recognized as adjustment to the opening balance of retained earnings on the date of initial application. We currently expect a transition adjustment of approximately $14.0 million due primarily to expected credit losses on loans, notes and accounts receivable. ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer of that transaction. The guidance amends ASC 808 to refer to unit-of-account guidance in ASC 606 and requires it to be used only when assessing whether a transaction is in the scope of ASC 606. ASU 2018-18 is effective for us for annual periods beginning on January 1, 2020. Entities are required to apply the amendments retrospectively to the date they initially applied ASC 606. We adopted ASU 2018-18 on January 1, 2020 without any cumulative effect. First Quarter of 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod tax allocations and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating income taxes to members of a consolidated group. ASU 2019-12 is effective for annual periods beginning on January 1, 2021, with earlier adoption permitted. We intend to adopt the ASU on the effective date of January 1, 2021 and are evaluating the potential impact ASU 2019-12 may have on our consolidated financial statements. ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. We intend to adopt the ASU on the effective date of January 1, 2021 and are evaluating the potential impact ASU 2020-01 may have on our consolidated financial statements.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of QIAGEN N.V. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Investments in either common stock or in-substance common stock of companies where we exercise significant influence over the operations but do not have control, and where we are not the primary beneficiary, are accounted for using the equity method. All other investments are accounted for as discussed under "Non-marketable Investments" below. When there is a portion of equity in an acquired subsidiary not attributable, directly or indirectly, to the Company, we record the fair value of the noncontrolling interests at the acquisition date and classify the amounts attributable to noncontrolling interests separately in equity in the consolidated financial statements. Any subsequent changes in the Company's ownership interest while the Company retains its controlling financial interest in its subsidiary are accounted for as equity transactions.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentrations of Risk	Concentrations of Risk We buy materials for products from many suppliers, and are not dependent on any one supplier or group of suppliers for the business as a whole. However, key components of certain products, including certain instrumentation components and chemicals, are available only from a single source. If supplies from these vendors were delayed or interrupted for any reason, we may not be able to obtain these materials timely or in sufficient quantities in order to produce certain products and sales levels could be negatively affected. Additionally, our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories. Fluctuations in the research and development budgets of these researchers and their organizations for applications in which our products are used could have a significant effect on the demand for our products. The financial instruments used in managing our foreign currency, equity and interest rate exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated international financial institutions. The carrying values of our financial instruments incorporate the non-performance risk by using market pricing for credit risk. However, we have no reason to believe that any counterparties will default on their obligations. In order to minimize our exposure with any single counterparty, we have entered into master agreements which allow us to manage the exposure with the respective counterparty on a net basis. Other financial instruments that potentially subject us to concentrations of credit risk are cash and cash equivalents, short-term investments, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and short-term investments by dealing with highly-rated financial institutions and investing in a broad and diverse range of financial instruments. We have established guidelines related to credit quality and maturities of investments intended to maintain safety and liquidity. Concentration of credit risk with respect to accounts receivable is limited due to a large and diverse customer base, which is dispersed over different geographic areas. Allowances are maintained for potential credit losses and such losses have historically been within expected ranges.
Foreign Currency Translation	Foreign Currency Translation
Segment Information	Segment Information We determined that we operate as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting . Our chief operating decision maker (CODM) makes decisions based on the Company as a whole. In addition, we have a common basis of organization and types of products and services which derive revenues and consistent product margins. Accordingly, we operate and make decisions as one reporting unit.
Warranty	Warranty We provide warranties on our products against defects in materials and workmanship for a period of 1 year. A provision for estimated future warranty costs is recorded in cost of sales at the time product revenue is recognized. Product warranty obligations are included in accrued and other current liabilities in the accompanying consolidated balance sheets.
Research and Development	Research and Development Research and product development costs are expensed as incurred. Research and development expenses consist primarily of salaries and related expenses, facility costs, and amounts paid to contract research organizations and laboratories for the provision of services and materials as well as costs for internal use or clinical trials.
Government Grants	Government Grants We recognize government grants when there is reasonable assurance that all conditions will be complied with and the grant will be received. Our government grants generally represent subsidies for specified activities and are therefore recognized when earned as a reduction of the expenses recorded for the activity that the grants are intended to compensate. Thus, when the grant relates to research and development expense, the grant is recognized over the same period that the related costs are incurred. Otherwise, amounts received under government grants are recorded as liabilities in the balance sheet. When the grant relates to an asset, the nominal amount of the grant is deducted from the carrying amount of the asset and recognized over the same period that the related asset is depreciated.
Borrowing Costs	Borrowing Costs Borrowing costs directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets (qualifying asset) when such borrowing costs are significant. All other borrowing costs are expensed in the period they occur.
Revenue Recognition and Shipping and Handling Income and Costs	Shipping and Handling Income and Costs Revenue Recognition
Advertising Costs	Advertising Costs
General and Administrative, Restructuring, Integration and Other	General and Administrative General and administrative expenses primarily represent the costs required to support administrative infrastructure. These costs include licensing costs in connection with continued investments information technology improvements, including cyber security, across the organization as well as personnel in administrative functions. Restructuring, Acquisition, Integration and Other We incur indirect acquisition and business integration costs in connection with business combinations. These costs represent incremental costs that we believe would not have been incurred absent the business combinations. Major components of these costs include consulting and related fees incurred to integrate or restructure the acquired operations, payroll and related costs for employees remaining with the Company on a transitional basis and public relations, advertising and media costs for re-branding of the combined organization. Restructuring costs include personnel costs (principally termination benefits) as well as contract and other costs, primarily contract termination costs. Termination benefits are accounted for in accordance with FASB ASC Topic 712, Compensation - Nonretirement Postemployment Benefits, and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits, the similarity of benefits under the current plan and prior plans, and the existence of statutory required minimum benefits. Contract and other costs are accounted for in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations
Income Taxes	Income Taxes We account for income taxes under the liability method. Under this method, total income tax expense is the amount of income taxes expected to be payable for the current year plus the change from the beginning of the year for deferred income tax assets and liabilities established for the expected further tax consequences resulting from differences in the financial statement carrying amount and the tax basis of assets and liabilities. Deferred tax assets and/or liabilities are determined by multiplying the differences between the financial statement carrying amount and the tax reporting bases for assets and liabilities by the enacted tax rates expected to be in effect when such differences are recovered or settled. Deferred tax assets are reduced by a valuation allowance to the amount more likely than not to be realized. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Tax benefits are initially recognized in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement with the taxing authority using the cumulative probability method, assuming the tax authority has full knowledge of the position and all relevant facts. Our policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties within the income tax expense.
Derivative Instruments	Derivative Instruments We enter into derivative financial instrument contracts to minimize the variability of cash flows or income statement impact associated with the anticipated transactions being hedged or to hedge fluctuating interest rates. As changes in foreign currency or interest rate impact the value of anticipated transactions, the fair value of the forward or swap contracts also changes, offsetting foreign currency or interest rate fluctuations. Derivative instruments are recorded on the balance sheet at fair value. Changes in fair value of derivatives are recorded in current earnings or other comprehensive income, depending on whether a derivative is designated as part of a hedge transaction.
Share-Based Payments	Share-Based Payments Compensation cost for all share-based payments is recorded based on the grant date fair value, less an estimate for pre-vesting forfeitures, recognized in expense over the service period using an accelerated method. Forfeiture Rate— This is the estimated percentage of grants that are expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimated the forfeiture rate based on historical forfeiture experience. Restricted Stock Units and Performance Stock Units: Restricted stock units and performance stock units represent rights to receive Common Shares at a future date. The fair market value of restricted and performance stock units is determined based on the number of stock units granted and the fair market value of our shares on the grant date. The fair market value at the time of the grant, less an estimate for pre-vesting forfeitures, is recognized in expense over the vesting period. At each reporting period, the estimated performance achievement of the performance stock units is assessed and any change in the estimated achievement is recorded on a cumulative basis in the period of adjustment.
Cash and Cash Equivalents	Cash and Cash Equivalents
Restricted Cash	Restricted Cash
Short Term Investments	Short-Term Investments Short-term investments are classified as “available for sale” and stated at fair value, which is equivalent to the amortized cost, in the accompanying balance sheet. Interest income is accrued when earned and changes in fair market values are reflected in other income (expense), net. The amortization of premiums and accretion of discounts to maturity arising from acquisition is included in interest income. A decline in fair value that is judged to be other-than-temporary is accounted for as a realized loss and the write-down is included in the consolidated statements of income. Realized gains and losses, determined on a specific identification basis on the sale of short-term investments, are included in income.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amount of cash and cash equivalents, notes receivable, accounts receivable, accounts payable and accrued liabilities approximate their fair values because of the short maturities of those instruments. The carrying value of our variable rate debt and capital leases approximates their fair values because of the short maturities and/or interest rates which are comparable to those available to us on similar terms. The fair values of the Cash Convertible Notes are based on an estimation using available over-the-counter market information. The fair values of the Private Placement Senior Notes were estimated using the changes in the U.S. Treasury rates and the fair value of the German Private Placement is based on an estimation using changes in the euro swap rates
Accounts Receivable	Accounts Receivable and Allowance for Doubtful Accounts Our accounts receivable are unsecured and we are at risk to the extent such amounts become uncollectible. We continually monitor accounts receivable balances, and provide for an allowance for doubtful accounts at the time collection becomes
Inventories	Inventories
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment, including equipment acquired under capital lease obligations, are stated at cost less accumulated amortization. Capitalized internal-use software costs include only those direct costs associated with the actual development or acquisition of computer software solely to meet internal needs and cloud-based applications to deliver our service and comprise costs associated with the design, coding, installation and testing of the system. Costs associated with preliminary development, such as the evaluation and selection of alternatives, as well as training, maintenance and support are expensed as incurred. Costs for software to be sold, leased or otherwise marketed that are related to the conceptual formulation and design are expensed as incurred. Costs incurred to produce software products and the software components of products to be sold, leased or marketed after technological feasibility is established are capitalized and amortized in accordance with the accounting standards for the costs of software to be sold, leased, or otherwise marketed. All other depreciation is computed using the straight-line method over the estimated useful lives of the assets ( 3 to 40 years). Amortization of leasehold improvements is computed on a straight-line basis over the lesser of the remaining life of the lease or the estimated useful life of the improvement asset. We have a policy of capitalizing expenditures that materially increase assets’ useful lives and charging ordinary maintenance and repairs to operations as incurred. When property or equipment is disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in earnings.
Business Combinations	Business Combinations We include the results of operations of the businesses that we acquire as of the acquisition date. The purchase price of an acquired business is allocated to the individual assets acquired and liabilities assumed based on their fair values at the date of acquisition. Those fair values are determined using income, cost and market approaches, most of which depend upon significant inputs that are not observable in the market, or level 3 measurements. The excess of purchase price over the fair value of identifiable assets acquired and liabilities assumed is recorded as goodwill. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. The purchase price for some business combinations includes consideration that is contingent on the achievement of net sales or earnings targets by the acquired business. Contingent consideration is measured initially and on a recurring basis at fair value. Payments to settle the acquisition-date fair value of contingent consideration are presented as financing activities on the statement of cash flows; any payments in excess of the acquisition-date fair value are presented as operating activities.
Acquired Intangibles and Goodwill	Acquired Intangibles and Goodwill Acquired intangibles with alternative future uses are carried at cost less accumulated amortization and consist of licenses to technology held by third parties and other acquired intangible assets. Amortization is computed over the estimated useful life of the underlying patents, which has historically ranged from 1 to 20 years. Purchased intangible assets acquired in business combinations, other than goodwill, are amortized over their estimated useful lives unless these lives are determined to be indefinite. Intangibles are assessed for recoverability considering the contract life and the period of time over which the intangible will contribute to future cash flow. The unamortized cost of intangible assets, where cash flows are independent and identifiable from other assets, is evaluated periodically and adjusted, if necessary, if events and circumstances indicate that a decline in value below the carrying amount has occurred. Intangible asset impairments recorded during the year ended December 31, 2019 are further discussed in Note 6 "Restructuring" . Amortization expense related to developed technology and patent and license rights which have been acquired in a business combination is included in cost of sales. Amortization of trademarks, customer base and non-compete agreements which have been acquired in a business combination is recorded in operating expense under the caption 'acquisition-related intangible amortization'. Amortization expenses of intangible assets not acquired in a business combination are recorded within either the cost of sales, research and development or sales and marketing line items based on the use of the asset. We dispose the gross carrying amount and accumulated amortization of fully amortized intangible assets from historic business combinations once they are considered fully integrated into our business. The fair value of in-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until completion or abandonment of the related research and development activities. IPR&D is tested for impairment annually or when any event or circumstance indicates that the fair value may be below the carrying value. If and when research and development is complete, the associated asset is amortized over the estimated useful life. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired arising from business combinations. Goodwill is subject to impairment tests annually or earlier if indicators of potential impairment exist, using a fair-value-based approach. We have elected to perform our annual test for indications of impairment as of October 1 st
Investments	Investments We have investments in non-marketable equity securities issued by privately held companies. These investments are included in other long-term assets in the accompanying consolidated balance sheets. Non-marketable investments through which we exercise significant influence but do not have control are accounted for using the equity method. We monitor for changes in circumstances that may require a reassessment of the level of influence. Following the adoption of ASU 2016-01 on January 1, 2018, our non-marketable equity securities not accounted for under the equity method are either carried at fair value or under the measurement alternative. Under the measurement alternative, the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date. Investments are evaluated periodically, or when impairment indicators are noted, to determine if declines in value are other-than-temporary. In making that determination, we consider all available evidence relating to the realizable value of a security. This evidence includes, but is not limited to, the following: • adverse financial conditions of a specific issuer, segment, industry, region or other variables; • the length of time and the extent to which the fair value has been less than cost; and • the financial condition and near-term prospects of the issuer. We consider whether the fair values of any of our non-marketable investments have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If any such decline is considered to be other than temporary (based on various factors, including historical financial results, product development activities and the overall health of the affiliate’s industry), then a write-down of the investment would be recorded in operating expense to its estimated fair value.
Variable Interest Entities	Variable Interest Entities We evaluate at the inception of each arrangement whether we have made an investment in an entity that is considered a variable interest entity (VIE) or if we hold other variable interests in an arrangement that is considered a variable interest entity (VIE). We consolidate VIEs when we are the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE; and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is still a VIE and, if so, whether we are the primary beneficiary. If we are not the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE as an investment in a non-marketable investment or in accordance with other applicable GAAP.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable. We consider, amongst other indicators, a history of operating losses or a change in expected sales levels to be indicators of potential impairment. Assets are grouped and evaluated for impairment at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other groups of assets. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying amount of the asset exceeds fair value which is determined by applicable market prices, when available. When market prices are not available, we generally measure fair value by discounting projected future cash flows of the asset. Considerable judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could differ from such estimates.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2019
Accounting Policies [Abstract]
Exchange Rates of Key Currencies	The exchange rates of key currencies were as follows: Closing rate at December 31, Annual average rate (US$ equivalent for one) 2019 2018 2019 2018 2017 Euro (EUR) 1.1234 1.1450 1.1196 1.1813 1.1292 Pound Sterling (GBP) 1.3204 1.2800 1.2768 1.3356 1.2882 Swiss Franc (CHF) 1.0350 1.0161 1.0062 1.0228 1.0156 Australian Dollar (AUD) 0.7023 0.7059 0.6954 0.7478 0.7666 Canadian Dollar (CAD) 0.7696 0.7337 0.7535 0.7719 0.7710 Japanese Yen (JPY) 0.0092 0.0091 0.0092 0.0091 0.0089 Chinese Yuan (CNY) 0.1437 0.1454 0.1448 0.1514 0.1480
Cash and Cash Equivalents	(in thousands) 2019 2018 Cash at bank and on hand $ 189,569 $ 208,083 Short-term bank deposits 434,078 950,996 Cash and Cash Equivalents $ 623,647 $ 1,159,079
Inventories	Inventories consisted of the following as of December 31, 2019 and 2018 : (in thousands) 2019 2018 Raw materials $ 26,077 $ 25,819 Work in process 45,729 38,659 Finished goods 98,898 98,434 Total inventories, net $ 170,704 $ 162,912

Revenue (Tables)

Revenue (Tables)	12 Months Ended
Revenue (Tables)	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue based on Product Categories and Customer Class	We disaggregate our revenue based on product categories and customer class as shown in the tables below for the years ended December 31, 2019 , 2018 and 2017 : 2019 (in thousands) Consumables and related Instruments Total Molecular Diagnostics $ 665,866 $ 71,266 $ 737,132 Life Sciences 688,281 101,011 789,292 Academia / Applied Testing 418,518 69,114 487,632 Pharma 269,763 31,897 301,660 Total $ 1,354,147 $ 172,277 $ 1,526,424 2018 (in thousands) Consumables and related Instruments Total Molecular Diagnostics $ 649,602 $ 82,197 $ 731,799 Life Sciences 665,857 104,192 770,049 Academia / Applied Testing 407,370 72,131 479,501 Pharma 258,487 32,061 290,548 Total $ 1,315,459 $ 186,389 $ 1,501,848 2017 (in thousands) Consumables and related Instruments Total Molecular Diagnostics $ 605,462 $ 77,702 $ 683,164 Life Sciences 637,253 97,119 734,372 Academia / Applied Testing 392,066 67,477 459,543 Pharma 245,187 29,642 274,829 Total $ 1,242,715 $ 174,821 $ 1,417,536

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	12 Months Ended
Acquisitions and Divestitures (Tables)	Dec. 31, 2019
Asset Acquisitions, Business Combinations And Divestitures [Abstract]
Purchase Price Allocation	The final purchase price allocation differed from the initial preliminary purchase price allocation as follows: (in thousands) Final Preliminary As of April 27, 2018 Difference Purchase Price: Cash consideration $ 148,780 $ 148,780 $ — Fair value of contingent consideration 37,377 36,751 626 $ 186,157 $ 185,531 $ 626 Final Allocation: Cash and cash equivalents $ 7,357 $ 7,357 $ — Prepaid expenses and other current assets 1,432 1,432 — Inventories 1,868 1,868 — Income tax receivables 2,213 2,213 — Accounts payable (1,412 ) (1,412 ) — Accruals and other current liabilities (1,785 ) (560 ) (1,225 ) Fixed and other long-term assets 6,306 6,434 (128 ) Developed technology 31,300 80,100 (48,800 ) In-process research and development 24,300 — 24,300 Goodwill 117,621 97,268 20,353 Deferred tax liability on fair value of identifiable intangible assets acquired (3,043 ) (9,169 ) 6,126 Total $ 186,157 $ 185,531 $ 626

Restructuring and Impairments (

Restructuring and Impairments (Tables)	12 Months Ended
Restructuring and Impairments (Tables)	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Costs Related to the Restructuring Program	Cumulative costs for this program were as follows: (in thousands) Personnel Related Contract and Other Costs Inventory Write-offs & Asset Impairments Total Cost of sales $ — $ — $ 3,039 $ 3,039 Restructuring, acquisition, integration and other, net 6,174 4,583 — 10,757 Total 2017 costs 6,174 4,583 3,039 13,796 Cost of sales 424 1,193 — 1,617 Restructuring, acquisition, integration and other, net 4,207 4,232 1,610 10,049 Total 2018 costs 4,631 5,425 1,610 11,666 Restructuring, acquisition, integration and other, net (1,100 ) — — (1,100 ) Total 2019 releases (1,100 ) — — (1,100 ) Total cumulative costs $ 9,705 $ 10,008 $ 4,649 $ 24,362
Summary of Cash Components of Restructuring Activity	The following table summarizes the cash components of the restructuring activity. (in thousands) Personnel Related Consulting Costs Total Liability at December 31, 2017 $ 6,222 $ 4,585 $ 10,807 Additional costs in 2018 6,468 5,554 12,022 Release of excess accrual (1,837 ) (129 ) (1,966 ) Payments (6,892 ) (7,149 ) (14,041 ) Foreign currency translation adjustment (141 ) (17 ) (158 ) Liability at December 31, 2018 $ 3,820 $ 2,844 $ 6,664 Release of excess accrual (1,100 ) — (1,100 ) Payments (2,269 ) (2,828 ) (5,097 ) Foreign currency translation adjustment (49 ) (16 ) (65 ) Liability at December 31, 2019 $ 402 $ — $ 402 The following is a summary of the charges recorded during the year ended December 31, 2019 . Year ended December 31, 2019 Consolidated Statement of (Loss) Income Classification and Type of Charge (in thousands) Note Total Restructuring, acquisition, integration and other, net Personnel related (of which $2,956 due to related parties) (22) $ 70,578 Contract termination costs (of which $15,676 due to related parties) 42,099 Consulting fees 10,150 Accounts receivable (of which $5,984 due from related parties) 10,825 Inventories 12,336 Prepaid expenses and other assets (of which $12,915 was long-term and $2,270 due from related parties) 17,012 163,000 Long-lived asset impairments Property, plant and equipment (9) 98,472 Intangible assets (11) 40,301 138,773 Other (expense) income, net Equity method investment impairment (10) 4,799 Total $ 306,572 Of the total costs incurred, $60.2 million are accrued as of December 31, 2019 in accrued and other current liabilities in the accompanying consolidated balance sheet as summarized in the following table that includes the cash components of the restructuring activity. (in thousands) Personnel Related Contract Termination Consulting Fees Total Costs incurred in 2019 $ 44,640 $ 42,099 $ 10,150 $ 96,889 Payments (17,272 ) (18,294 ) (2,162 ) (37,728 ) Foreign currency translation adjustment 631 493 (53 ) 1,071 Liability at December 31, 2019 $ 27,999 $ 24,298 $ 7,935 $ 60,232 The following table summarizes the cash components of the restructuring activity. (in thousands) Personnel Related Facility Related Contract and Other Costs Total Liability at December 31, 2017 $ 4,294 $ 1,052 $ 1,066 $ 6,412 Release of excess accrual (343 ) (838 ) (546 ) (1,727 ) Payments (3,648 ) (214 ) (494 ) (4,356 ) Foreign currency translation adjustment (48 ) — (26 ) (74 ) Liability at December 31, 2018 $ 255 $ — $ — $ 255 Release of excess accrual (31 ) — — (31 ) Payments (225 ) — — (225 ) Foreign currency translation adjustment 1 — — 1 Liability at December 31, 2019 $ — $ — $ — $ —

Short-Term Investments (Tables)

Short-Term Investments (Tables)	12 Months Ended
Short-Term Investments (Tables)	Dec. 31, 2019
Short-term Investments [Abstract]
Summary of Short-Term Investments	(in thousands) December 31, 2019 December 31, 2018 Money market deposits $ 87,468 $ 20,000 Commercial paper 22,459 179,219 Loans receivable 19,659 35,037 Total $ 129,586 $ 234,256

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2019
Prepaid Expense and Other Assets [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets are summarized as follows as of December 31, 2019 and 2018 : (in thousands) Note 2019 2018 Prepaid expenses $ 45,409 $ 48,250 Other receivables 37,025 11,127 Value added tax 20,347 24,416 Cash collateral (14) 2,683 25,368 Total prepaid expenses and other current assets $ 105,464 $ 109,161

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Including Equipment Under Capital Lease Obligations	Property, plant and equipment, including equipment acquired under capital lease obligations, are summarized as follows as of December 31, 2019 and 2018 : (in thousands) Estimated useful life 2019 2018 Land — $ 17,684 $ 17,938 Buildings and improvements 5-40 341,032 322,751 Machinery and equipment 3-10 292,294 306,750 Computer software 3-7 301,604 277,006 Furniture and office equipment 3-10 102,901 109,770 Construction in progress — 98,858 80,874 1,154,373 1,115,089 Less: Accumulated depreciation and amortization (699,130 ) (603,430 ) Property, plant and equipment, net $ 455,243 $ 511,659
Asset Impairment Charges	We recorded asset impairment charges as follows below for the years ended December 31, 2019 and 2018 . Year ended December 31, (in thousands) 2019 2018 Machinery and equipment $ 9,177 $ — Computer software 44,649 2,911 Furniture and office equipment 4,030 — Construction in progress 41,870 4,979 Total impairment in property, plant and equipment $ 99,726 $ 7,890

Investments (Tables)

Investments (Tables)	12 Months Ended
Investments (Tables)	Dec. 31, 2019
Investments [Abstract]
Summary of Investments in Marketable Equity Securities with Readily Determinable Fair Values	A summary of our investments in marketable equity securities that have readily determinable fair values that are classified as available-for-sale follows below. These investments are reported at fair value with gains and losses recorded in earnings beginning in January 2018 upon adoption of ASU 2016-01. Prior to adoption, these investments were reported at fair value with unrealized gains and losses recognized in accumulated other comprehensive income on the balance sheet. Accordingly, upon adoption, we recorded a cumulative effect adjustment to decrease opening retained earnings at January 1, 2018 by a net of tax amount of $0.9 million (pre-tax $1.1 million ) for unrealized losses as of the adoption date. (in thousands, except shares held) As of December 31, 2019 HTG Molecular Diagnostics, Inc (HTGM) Oncimmune Holdings plc (Oncimmune) Shares held 833,333 560,416 Cost basis $ 2,000 $ — Fair value $ 585 $ 285 Total cumulative unrealized (loss) gain $ (1,415 ) $ 285 (in thousands, except shares held) As of December 31, 2018 HTGM Curetis N.V. (Curetis) Shares held 833,333 204,000 Cost basis $ 2,000 $ 1,444 Fair value $ 2,117 $ 350 Total cumulative unrealized gain (loss) $ 117 $ (1,094 )
Summary of Equity Method Investments Included in Other Assets	A summary of our non-marketable investments accounted for as equity method investments is as follows: Equity investments as of December 31, Share of income (loss) for the years ended December 31, ($ in thousands) Ownership Percentage 2019 2018 2019 2018 2017 PreAnalytiX GmbH 50.00 % $ 5,452 $ 5,405 $ 3,971 $ 4,062 $ 3,818 Suzhou Fuda Business Management and Consulting Partnership 33.67 % 3,100 3,138 — — — TVM Life Science Ventures III 4.80 % 1,219 — (330 ) — — Apis Assay Technologies Ltd 19.00 % 719 770 (51 ) — — Hombrechtikon Systems Engineering AG 19.00 % (761 ) 378 (1,124 ) (668 ) (346 ) MAQGEN Biotechnology Co., Ltd 40.00 % — 5,154 (383 ) (579 ) (542 ) Biotype Innovation GmbH 0.00 % — — — (123 ) 39 Pyrobett 19.00 % — — — (100 ) 195 $ 9,729 $ 14,845 $ 2,083 $ 2,592 $ 3,164
Changes in Non-Marketable Investments Not Accounted for Under the Equity Method	The changes in these investments which are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 59,484 $ 33,605 Cash investments in equity securities, net 3,619 9,633 Net increases due to observable price changes 7,760 13,104 Conversion of note receivable to equity securities — 11,369 Sale of equity securities — (5,400 ) Full acquisition of equity securities — (2,710 ) Foreign currency translation adjustments (14 ) (117 ) Balance at end of year $ 70,849 $ 59,484

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
Goodwill and Intangible Assets (Tables)	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Intangible Assets	The changes in intangible assets for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 475,043 $ 499,318 Additions 286,159 32,159 Additions from acquisitions 36,458 81,200 Amortization (122,560 ) (118,576 ) Disposals — (4,426 ) Impairments (40,301 ) — Foreign currency translation adjustments (2,365 ) (14,632 ) Balance at end of year $ 632,434 $ 475,043 The changes in goodwill for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 2,108,536 $ 2,012,904 Business combinations 34,807 142,287 Purchase adjustments (236 ) — Disposals (225 ) (5,682 ) Foreign currency translation adjustments (2,379 ) (40,973 ) Balance at end of year $ 2,140,503 $ 2,108,536 The following sets forth the intangible assets by major asset class as of December 31, 2019 and 2018 : 2019 2018 (in thousands) Weighted Average Life (in years) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortized Intangible Assets: Patent and license rights 10.19 $ 320,406 $ (216,554 ) $ 448,220 $ (310,040 ) Developed technology 10.96 766,966 (346,085 ) 770,955 (561,615 ) Customer base, trademarks, and non-compete agreements 11.68 314,638 (213,881 ) 427,512 (323,024 ) 10.95 $ 1,402,010 $ (776,520 ) $ 1,646,687 $ (1,194,679 ) Unamortized Intangible Assets: In-process research and development $ 6,944 $ 23,035 Goodwill 2,140,503 2,108,536 $ 2,147,447 $ 2,131,571
Amortization of Intangibles for the Next Five Years	Amortization of intangibles for the next five years is expected to be approximately: (in thousands) Amortization Years ended December 31: 2020 $ 100,891 2021 $ 92,512 2022 $ 78,454 2023 $ 76,239 2024 $ 71,910

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2019
Leases [Abstract]
Supplemental Balance Sheet and Other Information	Supplemental balance sheet and other information related to leases was as follows: (in thousands, except lease term and discount rate) Location in balance sheet December 31, 2019 Operating lease right-of-use assets Other long-term assets $ 57,305 Current operating lease liabilities Accrued and other current liabilities $ 18,739 Long-term operating lease liabilities Other long-term liabilities $ 39,631 Weighted average remaining lease term - operating leases (in years) 3.71 Weighted average discount rate - operating leases 2.39 %
Components of Lease Expense	The components of lease expense were as follows: Year Ended (in thousands) 2019 Operating lease cost $ 24,378
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: Year Ended (in thousands) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ (26,113 ) Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 24,670
Maturities of Lease Liabilities	Maturities of lease liabilities were as follows: (in thousands) Operating Leases 2020 $ 19,914 2021 16,009 2022 11,885 2023 7,119 2024 3,391 Thereafter 3,202 Total lease payments (1) 61,520 Less imputed interest (3,150 ) Total $ 58,370 (1) Total lease payments exclude payments associated to the lease agreement discussed below that has not yet commenced.

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	12 Months Ended
Accrued and Other Current Liabilities (Tables)	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
Accrued and Other Current Liabilities	Accrued and other current liabilities at December 31, 2019 and 2018 consist of the following: (in thousands) Note 2019 2018 Accrued contingent consideration and milestone payments (15) $ 142,604 $ 27,820 Accrued expenses and other liabilities 93,204 103,449 Payroll and related accruals 66,866 66,871 Restructuring (6) 62,227 6,850 Deferred revenue (4) 48,525 45,358 Operating lease liabilities (12) 18,739 — Accrued royalties (22) 5,481 5,469 Accrued interest on long-term debt (16) 5,257 6,200 Cash collateral (14) 1,400 1,000 Total accrued and other current liabilities $ 444,303 $ 263,017

Derivatives and Hedging (Tables

Derivatives and Hedging (Tables)	12 Months Ended
Derivatives and Hedging (Tables)	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Value Amounts of Derivative Instruments	The following table summarizes the fair value amounts of derivative instruments reported in the consolidated balance sheets as of December 31, 2019 and 2018 : As of December 31, 2019 As of December 31, 2018 (in thousands) Current Asset Long-Term Asset Current Asset Long-Term Asset Assets: Derivative instruments designated as hedges Interest rate contracts - fair value hedge (1) $ — $ 2,474 $ — $ — Total derivative instruments designated as hedges $ — $ 2,474 $ — $ — Undesignated derivative instruments Embedded conversion option $ — $ — $ — $ 349 Call options 101,179 189,792 100,081 295,014 Foreign exchange contracts 6,689 — 2,673 — Total undesignated derivative instruments $ 107,868 $ 189,792 $ 102,754 $ 295,363 Total Derivative Assets $ 107,868 $ 192,266 $ 102,754 $ 295,363 As of December 31, 2019 As of December 31, 2018 (in thousands) Current Liability Long-Term Liability Current Liability Long-Term Liability Liabilities: Derivative instruments designated as hedges Interest rate contracts - cash flow hedge (1) $ — $ (6,027 ) $ — $ (17,574 ) Interest rate contracts - fair value hedge (1) — — (473 ) (721 ) Total derivative instruments designated as hedges $ — $ (6,027 ) $ (473 ) $ (18,295 ) Undesignated derivative instruments Cash convertible notes embedded conversion option $ (101,361 ) $ (190,902 ) $ (100,164 ) $ (299,098 ) Foreign exchange contracts (1,814 ) — (5,957 ) — Total undesignated derivative instruments $ (103,175 ) $ (190,902 ) $ (106,121 ) $ (299,098 ) Total Derivative Liabilities $ (103,175 ) $ (196,929 ) $ (106,594 ) $ (317,393 ) _________________ (1) The fair value amounts for the interest rate contracts do not include accrued interest.
Summary of the Classification of Gains and Losses on Derivative Instruments and Balance Sheet Line Items in Which the Hedged Item is Included	The following tables summarize the gains and losses on derivative instruments for the years ended December 31, 2019 , 2018 and 2017 : Year ended December 31, 2019 2018 2017 (in thousands) Other income (expense), net Other income (expense), net Other income (expense), net Total amounts presented in the Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded $ 432 $ 5,598 $ (4 ) Gains (Losses) on Derivatives in Cash Flow Hedges Interest rate contracts Amount of (loss) gain reclassified from accumulated other comprehensive income $ (3,888 ) $ (9,774 ) $ 26,136 Amounts excluded from effectiveness testing — — — Gains (Losses) on Derivatives in Fair Value Hedges Interest rate contracts Hedged item (3,668 ) 2,051 2,199 Derivatives designated as hedging instruments 3,668 (2,051 ) (2,199 ) Gains (Losses) Derivatives Not Designated as Hedging Instruments Embedded conversion option (349 ) 131 217 Call options (104,125 ) 74,682 37,414 Cash convertible notes embedded cash conversion option 106,998 (76,500 ) (36,741 ) Foreign exchange contracts 1,835 (19,857 ) 11,813 Total gains (losses) $ 471 $ (31,318 ) $ 38,839 The following tables summarizes the balance sheet line items in which the hedged item is included as of December 31, 2019 and 2018 : Carrying Amount of the Hedged Assets (Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities) (in thousands) December 31, December 31, December 31, December 31, Current portion of long-term debt $ — $ (72,483 ) $ — $ (473 ) Long-term debt $ (129,290 ) $ (126,030 ) $ 2,474 $ (721 )

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
Financial Instruments and Fair Value Measurements (Tables)	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on a Recurring Basis	The following table presents our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis: As of December 31, 2019 As of December 31, 2018 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ 129,586 $ — $ 129,586 $ 350 $ 234,256 $ — $ 234,606 Marketable equity securities 870 — — 870 2,117 — — 2,117 Non-marketable equity securities — — 70,849 70,849 — — 59,484 59,484 Call option — 290,971 — 290,971 — 395,095 — 395,095 Foreign exchange contracts — 6,689 — 6,689 — 2,673 — 2,673 Embedded conversion option — — — — — 349 — 349 Interest rate contracts — 2,474 — 2,474 — — — — $ 870 $ 429,720 $ 70,849 $ 501,439 $ 2,467 $ 632,373 $ 59,484 $ 694,324 Liabilities: Foreign exchange contracts $ — $ (1,814 ) $ — $ (1,814 ) $ — $ (5,957 ) $ — $ (5,957 ) Interest rate contracts — (6,027 ) — (6,027 ) — (18,768 ) — (18,768 ) Cash conversion option — (292,263 ) — (292,263 ) — (399,262 ) — (399,262 ) Contingent consideration — — (162,160 ) (162,160 ) — — (48,971 ) (48,971 ) $ — $ (300,104 ) $ (162,160 ) $ (462,264 ) $ — $ (423,987 ) $ (48,971 ) $ (472,958 )
Summary of Activity for Liabilities with Level 3 Inputs	For contingent consideration liabilities with Level 3 inputs, the following table summarizes the activity for the years ended December 31, 2019 and 2018 : (in thousands) 2019 2018 Balance at beginning of year $ (48,971 ) $ (11,539 ) Additions from acquisitions (132,422 ) (53,962 ) Payments 11,800 16,530 Gain included in earnings 7,433 — Balance at end of year $ (162,160 ) $ (48,971 )
Carrying Values and Estimated Fair Values of Long-Term Debt	The table below presents the carrying values and the estimated fair values of financial instruments not presented in the tables above. As of December 31, 2019 As of December 31, 2018 (in thousands) Carrying Amount Level 1 Level 2 Carrying Amount Level 1 Level 2 Long-term debt including current portion: Cash convertible notes $ 1,046,511 $ 1,296,334 $ — $ 1,439,931 $ 1,794,000 $ — U.S. Private placement 328,984 — 329,157 398,107 — 391,700 German private placement 330,857 — 334,371 336,168 — 337,768 $ 1,706,352 $ 1,296,334 $ 663,528 $ 2,174,206 $ 1,794,000 $ 729,468

Lines of Credit and Debt (Table

Lines of Credit and Debt (Tables)	12 Months Ended
Lines of Credit and Debt (Tables)	Dec. 31, 2019
Debt Instruments [Abstract]
Total Long-Term Debt, Net of Debt Issuance Costs	At December 31, 2019 and 2018 , total current long-term debt, net of debt issuance costs of $10.8 million and $14.2 million , respectively, consists of the following: (in thousands) 2019 2018 0.375% Senior Unsecured Cash Convertible Notes due 2019 $ — $ 427,445 0.875% Senior Unsecured Cash Convertible Notes due 2021 285,244 279,492 0.500% Senior Unsecured Cash Convertible Notes due 2023 347,995 335,201 1.000% Senior Unsecured Cash Convertible Notes due 2024 413,272 397,793 3.19% Series A Senior Notes due October 16, 2019 — 72,483 3.75% Series B Senior Notes due October 16, 2022 302,040 298,691 3.90% Series C Senior Notes due October 16, 2024 26,944 26,933 German Private Placement (Schuldschein) 330,857 336,168 Total long-term debt $ 1,706,352 $ 2,174,206 Less current portion 285,244 503,116 Long-term portion $ 1,421,108 $ 1,671,090
Future Maturities of Long-Term Debt	Future maturities (stated at the carrying values) of long-term debt as of December 31, 2019 , are as follows: Year ending December 31, (in thousands) 2020 $ 285,244 2021 38,716 2022 471,432 2023 347,995 2024 546,716 thereafter 16,249 $ 1,706,352
Interest Rate, Corresponding Maturities, and Contingent Conversion Periods of Cash Convertible Notes	The interest rate and corresponding maturity of each Note are summarized in the table below. The Cash Convertible Notes are solely convertible into cash in whole, but not in part, at the option of noteholders under the circumstances described below and during the contingent conversion periods as shown in the table below. Cash Convertible Notes Annual Interest Rate Date of Interest Payments Maturity Date Contingent Conversion Period Conversion Rate per $200,000 Principal Amount 2021 Notes 0.875% March 19 and September 19 March 19, 2021 From April 29, 2014 to September 18, 2020 7,063.1647 2023 Notes 0.500% March 13 and September 13 September 13, 2023 From October 24, 2017 to March 13, 2023 4,829.7279 2024 Notes 1.000% May 13 and November 13 November 13, 2024 From December 24, 2018 to August 2, 2024 4,360.3098
Interest Expense Related to the Cash Convertible Notes	Interest expense related to the Cash Convertible Notes was comprised of the following: Year-Ended December 31 (in thousands) 2019 2018 Coupon interest $ 9,954 $ 6,890 Amortization of original issuance discount 36,966 32,114 Amortization of debt issuance costs 3,014 3,485 Total interest expense related to the Cash Convertible Notes $ 49,934 $ 42,489
Summary of German Private Placement Tranches	A summary of the tranches as of December 31, 2019 and December 31, 2018 is as follows: Carrying Value (in thousands) as of Currency Notional Amount Interest Rate Maturity December 31, 2019 December 31, 2018 EUR €11.5 million Fixed 0.4% March 2021 $ 12,905 $ 13,143 EUR €23.0 million Floating EURIBOR + 0.4% March 2021 25,811 26,286 EUR €21.5 million Fixed 0.68% October 2022 24,112 24,561 EUR €64.5 million Floating EURIBOR + 0.5% October 2022 72,335 73,684 USD $45.0 million Floating LIBOR + 1.2% October 2022 44,919 44,891 EUR €25.0 million Floating EURIBOR + 0.5% October 2022 28,026 28,543 EUR €64.0 million Fixed 1.09% June 2024 71,747 73,097 EUR €31.0 million Floating EURIBOR + 0.7% June 2024 34,753 35,406 EUR €14.5 million Fixed 1.61% June 2027 16,249 16,557 $ 330,857 $ 336,168

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Before Income Taxes	(Loss) income before income taxes for the years ended December 31, 2019 , 2018 and 2017 consisted of: (in thousands) 2019 2018 2017 Pretax income in The Netherlands $ 17,455 $ (1,675 ) $ 42,220 Pretax (loss) income from foreign operations (95,231 ) 227,412 72,155 $ (77,776 ) $ 225,737 $ 114,375
Provision for Income Taxes	Income tax (benefit) expense for the years ended December 31, 2019 , 2018 and 2017 are as follows: (in thousands) 2019 2018 2017 Current—The Netherlands $ 5,670 $ 5,794 $ 3,430 —Foreign 13,371 52,835 10,375 19,041 58,629 13,805 Deferred—The Netherlands 4,177 2,551 151 —Foreign (59,539 ) (25,823 ) 60,025 (55,362 ) (23,272 ) 60,176 Total income tax (benefit) expense $ (36,321 ) $ 35,357 $ 73,981
Difference Between Income Taxes Computed at Statutory Rate and Reported Income Taxes and Effective Tax Rate	The principal items comprising the differences between income taxes computed at The Netherlands statutory rate and our reported income taxes and effective tax rate for the years ended December 31, 2019 , 2018 and 2017 are as follows: 2019 2018 2017 (in thousands) Amount Percent Amount Percent Amount Percent Income taxes at The Netherlands statutory rate $ (19,444 ) 25.0 % $ 56,434 25.0 % $ 28,594 25.0 % Taxation of foreign operations, net (1) (25,720 ) 33.1 (33,994 ) (15.1 ) (38,635 ) (33.8 ) Tax impact from intangible property transfer (21,122 ) 27.2 — — — — Unrecognized tax benefits (2) 10,962 (14.1 ) 13,570 6.0 23,189 20.3 Tax impact from nondeductible items 7,986 (10.3 ) 2,949 1.3 2,645 2.3 Excess tax benefit related to share-based compensation (3,989 ) 5.1 (4,740 ) (2.1 ) (5,237 ) (4.6 ) Government incentives and other deductions (4) (7,516 ) 9.7 (2,892 ) (1.2 ) (6,519 ) (5.7 ) Changes in tax laws and rates (3) 331 (0.4 ) 1,907 0.8 12,958 11.3 Other items, net 1,306 (1.7 ) (1,170 ) (0.5 ) (5,658 ) (4.9 ) Valuation allowance (3) 20,885 (26.9 ) 3,293 1.5 62,644 54.8 Total income tax (benefit) expense $ (36,321 ) 46.7 % $ 35,357 15.7 % $ 73,981 64.7 % ____________________ (1) Our effective tax rate reflects the benefit of our global operations where certain income or loss is taxed at rates higher or lower than The Netherlands’ statutory rate of 25% as well as the benefit of some income being partially exempt from income taxes due to various intercompany operating and financing activities. The most significant tax benefits from these foreign operating and financing activities are attributable to subsidiaries in Germany, Singapore, Switzerland, Ireland, Dubai, and Luxembourg. These foreign tax benefits are due to a combination of favorable tax laws, regulations, rulings, and exemptions in these jurisdictions. (2) During 2019, we reassessed accruals for tax contingencies, primarily related to ongoing income tax audits. (3) The Netherlands' top statutory corporate income tax rate will be reduced to 21.7% from 25% beginning in 2021. Valuation allowance related to U.S. disallowed interest totaled $12.7 million in 2019 and $60.5 million in 2017. (4) Government incentives include favorable tax regulations in the U.S., Spain and the U.K. relating to research and development expense and other government incentives.
Changes in Amounts of Unrecognized Tax Benefits	Changes in the amount of unrecognized tax benefits for the years ended December 31, 2019 , 2018 , and 2017 are as follows: (in thousands) 2019 2018 2017 Balance at beginning of year $ 55,780 $ 44,033 $ 18,294 Additions based on tax positions related to the current year 5,770 3,359 12,212 Additions for tax positions of prior years 14,532 11,984 9,933 Decrease for tax position of prior years (9,073 ) — — Decrease related to settlements (7,605 ) — — Decrease due to lapse of statute of limitations (409 ) (1,238 ) — (Decrease) increase from currency translation (993 ) (2,358 ) 3,594 Balance at end of year $ 58,002 $ 55,780 $ 44,033
Components of Net Deferred Tax Assets and Liabilities	The components of the net deferred tax asset and liability at December 31, 2019 and 2018 are as follows: 2019 2018 (in thousands) Deferred Tax Asset Deferred Tax Liability Deferred Tax Asset Deferred Tax Liability Net operating loss and tax credit carryforward $ 50,274 $ — $ 27,293 $ — Accrued and other liabilities 17,977 — 15,480 — Inventory 4,726 (1,439 ) 3,978 (1,725 ) Unrealized gain (loss) on investments — (4,973 ) 3,280 (4,855 ) Property, plant and equipment 5,297 (20,332 ) 3,604 (25,448 ) Intangible assets 1,078 (26,294 ) 1,721 (63,990 ) Share-based compensation 13,787 — 17,998 — Disallowed interest carryforwards 73,690 — 60,458 — Convertible notes 7,104 — 8,102 — Other 5,998 (6,174 ) 5,854 (3,614 ) 179,931 (59,212 ) 147,768 (99,632 ) Valuation allowance (87,619 ) — (68,651 ) — $ 92,312 $ (59,212 ) $ 79,117 $ (99,632 ) Net deferred tax assets (liabilities) $ 33,100 $ (20,515 )

Equity (Tables)

Equity (Tables)	12 Months Ended
Equity (Tables)	Dec. 31, 2019
Equity [Abstract]
Issuance of Warrants	Cash convertible notes Issued on Number of share warrants (in millions) Exercise price per share Proceeds from issuance of warrants, net of issuance costs (in millions) Warrants expire over a period of 50 trading days beginning on 2019 March 19, 2014 15.2 $32.0560 $40.6 December 27, 2018 2021 March 19, 2014 10.6 $32.0560 $28.3 December 29, 2020 2023 September 13, 2017 9.7 $50.9664 $45.3 June 26, 2023 2024 November 13, 2018 10.9 $52.1639 $72.4 August 27, 2024
Accumulated Other Comprehensive Income (Loss)	The following table is a summary of the components of accumulated other comprehensive loss as of December 31, 2019 and 2018 : (in thousands) 2019 2018 Net unrealized loss on hedging contracts, net of tax $ (2,289 ) $ (15,453 ) Net unrealized loss on pension, net of tax (561 ) (124 ) Foreign currency effects from intercompany long-term investment transactions, net of tax of $9.7 million and $9.3 million in 2019 and 2018, respectively (22,587 ) (21,662 ) Foreign currency translation adjustments (284,182 ) (273,405 ) Accumulated other comprehensive loss $ (309,619 ) $ (310,644 )

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	12 Months Ended
Earnings per Common Share (Tables)	Dec. 31, 2019
Earnings Per Share [Abstract]
Summary of the Computation of Earnings per Common Share	The following schedule summarizes the information used to compute earnings per common share: Years ended December 31, (in thousands, except per share data) 2019 2018 2017 Net (loss) income $ (41,455 ) $ 190,380 $ 40,394 Weighted average number of common shares used to compute basic net income per common share 226,777 226,640 228,074 Dilutive effect of stock options and restrictive stock units — 4,613 4,760 Dilutive effect of outstanding warrants — 2,203 175 Weighted average number of common shares used to compute diluted net income per common share 226,777 233,456 233,009 Outstanding options and awards having no dilutive effect, not included in above calculation 107 272 52 Outstanding warrants having no dilutive effect, not included in above calculation 32,938 35,939 30,434 Basic (loss) earnings per common share $ (0.18 ) $ 0.84 $ 0.18 Diluted (loss) earnings per common share $ (0.18 ) $ 0.82 $ 0.17

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments to Purchase Goods or Services and for Future License and Royalty Payments	At December 31, 2019 , we had commitments to purchase goods or services, and for future license and royalty payments. They are as follows: (in thousands) Purchase Commitments License & Royalty Commitments 2020 $ 126,121 $ 11,434 2021 35,915 9,012 2022 26,337 6,507 2023 3,223 4,382 2024 3,000 1,823 Thereafter — 4,297 $ 194,596 $ 37,455
Contingent Consideration Commitments	Pursuant to the purchase agreements for certain acquisitions and other contractual arrangements, we could be required to make additional contingent cash payments totaling up to $179.4 million based on the achievement of certain revenue and operating results milestones as follows: (in thousands) Contingent Cash Payments 2020 $ 152,750 2021 11,800 2022 5,900 2024 5,900 Anytime 12-month period from now until 2028 3,000 $ 179,350
Changes in the Carrying Amount of Warranty Liability	The changes in the carrying amount of warranty obligations for the years ended December 31, 2019 and 2018 are as follows: (in thousands) 2019 2018 Balance at beginning of year $ 2,848 $ 3,051 Provision charged to cost of sales 3,229 2,892 Usage (2,921 ) (2,760 ) Adjustments to previously provided warranties, net (1 ) (243 ) Currency translation (14 ) (92 ) Balance at end of year $ 3,141 $ 2,848

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
Segment Information (Tables)	Dec. 31, 2019
Segment Reporting Information, Additional Information [Abstract]
Net Sales	Our country of domicile is the Netherlands, which reported net sales of $15.8 million , $15.9 million and $15.0 million for the years ended 2019 , 2018 and 2017 , respectively, and these amounts are included in the line item Europe, Middle East and Africa as shown in the table below. (in thousands) 2019 2018 2017 Net Sales Americas: United States $ 663,869 $ 632,660 $ 579,906 Other Americas 58,121 60,359 73,478 Total Americas 721,990 693,019 653,384 Europe, Middle East and Africa 487,476 490,301 462,980 Asia Pacific, Japan and Rest of World 316,958 318,528 301,172 Total $ 1,526,424 $ 1,501,848 $ 1,417,536
Long-Lived Assets	(in thousands) 2019 2018 Long-lived assets Americas: United States $ 147,027 $ 152,381 Other Americas 3,507 3,748 Total Americas 150,534 156,129 Europe, Middle East and Africa: Germany 229,225 284,601 Other Europe, Middle East and Africa 49,004 50,051 Total Europe, Middle East and Africa 278,229 334,652 Asia Pacific and Japan 26,480 20,878 Total $ 455,243 $ 511,659

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
Share-Based Compensation (Tables)	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Summary of the Status of Employee Stock Options	A summary of the status of employee stock options as of December 31, 2019 and changes during the year then ended is presented below: All Employee Options Number of Shares (in thousands) Weighted Average Exercise Price Weighted Average Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2019 898 $ 20.04 Exercised (104 ) $ 19.95 Expired (2 ) $ 17.51 Outstanding at December 31, 2019 792 $ 20.06 1.78 $ 10,891 Vested at December 31, 2019 792 $ 20.06 1.78 $ 10,891 Vested and expected to vest at December 31, 2019 792 $ 20.06 1.78 $ 10,891
Summary of Stock Units	A summary of stock units as of December 31, 2019 and changes during the year are presented below: Stock Units Stock Units (in thousands) Weighted Average Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2019 8,343 Granted 1,618 Vested (3,517 ) Forfeited (1,261 ) Outstanding at December 31, 2019 5,183 2.57 $ 175,199 Vested and expected to vest at December 31, 2019 3,972 2.26 $ 134,254
Compensation Expense	Share-based compensation expense before taxes for the years ended December 31, 2019 , 2018 and 2017 totaled approximately $65.9 million , $40.1 million and $34.4 million , respectively, as shown in the table below. Compensation Expense (in thousands) 2019 2018 2017 Cost of sales $ 2,493 $ 2,879 $ 2,641 Research and development 5,810 6,457 6,102 Sales and marketing 7,947 9,372 6,820 General and administrative 23,706 21,405 19,614 Restructuring, acquisition, integration and other, net 25,938 — (735 ) Share-based compensation expense 65,894 40,113 34,442 Less: income tax benefit (1) 12,153 8,277 7,407 Net share-based compensation expense $ 53,741 $ 31,836 $ 27,035 (1) Does not include the excess tax benefit realized for the tax deductions of the share-based payment arrangements which totaled $4.0 million , $4.7 million and $5.2 million , respectively, for the years ended December 31, 2019 , 2018 and 2017 .

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2019
Related Party Transactions [Abstract]
Summary of Related Party Transactions	From time to time, we have transactions with other companies in which we hold an interest, all of which are individually and in the aggregate immaterial, as summarized in the table below. For the years ended December 31, (in thousands) 2019 2018 2017 Net sales $ 20,002 $ 23,358 $ 3,852 As of December 31, (in thousands) 2019 2018 Accounts receivable $ 7,589 $ 10,109 Prepaid expenses and other current assets $ 13,697 $ 3,873 Other long-term assets $ 16,830 $ 24,300 Accounts payable $ 1,775 $ 4,888 Accrued and other current liabilities $ 15,404 $ 5,488

Corporate Information and Bas_2

Corporate Information and Basis of Presentation (Details) customer in Millions	12 Months Ended
	Dec. 31, 2019employeecustomerclasscountry
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of customers \| customer	0.5
Number of major customer classes \| class	2,000,000
Number of employees \| employee	5,100
Number of countries with employees in direct subsidiaries (at least)	35
Number of countries products are marketed in (more than)	130

Effects of New Accounting Pro_2

Effects of New Accounting Pronouncements (Details) - USD ($)	Jan. 01, 2020	Dec. 31, 2019	Jan. 01, 2019	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liability		$ 58,370,000
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liability			$ 57,700,000
Operating lease right-of-use assets			57,400,000
Cumulative effect of adoption of new accounting policy			(316,000)
ASU 2016-02 \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy			$ (316,000)
ASU 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy				$ (1,306,000)
ASU 2014-09 \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy				(1,306,000)
ASU 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy				(900,000)
ASU 2016-01 \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy				(942,000)
ASU 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy				(16,096,000)
ASU 2016-16 \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy				$ (16,096,000)
ASU 2016-13 \| Retained Earnings \| Forecast \| Subsequent Event
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adoption of new accounting policy	$ 14,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)segmentreporting_unit	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Significant Accounting Policies [Line Items]
Net gain (loss) on foreign currency transactions	$ (5,700)	$ (12,300)	$ (3,300)
Number of operating segments \| segment	1
Number of reporting units \| reporting_unit	1
Standard product warranty term	1 year
Cost of sales	$ 521,162	500,888	494,975
Advertising costs	8,100	8,100	7,200
Restricted cash	5,743	0
Write-offs of accounts receivable	5,800	2,800	3,200
Provisions for doubtful accounts	$ 8,700	4,400	3,100
Minimum
Significant Accounting Policies [Line Items]
Estimated useful life of assets	3 years
Maximum
Significant Accounting Policies [Line Items]
Estimated useful life of assets	40 years
Patents \| Minimum
Significant Accounting Policies [Line Items]
Estimated useful lives finite intangible assets	1 year
Patents \| Maximum
Significant Accounting Policies [Line Items]
Estimated useful lives finite intangible assets	20 years
Shipping and Handling \| Sales and Marketing Expense
Significant Accounting Policies [Line Items]
Cost of sales	$ 27,900	$ 28,400	$ 28,600

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Exchange Rates of Key Currencies (Details)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Euro (EUR)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	1.1234	1.1450
Annual average rate	1.1196	1.1813	1.1292
Pound Sterling (GBP)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	1.3204	1.2800
Annual average rate	1.2768	1.3356	1.2882
Swiss Franc (CHF)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	1.0350	1.0161
Annual average rate	1.0062	1.0228	1.0156
Australian Dollar (AUD)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.7023	0.7059
Annual average rate	0.6954	0.7478	0.7666
Canadian Dollar (CAD)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.7696	0.7337
Annual average rate	0.7535	0.7719	0.7710
Japanese Yen (JPY)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.0092	0.0091
Annual average rate	0.0092	0.0091	0.0089
Chinese Yuan (CNY)
Schedule of Foreign Currency Exchange Rates [Line Items]
Closing rate	0.1437	0.1454
Annual average rate	0.1448	0.1514	0.1480

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash at bank and on hand	$ 189,569	$ 208,083
Short-term bank deposits	434,078	950,996
Cash and Cash Equivalents	$ 623,647	$ 1,159,079

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Raw materials	$ 26,077	$ 25,819
Work in process	45,729	38,659
Finished goods	98,898	98,434
Total inventories, net	$ 170,704	$ 162,912

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended			36 Months Ended
Revenue - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 1,526,424	$ 1,501,848	$ 1,417,536
Contract assets, current	5,500	6,900		$ 5,500
Contract liabilities	56,200	54,300		56,200
Contract liabilities, current	48,525	45,358		48,525
Revenue recognized related to advance customer payments previously received	48,300	44,500
Accrued and Other Current Liabilities
Disaggregation of Revenue [Line Items]
Contract liabilities, current	48,500	45,300		48,500
Other Long-Term Liabilities
Disaggregation of Revenue [Line Items]
Contract liabilities, noncurrent	7,700	9,000		$ 7,700
Instruments
Disaggregation of Revenue [Line Items]
Revenue	$ 172,277	$ 186,389	$ 174,821
Sales Revenue, Net \| Product Concentration Risk \| Consumable Products \| Minimum
Disaggregation of Revenue [Line Items]
Concentration risk				78.00%
Sales Revenue, Net \| Product Concentration Risk \| Consumable Products \| Maximum
Disaggregation of Revenue [Line Items]
Concentration risk				80.00%
Sales Revenue, Net \| Product Concentration Risk \| Related Revenue \| Minimum
Disaggregation of Revenue [Line Items]
Percentage of net sales				8.00%
Sales Revenue, Net \| Product Concentration Risk \| Related Revenue \| Maximum
Disaggregation of Revenue [Line Items]
Percentage of net sales				10.00%
Sales Revenue, Net \| Product Concentration Risk \| Instruments \| Minimum
Disaggregation of Revenue [Line Items]
Percentage of net sales				11.00%
Sales Revenue, Net \| Product Concentration Risk \| Instruments \| Maximum
Disaggregation of Revenue [Line Items]
Percentage of net sales				12.00%

Revenue - Performance Obligatio

Revenue - Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 $ in Millions	Dec. 31, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Remaining performance obligations	$ 20.4
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected recognition period	12 months
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected recognition period	18 months

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue based on Product Categories and Customer Class (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 1,526,424	$ 1,501,848	$ 1,417,536
Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	1,354,147	1,315,459	1,242,715
Instruments
Disaggregation of Revenue [Line Items]
Revenue	172,277	186,389	174,821
Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenue	737,132	731,799	683,164
Molecular Diagnostics \| Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	665,866	649,602	605,462
Molecular Diagnostics \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	71,266	82,197	77,702
Life Sciences
Disaggregation of Revenue [Line Items]
Revenue	789,292	770,049	734,372
Life Sciences \| Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	688,281	665,857	637,253
Life Sciences \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	101,011	104,192	97,119
Academia / Applied Testing
Disaggregation of Revenue [Line Items]
Revenue	487,632	479,501	459,543
Academia / Applied Testing \| Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	418,518	407,370	392,066
Academia / Applied Testing \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	69,114	72,131	67,477
Pharma
Disaggregation of Revenue [Line Items]
Revenue	301,660	290,548	274,829
Pharma \| Consumables and related
Disaggregation of Revenue [Line Items]
Revenue	269,763	258,487	245,187
Pharma \| Instruments
Disaggregation of Revenue [Line Items]
Revenue	$ 31,897	$ 32,061	$ 29,642

Acquisitions and Divestitures -

Acquisitions and Divestitures - Business Combinations, Narrative (Details) $ in Thousands	Dec. 31, 2019USD ($)	Apr. 27, 2018USD ($)	Jan. 31, 2019USD ($)	Apr. 30, 2018USD ($)	Sep. 30, 2019USD ($)business	Dec. 31, 2019USD ($)project
Business Acquisition [Line Items]
Weighted average amortization period for intangible assets						10 years 11 months 12 days
Number of research and development projects completed in period \| project						1
Expected completion period for remaining technologies within research and development						2 years
Developed Technology
Business Acquisition [Line Items]
Weighted average amortization period for intangible assets						10 years 11 months 15 days
N-of-One, Inc.
Business Acquisition [Line Items]
Cash consideration paid			$ 24,500
Additional Acquisitions
Business Acquisition [Line Items]
Cash consideration paid					$ 43,500
Number of companies acquired \| business					2
STAT-Dx
Business Acquisition [Line Items]
Cash consideration paid	$ 148,780	$ 148,780		$ 148,800
Potential contingent payments				44,300
Fair value of contingent consideration	$ 37,377	$ 36,751		$ 37,400
Direct acquisition costs						$ 2,000
STAT-Dx \| Developed Technology
Business Acquisition [Line Items]
Weighted average amortization period for intangible assets						10 years
STAT-Dx \| Discount Rate \| Minimum
Business Acquisition [Line Items]
Measurement input				0.065
STAT-Dx \| Discount Rate \| Maximum
Business Acquisition [Line Items]
Measurement input				0.069
Other 2018 Acquisition
Business Acquisition [Line Items]
Gain on revaluation in connection with acquisition of remaining minority interest				$ 4,800

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Apr. 27, 2018	Apr. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2017
Purchase Price Allocation
Goodwill	$ 2,140,503			$ 2,140,503	$ 2,108,536	$ 2,140,503	$ 2,012,904
Difference
Goodwill				(236)	$ 0
STAT-Dx
Purchase Price Allocation
Cash consideration	148,780	$ 148,780	$ 148,800
Fair value of contingent consideration	37,377	36,751	$ 37,400
Purchase price	186,157	185,531
Cash and cash equivalents	7,357	7,357		7,357		7,357
Prepaid expenses and other current assets	1,432	1,432		1,432		1,432
Inventory	1,868	1,868		1,868		1,868
Income tax receivables	2,213	2,213		2,213		2,213
Accounts payable	(1,412)	(1,412)		(1,412)		(1,412)
Accruals and other current liabilities	(1,785)	(560)		(1,785)		(1,785)
Fixed and other long-term assets	6,306	6,434		6,306		6,306
Goodwill	117,621	97,268		117,621		117,621
Deferred tax liability on fair value of identifiable intangible assets acquired	(3,043)	(9,169)		(3,043)		(3,043)
Total	186,157	185,531		186,157		186,157
Difference
Cash consideration						0
Fair value of contingent consideration						626
Fair value of contingent consideration						626
Cash and cash equivalents						0
Prepaid expenses and other current assets						0
Inventories						0
Income tax receivables						0
Accounts payable						0
Accruals and other current liabilities						(1,225)
Fixed and other long-term assets						(128)
Goodwill						20,353
Deferred tax liability on fair value of identifiable intangible assets acquired						6,126
Total						626
STAT-Dx \| Developed Technology
Purchase Price Allocation
Intangible assets	31,300	80,100		31,300		31,300
Difference
Intangible assets						(48,800)
STAT-Dx \| In-process research and development
Purchase Price Allocation
Intangible assets	$ 24,300	$ 0		$ 24,300		24,300
Difference
Intangible assets						$ 24,300

Acquisitions and Divestitures_3

Acquisitions and Divestitures - Asset Acquisitions, Narrative (Details) - Formulatrix, Inc. - USD ($) $ in Millions	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Asset Acquisition [Line Items]
Payments for digital PCR asset	$ 125
Present value of future expected payments			$ 134.3
Forecast
Asset Acquisition [Line Items]
Future milestone payments		$ 135.9

Acquisitions and Divestitures_4

Acquisitions and Divestitures - Divestitures, Narrative (Details) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 1,000	$ 16,394	$ 0
Disposed of By Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Portfolio sale price	$ 1,000			€ 15.1	$ 18,500
Proceeds from divestiture		16,400
Gain on divestiture		$ 8,000

Restructuring and Impairments -

Restructuring and Impairments - Summary of Charges Recorded (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring, acquisition, integration and other, net
Personnel related (due to related parties)	$ 2,956,000
Contract termination costs (due to related parties)	15,676,000
Accounts receivable (due from related parties)	5,984,000
Prepaid expenses and other assets (long-term)	12,915,000
Prepaid expenses and other assets (due from related parties)	2,270,000
Long-lived asset impairments
Property, plant and equipment	99,726,000	$ 7,890,000	$ 0
Intangible assets	40,301,000	$ 0
2019 Restructuring
Restructuring, acquisition, integration and other, net
Personnel related (of which $2,956 due to related parties)	70,578,000
Contract termination costs (of which $15,676 due to related parties)	42,099,000
Consulting fees	10,150,000
Accounts receivable (of which $5,984 due from related parties)	10,825,000
Inventories	12,336,000
Prepaid expenses and other assets (of which $12,915 was long-term and $2,270 due from related parties)	17,012,000
Restructuring, acquisition, integration and other, net	163,000,000
Long-lived asset impairments
Property, plant and equipment	98,472,000
Intangible assets	40,301,000
Long-lived asset impairments	138,773,000
Other (expense) income, net
Equity method investment impairment	4,799,000
Total	$ 306,572,000

Restructuring and Impairments_2

Restructuring and Impairments - Narrative (Details) - USD ($)	12 Months Ended			36 Months Ended	48 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring liability	$ 62,227,000	$ 6,850,000		$ 62,227,000	$ 62,227,000
Impairment in property, plant and equipment	99,726,000	7,890,000	$ 0
Intangible asset impairment charges	40,301,000	0
Restructuring costs incurred				24,000,000
Minimum
Restructuring Cost and Reserve [Line Items]
Future pre-tax costs expected to be incurred	15,000,000			15,000,000	15,000,000
Maximum
Restructuring Cost and Reserve [Line Items]
Future pre-tax costs expected to be incurred	23,000,000			23,000,000	23,000,000
2019 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring liability	60,232,000			60,232,000	60,232,000
Impairment in property, plant and equipment	98,472,000
Intangible asset impairment charges	40,301,000
Restructuring, acquisition, integration and other, net	163,000,000
Cash payments for restructuring	37,728,000
Equity method investment impairment	4,799,000
2019 Restructuring \| Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring liability	60,200,000			60,200,000	60,200,000
2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring liability	402,000	6,664,000	10,807,000	402,000	402,000
Restructuring, acquisition, integration and other, net	(1,100,000)	11,666,000	13,796,000	24,362,000
Cash payments for restructuring	5,097,000	14,041,000
Release of excess accrual	1,100,000	1,966,000
2017 Restructuring \| Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring liability	400,000	6,700,000		400,000	400,000
2017 Restructuring \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	(1,100,000)	10,049,000	10,757,000
2017 Restructuring \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		1,617,000	3,039,000
2017 Restructuring \| Inventory Write-offs & Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	1,610,000	3,039,000	4,649,000
2017 Restructuring \| Inventory Write-offs & Asset Impairments \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	1,610,000	0
2017 Restructuring \| Inventory Write-offs & Asset Impairments \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		0	3,039,000
2016 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring liability	0	255,000	6,412,000	$ 0	0
Restructuring costs incurred			19,700,000
Restructuring, acquisition, integration and other, net					$ 97,100,000
Cash payments for restructuring	225,000	4,356,000
Release of excess accrual	$ 31,000	$ 1,727,000
2016 Restructuring \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred			18,300,000
2016 Restructuring \| Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred			$ 1,400,000

Restructuring and Impairments_3

Restructuring and Impairments - Summary of Cash Components of Restructuring Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Restructuring Reserve [Roll Forward]
Beginning balance	$ 6,850
Ending balance	62,227	$ 6,850
2019 Restructuring
Restructuring Reserve [Roll Forward]
Additional costs	96,889
Payments	(37,728)
Foreign currency translation adjustment	1,071
Ending balance	60,232
2019 Restructuring \| Personnel Related
Restructuring Reserve [Roll Forward]
Additional costs	44,640
Payments	(17,272)
Foreign currency translation adjustment	631
Ending balance	27,999
2019 Restructuring \| Contract Termination
Restructuring Reserve [Roll Forward]
Additional costs	42,099
Payments	(18,294)
Foreign currency translation adjustment	493
Ending balance	24,298
2019 Restructuring \| Consulting Fees
Restructuring Reserve [Roll Forward]
Additional costs	10,150
Payments	(2,162)
Foreign currency translation adjustment	(53)
Ending balance	7,935
2017 Restructuring
Restructuring Reserve [Roll Forward]
Beginning balance	6,664	10,807
Additional costs		12,022
Release of excess accrual	1,100	1,966
Payments	(5,097)	(14,041)
Foreign currency translation adjustment	(65)	(158)
Ending balance	402	6,664
2017 Restructuring \| Personnel Related
Restructuring Reserve [Roll Forward]
Beginning balance	3,820	6,222
Additional costs		6,468
Release of excess accrual	1,100	1,837
Payments	(2,269)	(6,892)
Foreign currency translation adjustment	(49)	(141)
Ending balance	402	3,820
2017 Restructuring \| Contract and Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance	2,844	4,585
Additional costs		5,554
Release of excess accrual	0	129
Payments	(2,828)	(7,149)
Foreign currency translation adjustment	(16)	(17)
Ending balance	0	2,844
2016 Restructuring
Restructuring Reserve [Roll Forward]
Beginning balance	255	6,412
Release of excess accrual	31	1,727
Payments	(225)	(4,356)
Foreign currency translation adjustment	1	(74)
Ending balance	0	255
2016 Restructuring \| Personnel Related
Restructuring Reserve [Roll Forward]
Beginning balance	255	4,294
Release of excess accrual	31	343
Payments	(225)	(3,648)
Foreign currency translation adjustment	1	(48)
Ending balance	0	255
2016 Restructuring \| Facility Related
Restructuring Reserve [Roll Forward]
Beginning balance	0	1,052
Release of excess accrual	0	838
Payments	0	(214)
Foreign currency translation adjustment	0	0
Ending balance	0	0
2016 Restructuring \| Contract and Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance	0	1,066
Release of excess accrual	0	546
Payments	0	(494)
Foreign currency translation adjustment	0	(26)
Ending balance	$ 0	$ 0

Restructuring and Impairments_4

Restructuring and Impairments - Costs Related to the Restructuring Program (Details) - USD ($) $ in Thousands	12 Months Ended			36 Months Ended	48 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring	$ 62,227	$ 6,850		$ 62,227	$ 62,227
2019 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring	60,232			60,232	60,232
Restructuring, acquisition, integration and other, net	163,000
2019 Restructuring \| Personnel Related
Restructuring Cost and Reserve [Line Items]
Restructuring	27,999			27,999	27,999
2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring	402	6,664	$ 10,807	402	402
Restructuring, acquisition, integration and other, net	(1,100)	11,666	13,796	24,362
2017 Restructuring \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		1,617	3,039
2017 Restructuring \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	(1,100)	10,049	10,757
2017 Restructuring \| Personnel Related
Restructuring Cost and Reserve [Line Items]
Restructuring	402	3,820	6,222	402	402
Restructuring, acquisition, integration and other, net	(1,100)	4,631	6,174	9,705
2017 Restructuring \| Personnel Related \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		424	0
2017 Restructuring \| Personnel Related \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	(1,100)	4,207	6,174
2017 Restructuring \| Contract and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	5,425	4,583	10,008
2017 Restructuring \| Contract and Other Costs \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		1,193	0
2017 Restructuring \| Contract and Other Costs \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	4,232	4,583
2017 Restructuring \| Inventory Write-offs & Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	1,610	3,039	4,649
2017 Restructuring \| Inventory Write-offs & Asset Impairments \| Cost of sales
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net		0	3,039
2017 Restructuring \| Inventory Write-offs & Asset Impairments \| Restructuring, acquisition, integration and other, net
Restructuring Cost and Reserve [Line Items]
Restructuring, acquisition, integration and other, net	0	1,610	0
2016 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring	0	255	6,412	0	0
Restructuring, acquisition, integration and other, net					97,100
2016 Restructuring \| Personnel Related
Restructuring Cost and Reserve [Line Items]
Restructuring	$ 0	$ 255	$ 4,294	$ 0	$ 0

Short-Term Investments - Narrat

Short-Term Investments - Narrative (Details) $ in Thousands, € in Millions	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2018USD ($)
Investment [Line Items]
Short-term investments		$ 129,586		$ 234,256
USD Denominated
Investment [Line Items]
Short-term investments		$ 65,000		$ 134,100
EUR Denominated
Investment [Line Items]
Short-term investments \| €	€ 57.5		€ 87.5

Short-Term Investments - Summar

Short-Term Investments - Summary of Short-Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule of Investments [Line Items]
Short-term investments	$ 129,586	$ 234,256
Money market deposits
Schedule of Investments [Line Items]
Short-term investments	87,468	20,000
Commercial paper
Schedule of Investments [Line Items]
Short-term investments	22,459	179,219
Loans receivable
Schedule of Investments [Line Items]
Short-term investments	$ 19,659	$ 35,037

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expense and Other Assets [Abstract]
Prepaid expenses	$ 45,409	$ 48,250
Other receivables	37,025	11,127
Value added tax	20,347	24,416
Cash collateral	2,683	25,368
Total prepaid expenses and other current assets	$ 105,464	$ 109,161

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment, Including Equipment Under Capital Lease Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,154,373	$ 1,115,089
Less: Accumulated depreciation and amortization	(699,130)	(603,430)
Property, plant and equipment, net	$ 455,243	511,659
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 17,684	17,938
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 341,032	322,751
Buildings and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Buildings and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 292,294	306,750
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Computer software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 301,604	277,006
Computer software \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Computer software \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 102,901	109,770
Furniture and office equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and office equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 98,858	$ 80,874

Property, Plant and Equipment_2

Property, Plant and Equipment - Asset Impairment Charges (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	$ 99,726,000	$ 7,890,000	$ 0
Machinery and equipment
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	9,177,000	0
Computer software
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	44,649,000	2,911,000
Furniture and office equipment
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	4,030,000	0
Construction in progress
Property, Plant and Equipment [Line Items]
Impairment in property, plant and equipment	$ 41,870,000	$ 4,979,000

Property, Plant and Equipment_3

Property, Plant and Equipment - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	$ 99,726,000	$ 7,890,000	$ 0
Depreciation and amortization	86,000,000	87,900,000	82,500,000
Amortization expense related to computer software costs	18,300,000	17,200,000	13,900,000
Unamortized balance of computer software to be sold, leased or marketed	36,600,000	100,500,000
Long-lived asset impairments	140,031,000	7,987,000	0
Repairs and maintenance expense	10,700,000	12,100,000	$ 12,700,000
Other Identified Impairment
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	1,200,000
Computer Software
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	44,649,000	2,911,000
Long-lived asset impairments		7,900,000
Computer Software to be Sold, Leased or Marketed
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	65,900,000
Strategic Shifts \| Computer Software
Property, Plant and Equipment [Line Items]
Long-lived asset impairments		6,300,000
2019 Restructuring
Property, Plant and Equipment [Line Items]
Long-lived asset impairments	$ 98,472,000
2017 Restructuring \| Computer Software
Property, Plant and Equipment [Line Items]
Long-lived asset impairments		$ 1,600,000

Investments - Summary of Invest

Investments - Summary of Investments in Marketable Equity Securities with Readily Determinable Fair Values (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 30, 2019
HTG Molecular Diagnostics, Inc (HTGM)
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)	833,333
Cost basis	$ 2,000
Fair value	585	$ 2,117
Total cumulative unrealized (loss) gain	$ (1,415)	$ 117
Oncimmune Holdings plc (Oncimmune)
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)	560,416
Cost basis	$ 0
Fair value	285		$ 700
Total cumulative unrealized (loss) gain	285
Curetis N.V. (Curetis)
Debt and Equity Securities, FV-NI [Line Items]
Shares held (in shares)		204,000
Cost basis		$ 1,444
Fair value		350
Total realized gain (loss) during the period	$ (2,100)	(100)
Total cumulative unrealized (loss) gain		$ (1,094)

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended			24 Months Ended
Investments - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Dec. 30, 2019	Jan. 01, 2018
Investment [Line Items]
Carrying value of equity investments	$ 9,729	$ 14,845		$ 9,729
Non-marketable investments	70,849	59,484	$ 33,605	70,849
Investments in equity securities	3,619	9,633
Gain due to observable price changes	7,760	13,104		20,900
Related party note receivable converted	0	11,369
Book value of interest in non-publicly traded company sold		5,400
Proceeds from sale of interest in non-publicly traded company		10,500
Gain on sale of interest in non-publicly traded company	5,100
Impairments to non-marketable investments not accounted for under the equity method			5,100
Other Income (Expense), Net
Investment [Line Items]
Impairment of equity method investment	4,800	6,100
Other Long-Term Assets
Investment [Line Items]
Carrying value of equity investments	10,500			10,500
Other Long-Term Liabilities
Investment [Line Items]
Carrying value of equity investments	(800)			(800)
VIE
Investment [Line Items]
Carrying value of equity investments	1,200	1,100		1,200
Non-marketable investments	41,000	41,000		41,000
VIE \| Other Long-Term Assets
Investment [Line Items]
Carrying value of equity investments	1,900			1,900
VIE \| Other Long-Term Liabilities
Investment [Line Items]
Carrying value of equity investments	$ 800			$ 800
Oncimmune
Investment [Line Items]
Shares received (in shares)	560,416			560,416
Fair value of equity securities	$ 285			$ 285	$ 700
HTGM
Investment [Line Items]
Shares received (in shares)	833,333			833,333
Fair value of equity securities	$ 585	$ 2,117		$ 585
Curetis
Investment [Line Items]
Shares received (in shares)		204,000
Fair value of equity securities		$ 350
Equity method investment, shares sold (in shares)	204,000	116,424
Recognized gain (loss) due to change in fair market value of shares	$ (2,100)	$ (100)
Curetis \| Other Income (Expense), Net
Investment [Line Items]
Recognized gain (loss) on sale of investments	$ 300
TVM Life Science Ventures III
Investment [Line Items]
Ownership percentage	4.80%			4.80%
Carrying value of equity investments	$ 1,219	0		$ 1,219
QIAGEN (Suzhou) Institute of Translation Research Co., Ltd.
Investment [Line Items]
Proceeds from sale of equity-method investee			$ 3,500
NeuMoDx
Investment [Line Items]
Investments in equity securities		9,300
Predetermined price to acquire remaining shares		$ 234,000
ASU 2016-01
Investment [Line Items]
Cumulative effect adjustment						$ 900
Cumulative effect adjustment, pre-tax						$ 1,100

Investments - Summary of Equity

Investments - Summary of Equity Method Investments Included in Other Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Investment [Line Items]
Equity investments	$ 9,729	$ 14,845
Share of income (loss) for the year	$ 2,083	2,592	$ 3,164
PreAnalytiX GmbH
Investment [Line Items]
Ownership percentage	50.00%
Equity investments	$ 5,452	5,405
Share of income (loss) for the year	$ 3,971	4,062	3,818
Suzhou Fuda Business Management and Consulting Partnership
Investment [Line Items]
Ownership percentage	33.67%
Equity investments	$ 3,100	3,138
Share of income (loss) for the year	$ 0	0	0
TVM Life Science Ventures III
Investment [Line Items]
Ownership percentage	4.80%
Equity investments	$ 1,219	0
Share of income (loss) for the year	$ (330)	0	0
Apis Assay Technologies Ltd
Investment [Line Items]
Ownership percentage	19.00%
Equity investments	$ 719	770
Share of income (loss) for the year	$ (51)	0	0
Hombrechtikon Systems Engineering AG
Investment [Line Items]
Ownership percentage	19.00%
Equity investments	$ (761)	378
Share of income (loss) for the year	$ (1,124)	(668)	(346)
MAQGEN Biotechnology Co., Ltd
Investment [Line Items]
Ownership percentage	40.00%
Equity investments	$ 0	5,154
Share of income (loss) for the year	$ (383)	(579)	(542)
Biotype Innovation GmbH
Investment [Line Items]
Ownership percentage	0.00%
Equity investments	$ 0	0
Share of income (loss) for the year	$ 0	(123)	39
Pyrobett
Investment [Line Items]
Ownership percentage	19.00%
Equity investments	$ 0	0
Share of income (loss) for the year	$ 0	$ (100)	$ 195

Investments - Changes in Non-Ma

Investments - Changes in Non-Marketable Investments Not Accounted for Under the Equity Method (Details) - USD ($) $ in Thousands	12 Months Ended		24 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Equity Securities Without Readily Determinable Fair Value [Roll Forward]
Balance at beginning of year	$ 59,484	$ 33,605	$ 33,605
Cash investments in equity securities, net	3,619	9,633
Net increases due to observable price changes	7,760	13,104	20,900
Conversion of note receivable to equity securities	0	11,369
Sale of equity securities	0	(5,400)
Full acquisition of equity securities	0	(2,710)
Foreign currency translation adjustments	(14)	(117)
Balance at end of year	$ 70,849	$ 59,484	$ 70,849

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Intangible Assets by Major Asset Class (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years 11 months 12 days
Gross Carrying Amount	$ 1,402,010	$ 1,646,687
Accumulated Amortization	(776,520)	(1,194,679)
Goodwill	2,140,503	2,108,536	$ 2,012,904
Intangible assets	2,147,447	2,131,571
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 6,944	23,035
Patent and license rights
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years 2 months 8 days
Gross Carrying Amount	$ 320,406	448,220
Accumulated Amortization	$ (216,554)	(310,040)
Developed technology
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years 11 months 15 days
Gross Carrying Amount	$ 766,966	770,955
Accumulated Amortization	$ (346,085)	(561,615)
Customer base, trademarks, and non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	11 years 8 months 4 days
Gross Carrying Amount	$ 314,638	427,512
Accumulated Amortization	$ (213,881)	$ (323,024)

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Changes in Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets [Roll Forward]
Balance at beginning of year	$ 475,043	$ 499,318
Additions	286,159	32,159
Additions from acquisitions	36,458	81,200
Amortization	(122,560)	(118,576)	$ (133,800)
Disposals	0	(4,426)
Impairments	(40,301)	0
Foreign currency translation adjustments	(2,365)	(14,632)
Balance at end of year	632,434	475,043	499,318
Goodwill [Roll Forward]
Balance at beginning of year	2,108,536	2,012,904
Business combinations	34,807	142,287
Purchase adjustments	(236)	0
Disposals	(225)	(5,682)
Foreign currency translation adjustments	(2,379)	(40,973)
Balance at end of year	$ 2,140,503	$ 2,108,536	$ 2,012,904

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	$ 40,301	$ 0
Amortization of intangible assets	122,560	118,576	$ 133,800
Cash paid for purchases of intangible assets	156,934	40,990	$ 34,324
Intangible assets additions	286,159	32,159
Disposals of goodwill	225	5,682
Other Long-term Assets
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	500	3,300
Current Assets
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	144,900	25,800
Accruals
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	137,800	4,200
Prepayments
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	3,500	2,200
In-Process Research and Development
Indefinite-lived Intangible Assets [Line Items]
Reclassification of intangible assets	(15,900)
Patent and License Rights
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairment charges	28,100
Developed Technology
Finite-Lived Intangible Assets [Line Items]
Reclassification of intangible assets	$ 15,900
Amortization period	10 years
Intangible asset impairment charges	$ 12,100
Licenses
Finite-Lived Intangible Assets [Line Items]
Cash paid for purchases of intangible assets	$ 11,500	$ 11,900

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization of Intangibles for the Next Five Years (Details) $ in Thousands	Dec. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 100,891
2021	92,512
2022	78,454
2023	76,239
2024	$ 71,910

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
Lease liabilities	$ 58,370
Future undiscounted aggregate lease payments for lease not yet commenced	$ 44,500
Lease term for lease not yet commenced	15 years
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	9 years
ASU 2016-02
Lessee, Lease, Description [Line Items]
Lease assets		$ 57,400
Lease liabilities		57,700
Adjustment to retained earnings		(316)
Retained Earnings \| ASU 2016-02
Lessee, Lease, Description [Line Items]
Adjustment to retained earnings		$ (316)

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet and Other Information (Details) $ in Thousands	Dec. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	$ 18,739
Weighted average remaining lease term - operating leases	3 years 8 months 15 days
Weighted average discount rate - operating leases	2.39%
Other long-term assets
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 57,305
Accrued and other current liabilities
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	18,739
Other long-term liabilities
Lessee, Lease, Description [Line Items]
Long-term operating lease liabilities	$ 39,631

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating lease cost	$ 24,378

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ (26,113)
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 24,670

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 19,914
2021	16,009
2022	11,885
2023	7,119
2024	3,391
Thereafter	3,202
Total lease payments	61,520
Less imputed interest	(3,150)
Total	$ 58,370

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Accrued contingent consideration and milestone payments	$ 142,604	$ 27,820
Accrued expenses and other liabilities	93,204	103,449
Payroll and related accruals	66,866	66,871
Restructuring	62,227	6,850
Deferred revenue	48,525	45,358
Operating lease liabilities	18,739
Accrued royalties	5,481	5,469
Accrued interest on long-term debt	5,257	6,200
Cash collateral	1,400	1,000
Total accrued and other current liabilities	$ 444,303	$ 263,017

Derivatives and Hedging - Narra

Derivatives and Hedging - Narrative (Details)	12 Months Ended
Derivatives and Hedging - Narrative (Details)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015derivative
Derivative [Line Items]
Derivative gains (losses) included in accumulated other comprehensive income expected to be reclassified within twelve months	$ (1,900,000)
3.0% Note Receivable due October 2020
Derivative [Line Items]
Loans to related parties		$ 3,000,000
German Private Placement (Schuldschein) \| Private Placement Bond
Derivative [Line Items]
Face amount of debt instrument				$ 331,100,000
German Private Placement (Schuldschein) \| Private Placement Bond \| Designated as Hedging Instrument
Derivative [Line Items]
Face amount of debt instrument \| €			€ 255,000,000
Unrealized gain (loss) recorded in equity	(400,000)	(5,900,000)
Accrued Liabilities
Derivative [Line Items]
Derivative liability fair value	(1,400,000)	(1,000,000)
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative asset fair value	2,700,000	25,400,000
Interest Rate Swap
Derivative [Line Items]
Number of derivative instruments \| derivative						5
Interest Rate Swap \| Derivative Contracts 2015
Derivative [Line Items]
Derivative asset notional amount					$ 180,000,000
Interest Rate Swap \| Derivative Contracts 2015 \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Interest receivable	1,500,000	1,400,000
Interest Rate Swap \| Derivative Contracts 2014 \| Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Interest receivable		100,000
Interest Rate Swap \| Derivative Contracts 2014 \| Accrued and Other Current Liabilities
Derivative [Line Items]
Interest receivable	100,000
Foreign Exchange Contracts \| Undesignated Derivative Instruments
Derivative [Line Items]
Notional amount	$ 701,400,000	$ 792,700,000

Derivatives and Hedging - Summa

Derivatives and Hedging - Summary of Fair Value Amounts of Derivative Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Current Asset	$ 107,868	$ 102,754
Long-Term Asset	192,266	295,363
Current Liability	(103,175)	(106,594)
Long-Term Liability	(196,929)	(317,393)
Derivative instruments designated as hedges
Derivative [Line Items]
Current Asset	0	0
Long-Term Asset	2,474	0
Current Liability	0	(473)
Long-Term Liability	(6,027)	(18,295)
Derivative instruments designated as hedges \| Interest rate contracts \| Cash Flow Hedge
Derivative [Line Items]
Current Liability	0	0
Long-Term Liability	(6,027)	(17,574)
Derivative instruments designated as hedges \| Interest rate contracts \| Fair Value Hedge
Derivative [Line Items]
Current Asset	0	0
Long-Term Asset	2,474	0
Current Liability	0	(473)
Long-Term Liability	0	(721)
Undesignated derivative instruments
Derivative [Line Items]
Current Asset	107,868	102,754
Long-Term Asset	189,792	295,363
Current Liability	(103,175)	(106,121)
Long-Term Liability	(190,902)	(299,098)
Undesignated derivative instruments \| Embedded conversion option
Derivative [Line Items]
Current Asset	0	0
Long-Term Asset	0	349
Undesignated derivative instruments \| Call options
Derivative [Line Items]
Current Asset	101,179	100,081
Long-Term Asset	189,792	295,014
Undesignated derivative instruments \| Cash convertible notes embedded conversion option
Derivative [Line Items]
Current Liability	(101,361)	(100,164)
Long-Term Liability	(190,902)	(299,098)
Undesignated derivative instruments \| Foreign exchange contracts
Derivative [Line Items]
Current Asset	6,689	2,673
Long-Term Asset	0	0
Current Liability	(1,814)	(5,957)
Long-Term Liability	$ 0	$ 0

Derivatives and Hedging - Sum_2

Derivatives and Hedging - Summary of the Classification of Gains and Losses on Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Total amounts presented in the Consolidated Statements of Income in which the effects of cash flow and fair value hedges are recorded	$ 432	$ 5,598	$ (4)
Gains (Losses) on Derivatives in Cash Flow Hedges
Amount of (loss) gain reclassified from accumulated other comprehensive income	17,052	25,207	(50,067)
Other income (expense), net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Total gains (losses)	471	(31,318)	38,839
Derivative instruments designated as hedges \| Other income (expense), net
Gains (Losses) on Derivatives in Cash Flow Hedges
Amount of (loss) gain reclassified from accumulated other comprehensive income	(3,888)
Amount of (loss) gain reclassified from accumulated other comprehensive income		(9,774)	26,136
Amounts excluded from effectiveness testing	0	0	0
Derivative instruments designated as hedges \| Interest rate contracts \| Other income (expense), net
Gains (Losses) on Derivatives in Fair Value Hedges
Hedged item	(3,668)	2,051	2,199
Derivatives designated as hedging instruments	3,668	(2,051)	(2,199)
Undesignated derivative instruments \| Embedded conversion option \| Other income (expense), net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	(349)	131	217
Undesignated derivative instruments \| Call options \| Other income (expense), net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	(104,125)	74,682	37,414
Undesignated derivative instruments \| Cash convertible notes embedded conversion option \| Other income (expense), net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	106,998	(76,500)	(36,741)
Undesignated derivative instruments \| Foreign exchange contracts \| Other income (expense), net
Gains (Losses) Derivatives Not Designated as Hedging Instruments
Gains (losses) on derivatives not designated as hedging instruments	$ 1,835	$ (19,857)	$ 11,813

Derivatives and Hedging - Sum_3

Derivatives and Hedging - Summary of the Balance Sheet Line Items in Which the Hedged Item is Included (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current portion of long-term debt
Derivative [Line Items]
Carrying Amount of the Hedged Assets (Liabilities)	$ 0	$ (72,483)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities)	0	(473)
Long-term debt
Derivative [Line Items]
Carrying Amount of the Hedged Assets (Liabilities)	(129,290)	(126,030)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of Hedged Assets (Liabilities)	$ 2,474	$ (721)

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	$ 179,400
Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	162,160	$ 48,971
Level 3 \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	162,160	48,971
Accrued and Other Current Liabilities \| Level 3 \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration, current	142,600
Other Long-Term Liabilities \| Level 3 \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration, noncurrent	19,600
Contingent Consideration \| Restructuring, acquisition, integration and other, net
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain included in earnings		7,400
Contingent Consideration \| Level 3 \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Additions from acquisitions	132,422	53,962
Contingent Consideration \| Level 3 \| Restructuring, acquisition, integration and other, net \| Recurring Basis
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Gain included in earnings	$ 7,433	$ 0
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Rate of achievement of milestones rate	0.00%
Discount rate used for analysis of future milestones	2.40%
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Rate of achievement of milestones rate	100.00%
Discount rate used for analysis of future milestones	6.90%

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Liabilities:
Contingent consideration	$ 179,400
Recurring Basis
Assets:
Foreign exchange contracts	6,689	$ 2,673
Total assets	501,439	694,324
Liabilities:
Foreign exchange contracts	(1,814)	(5,957)
Contingent consideration	162,160	48,971
Total liabilities	(462,264)	(472,958)
Recurring Basis \| Short-term investments
Assets:
Fair value of investment	129,586	234,606
Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	870	2,117
Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	70,849	59,484
Recurring Basis \| Call option
Assets:
Derivative assets	290,971	395,095
Recurring Basis \| Embedded conversion option
Assets:
Embedded conversion option	0	349
Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	2,474	0
Liabilities:
Derivative liabilities	(6,027)	(18,768)
Recurring Basis \| Cash conversion option
Liabilities:
Derivative liabilities	(292,263)	(399,262)
Level 1 \| Recurring Basis
Assets:
Foreign exchange contracts	0	0
Total assets	870	2,467
Liabilities:
Foreign exchange contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Level 1 \| Recurring Basis \| Short-term investments
Assets:
Fair value of investment	0	350
Level 1 \| Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	870	2,117
Level 1 \| Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	0	0
Level 1 \| Recurring Basis \| Call option
Assets:
Derivative assets	0	0
Level 1 \| Recurring Basis \| Embedded conversion option
Assets:
Embedded conversion option	0	0
Level 1 \| Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	0	0
Liabilities:
Derivative liabilities	0	0
Level 1 \| Recurring Basis \| Cash conversion option
Liabilities:
Derivative liabilities	0	0
Level 2 \| Recurring Basis
Assets:
Foreign exchange contracts	6,689	2,673
Total assets	429,720	632,373
Liabilities:
Foreign exchange contracts	(1,814)	(5,957)
Contingent consideration	0	0
Total liabilities	(300,104)	(423,987)
Level 2 \| Recurring Basis \| Short-term investments
Assets:
Fair value of investment	129,586	234,256
Level 2 \| Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	0	0
Level 2 \| Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	0	0
Level 2 \| Recurring Basis \| Call option
Assets:
Derivative assets	290,971	395,095
Level 2 \| Recurring Basis \| Embedded conversion option
Assets:
Embedded conversion option	0	349
Level 2 \| Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	2,474	0
Liabilities:
Derivative liabilities	(6,027)	(18,768)
Level 2 \| Recurring Basis \| Cash conversion option
Liabilities:
Derivative liabilities	(292,263)	(399,262)
Level 3 \| Recurring Basis
Assets:
Foreign exchange contracts	0	0
Total assets	70,849	59,484
Liabilities:
Foreign exchange contracts	0	0
Contingent consideration	162,160	48,971
Total liabilities	(162,160)	(48,971)
Level 3 \| Recurring Basis \| Short-term investments
Assets:
Fair value of investment	0	0
Level 3 \| Recurring Basis \| Marketable equity securities
Assets:
Fair value of investment	0	0
Level 3 \| Recurring Basis \| Non-marketable equity securities
Assets:
Fair value of investment	70,849	59,484
Level 3 \| Recurring Basis \| Call option
Assets:
Derivative assets	0	0
Level 3 \| Recurring Basis \| Embedded conversion option
Assets:
Embedded conversion option	0	0
Level 3 \| Recurring Basis \| Interest rate contracts
Assets:
Derivative assets	0	0
Liabilities:
Derivative liabilities	0	0
Level 3 \| Recurring Basis \| Cash conversion option
Liabilities:
Derivative liabilities	$ 0	$ 0

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Summary of Activity for Liabilities with Level 3 Inputs (Details) - Contingent consideration - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Level 3 \| Recurring Basis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ (48,971)	$ (11,539)
Additions from acquisitions	(132,422)	(53,962)
Payments	11,800	16,530
Balance	(162,160)	(48,971)
Restructuring, acquisition, integration and other, net
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Gain included in earnings		7,400
Restructuring, acquisition, integration and other, net \| Level 3 \| Recurring Basis
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Gain included in earnings	$ 7,433	$ 0

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements - Carrying Values and Estimated Fair Values of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	$ 1,706,352	$ 2,174,206
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	1,296,334	1,794,000
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	663,528	729,468
Cash convertible notes \| Senior unsecured notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	1,046,511	1,439,931
Cash convertible notes \| Senior unsecured notes \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	1,296,334	1,794,000
Cash convertible notes \| Senior unsecured notes \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
U.S. Private placement \| Senior unsecured notes \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	329,200	391,700
U.S. Private placement \| Private placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	328,984	398,107
U.S. Private placement \| Private placement \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
U.S. Private placement \| Private placement \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	329,157	391,700
German private placement \| Private placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	330,857	336,168
German private placement \| Private placement \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	0	0
German private placement \| Private placement \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 334,371	$ 337,768

Lines of Credit and Debt - Narr

Lines of Credit and Debt - Narrative (Details)	3 Months Ended	12 Months Ended
Lines of Credit and Debt - Narrative (Details)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)line_of_credit	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)	Oct. 31, 2012
Debt Instrument [Line Items]
Credit facilities available and undrawn					€ 426,600,000	$ 479,200,000
Syndicated multi-currency term loan \| €					€ 400,000,000
Commitment fee calculation basis on applicable margin, percent		35.00%
Commitment fee paid		$ 1,000,000
Repayment of long-term debt		506,400,000	$ 0	$ 0
Deferred finance costs			14,200,000			$ 10,800,000
Interest expense on long-term debt		68,000,000	61,200,000	$ 43,600,000
Minimum
Debt Instrument [Line Items]
Stated interest rate					0.40%	0.40%
Maximum
Debt Instrument [Line Items]
Stated interest rate					1.20%	1.20%
Cash Convertible Notes
Debt Instrument [Line Items]
Repayment of long-term debt		506,400,000
Cash Convertible Notes \| 2019 Notes
Debt Instrument [Line Items]
Repayment of long-term debt	$ 430,000,000	430,000,000
Cash Convertible Notes \| 2021 Notes
Debt Instrument [Line Items]
Stated interest rate					0.875%	0.875%
Repayment of long-term debt	3,400,000	3,400,000
Senior Unsecured Notes \| 2019 Notes
Debt Instrument [Line Items]
Stated interest rate					0.375%	0.375%
Senior Unsecured Notes \| U.S. Private Placement
Debt Instrument [Line Items]
Stated interest rate					3.19%	3.19%	3.19%
Repayment of long-term debt		$ 73,000,000
Senior Unsecured Notes \| 2021 Notes
Debt Instrument [Line Items]
Stated interest rate					0.875%	0.875%
Syndicated Multi-Currency Revolving Credit Facility
Debt Instrument [Line Items]
Lines of credit			$ 0			$ 0
Four Credit Facilities
Debt Instrument [Line Items]
Credit facilities available and undrawn \| €					€ 26,600,000
Number of lines of credit \| line_of_credit		3
One Month
Debt Instrument [Line Items]
Interest period length		1 month
Two Months
Debt Instrument [Line Items]
Interest period length		2 months
Three Months
Debt Instrument [Line Items]
Interest period length		3 months
Six Months
Debt Instrument [Line Items]
Interest period length		6 months
Call Options \| 2021 Notes
Debt Instrument [Line Items]
Cash paid for the intrinsic value of the embedded cash conversion option	$ 400,000

Lines of Credit and Debt - Tota

Lines of Credit and Debt - Total Long-Term Debt, Net of Debt Issuance Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Oct. 31, 2012
Debt Instrument [Line Items]
Total long-term debt	$ 1,706,352	$ 2,174,206
Less current portion	285,244	503,116
Long-term debt, net of current portion	1,421,108	1,671,090
Senior Unsecured Notes \| 0.375% Senior Unsecured Cash Convertible Notes due 2019
Debt Instrument [Line Items]
Total long-term debt	$ 0	427,445
Stated interest rate	0.375%
Senior Unsecured Notes \| 0.875% Senior Unsecured Cash Convertible Notes due 2021
Debt Instrument [Line Items]
Total long-term debt	$ 285,244	279,492
Stated interest rate	0.875%
Senior Unsecured Notes \| 0.500% Senior Unsecured Cash Convertible Notes due 2023
Debt Instrument [Line Items]
Total long-term debt	$ 347,995	335,201
Stated interest rate	0.50%
Senior Unsecured Notes \| 1.000% Senior Unsecured Cash Convertible Notes due 2024
Debt Instrument [Line Items]
Total long-term debt	$ 413,272	397,793
Stated interest rate	1.00%
Senior Unsecured Notes \| 3.19% Series A Senior Notes due October 16, 2019
Debt Instrument [Line Items]
Total long-term debt	$ 0	72,483
Stated interest rate	3.19%		3.19%
Senior Unsecured Notes \| 3.75% Series B Senior Notes due October 16, 2022
Debt Instrument [Line Items]
Total long-term debt	$ 302,040	298,691
Stated interest rate	3.75%		3.75%
Senior Unsecured Notes \| 3.90% Series C Senior Notes due October 16, 2024
Debt Instrument [Line Items]
Total long-term debt	$ 26,944	26,933
Stated interest rate	3.90%		3.90%
Private Placement \| German Private Placement (Schuldschein)
Debt Instrument [Line Items]
Total long-term debt	$ 330,857	$ 336,168

Lines of Credit and Debt - Futu

Lines of Credit and Debt - Future Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instruments [Abstract]
2020	$ 285,244
2021	38,716
2022	471,432
2023	347,995
2024	546,716
thereafter	16,249
Total long-term debt	$ 1,706,352	$ 2,174,206

Lines of Credit and Debt - Cash

Lines of Credit and Debt - Cash Convertible Notes due 2019, 2021, 2023 and 2024 (Details)	Nov. 13, 2018USD ($)	Sep. 13, 2017USD ($)	Mar. 19, 2014USD ($)	Dec. 31, 2019USD ($)trading_day	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Proceeds from long-term debt, net of issuance costs				$ 0	$ 0	$ 329,875,000
Cash Convertible Notes
Debt Instrument [Line Items]
Threshold trading days \| trading_day				20
Consecutive trading days \| trading_day				30
Threshold percentage of stock price trigger				130.00%
Redemption price percentage				100.00%
Percentage of principal amount outstanding				20.00%
Cash Convertible Notes \| 2019, 2021, 2023 and 2024 Notes
Debt Instrument [Line Items]
Consecutive trading days \| trading_day				20
Threshold percentage of stock price trigger				25.00%
Cash settlement amount period				50 days
Cash Convertible Notes \| 2019 and 2021 Notes
Debt Instrument [Line Items]
Convertible debt			$ 730,000,000
Proceeds from issuance of debt			680,700,000
Repayments of debt			372,500,000
Consecutive trading days \| trading_day				10
Threshold percentage of stock price trigger				98.00%
Threshold business period				5 days
Debt issuance cost			13,100,000
Cash Convertible Notes \| 2019 Notes
Debt Instrument [Line Items]
Convertible debt			430,000,000
Term of debt instrument							5 years
Effective interest rate							2.937%
Cash Convertible Notes \| 2019 Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value							$ 51,200,000
Cash Convertible Notes \| 2021 Notes
Debt Instrument [Line Items]
Convertible debt			$ 300,000,000
Term of debt instrument							7 years
Effective interest rate							3.809%
Cash Convertible Notes \| 2021 Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value							$ 54,000,000
Cash Convertible Notes \| 2023 and 2024 Notes
Debt Instrument [Line Items]
Threshold business period				10 days
Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Convertible debt		$ 400,000,000
Proceeds from long-term debt, net of issuance costs		365,600,000
Term of debt instrument						6 years
Effective interest rate						3.997%
Debt issuance cost		$ 6,200,000
Cash Convertible Notes \| 2023 Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value						$ 74,500,000
Cash Convertible Notes \| 2024 Notes
Debt Instrument [Line Items]
Convertible debt	$ 500,000,000
Proceeds from issuance of debt	468,900,000
Term of debt instrument					6 years
Effective interest rate					4.782%
Debt issuance cost	$ 5,700,000
Debt issuance costs accrued				$ 200,000
Cash Convertible Notes \| 2024 Notes \| Call Options
Debt Instrument [Line Items]
Derivative liability fair value					$ 98,500,000

Lines of Credit and Debt - Inte

Lines of Credit and Debt - Interest Rate, Corresponding Maturities, and Contingent Conversion Periods of Cash Convertible Notes (Details) - Cash Convertible Notes	12 Months Ended
	Dec. 31, 2019
2021 Notes
Debt Instrument [Line Items]
Annual interest rate	0.875%
Conversion rate per $200,000 principal amount	0.0353158235
2023 Notes
Debt Instrument [Line Items]
Annual interest rate	0.50%
Conversion rate per $200,000 principal amount	0.0241486395
2024 Notes
Debt Instrument [Line Items]
Annual interest rate	1.00%
Conversion rate per $200,000 principal amount	0.021801549

Lines of Credit and Debt - In_2

Lines of Credit and Debt - Interest Expense Related to the Cash Convertible Notes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 40,763	$ 35,537	$ 24,773
Cash Convertible Notes
Debt Instrument [Line Items]
Coupon interest	9,954	6,890
Amortization of original issuance discount	36,966	32,114
Amortization of debt issuance costs	3,014	3,485
Total interest expense related to the Cash Convertible Notes	$ 49,934	$ 42,489

Lines of Credit and Debt - Ca_2

Lines of Credit and Debt - Cash Convertible Notes Call Spread Overlay (Details) - USD ($)	Nov. 13, 2018	Sep. 13, 2017	Mar. 19, 2014	Nov. 30, 2018	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2014
Debt Instrument [Line Items]
Payments for call options								$ 0	$ 97,277,000	$ 73,646,000
Proceeds from issuance of warrants, net of issuance costs								0	72,406,000	45,396,000
Cash received upon the exercise of call options								134,737,000	0	0
Cash paid for the intrinsic value of the embedded cash conversion option								133,763,000	$ 0	0
Cash Convertible Notes \| 2019 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs			$ 40,600,000
Cash Convertible Notes \| 2021 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs			$ 28,300,000
Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs		$ 45,300,000
Cash Convertible Notes \| 2024 Notes
Debt Instrument [Line Items]
Proceeds from issuance of warrants, net of issuance costs	$ 72,400,000			$ 72,400,000
Call Spread Overlay
Debt Instrument [Line Items]
Proceeds from issuance of warrants											$ 69,400,000
Net cash outlay for call spread overlay				24,900,000						28,300,000	35,800,000
Warrant issuance costs				500,000						300,000
Option issuance costs				500,000						100,000
Accrual of warrant and option issuance costs								$ 48,000
Call Spread Overlay \| Cash Convertible Notes \| 2019 and 2021 Notes
Debt Instrument [Line Items]
Payments for call options											105,200,000
Call Spread Overlay \| Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Payments for call options											$ 73,700,000
Call Options \| 2019 Notes
Debt Instrument [Line Items]
Cash received upon the exercise of call options						$ 133,200,000
Cash paid for the intrinsic value of the embedded cash conversion option						132,700,000
Gain on exercise of call options and payment of embedded cash conversion option						500,000
Call Options \| 2021 Notes
Debt Instrument [Line Items]
Cash received upon the exercise of call options					$ 400,000
Cash paid for the intrinsic value of the embedded cash conversion option						1,100,000
Gain on exercise of call options and payment of embedded cash conversion option							$ 400,000
Receivable recorded upon exercise of call options						$ 700,000
Proceeds from collection of the receivable recorded upon exercise of call options					$ 700,000
Call Options \| Cash Convertible Notes \| 2023 Notes
Debt Instrument [Line Items]
Payments for call options										$ 73,700,000
Call Options \| Cash Convertible Notes \| 2024 Notes
Debt Instrument [Line Items]
Payments for call options				$ 97,300,000

Lines of Credit and Debt - Priv

Lines of Credit and Debt - Private Placement and German Private Placement (Schuldschein) (Details)	1 Months Ended	12 Months Ended
	Oct. 31, 2012USD ($)series	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Number of series of notes issued \| series	3
Repayment of long-term debt		$ 506,400,000	$ 0	$ 0
Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		663,528,000	729,468,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Face amount of debt instrument	$ 400,000,000
Weighted average interest rate of long-term debt	3.66%
Senior Unsecured Notes \| Designated as Hedging Instrument
Debt Instrument [Line Items]
Face amount of debt instrument		$ 127,000,000					$ 200,000,000
Senior Unsecured Notes \| Series A, Series B and Series C Private Placement Notes
Debt Instrument [Line Items]
Debt issuance cost	$ 2,100,000
Senior Unsecured Notes \| 3.19% Series A Senior Notes due October 16, 2019
Debt Instrument [Line Items]
Face amount of debt instrument	$ 73,000,000
Term of debt instrument	7 years
Stated interest rate	3.19%	3.19%
Repayment of long-term debt		$ 73,000,000
Senior Unsecured Notes \| 3.75% Series B Senior Notes due October 16, 2022
Debt Instrument [Line Items]
Face amount of debt instrument	$ 300,000,000
Term of debt instrument	10 years
Stated interest rate	3.75%	3.75%
Senior Unsecured Notes \| 3.90% Series C Senior Notes due October 16, 2024
Debt Instrument [Line Items]
Face amount of debt instrument	$ 27,000,000
Term of debt instrument	12 years
Stated interest rate	3.90%	3.90%
Senior Unsecured Notes \| Private Placement \| Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		$ 329,200,000	391,700,000
Private Placement Bond \| Private Placement \| Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		329,157,000	391,700,000
Private Placement Bond \| German Private Placement (Schuldschein)
Debt Instrument [Line Items]
Face amount of debt instrument						$ 331,100,000
Debt issuance cost						$ 1,200,000
Private Placement Bond \| German Private Placement (Schuldschein) \| Designated as Hedging Instrument
Debt Instrument [Line Items]
Face amount of debt instrument \| €					€ 255,000,000
Unrealized gain (loss) recorded in equity		(400,000)	(5,900,000)
Private Placement Bond \| German Private Placement (Schuldschein) \| Level 2
Debt Instrument [Line Items]
Fair value of long-term debt		$ 334,371,000	$ 337,768,000

Lines of Credit and Debt - Summ

Lines of Credit and Debt - Summary of German Private Placement Tranches (Details) - Designated as Hedging Instrument $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Carrying Value		$ 330,857	$ 336,168
March 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 11.5
Interest Rate		0.40%
Carrying Value		$ 12,905	13,143
March 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 23
Carrying Value		$ 25,811	26,286
March 2021 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.40%	0.40%
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 21.5
Interest Rate		0.68%
Carrying Value		$ 24,112	24,561
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 64.5
Carrying Value		$ 72,335	73,684
October 2022 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.50%	0.50%
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount		$ 45,000
Carrying Value		$ 44,919	44,891
October 2022 \| LIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	1.20%	1.20%
October 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 25
Carrying Value		$ 28,026	28,543
October 2022 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.50%	0.50%
June 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 64
Interest Rate		1.09%
Carrying Value		$ 71,747	73,097
June 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 31
Carrying Value		$ 34,753	35,406
June 2024 \| EURIBOR
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Rate	0.70%	0.70%
June 2027
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount \| €	€ 14.5
Interest Rate		1.61%
Carrying Value		$ 16,249	$ 16,557

Income Taxes - Income Before In

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Pretax income in The Netherlands	$ 17,455	$ (1,675)	$ 42,220
Pretax (loss) income from foreign operations	(95,231)	227,412	72,155
(Loss) income before income tax (benefit) expense	$ (77,776)	$ 225,737	$ 114,375

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Current—The Netherlands	$ 5,670	$ 5,794	$ 3,430
—Foreign	13,371	52,835	10,375
Provision for income tax current, total	19,041	58,629	13,805
Deferred—The Netherlands	4,177	2,551	151
—Foreign	(59,539)	(25,823)	60,025
Provision for income tax deferred, total	(55,362)	(23,272)	60,176
Total income tax (benefit) expense	$ (36,321)	$ 35,357	$ 73,981

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
The Netherlands statutory income tax rate	25.00%	25.00%	25.00%
Unrecognized tax benefit, net	$ 58,000	$ 55,800
Unrecognized tax benefits which may be realized	31,400
Recognized interest (income) expense	1,600	1,100	$ 1,500
Accrued interest included in accrued and other liabilities	2,500	4,100
Deferred tax assets	33,100
Deferred tax liabilities		20,515
Total foreign net operating losses	682,500
Disallowed interest carryforwards	280,000
Tax credits	1,300
Deferred tax asset valuation allowance	87,619	68,651
Net increase (decrease) in deferred tax asset valuation allowance	19,000	800	62,300
Earnings retained by subsidiaries and equity accounted investments	699,000
Undistributed earnings not permanently reinvested	26,400
Deferred tax liabilities on unremitted earnings of certain subsidiary	1,500	$ 900
Interest Carryforward
Operating Loss Carryforwards [Line Items]
Deferred tax asset valuation allowance	12,700		$ 60,500
Germany
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	394,000
U.S.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	133,800
Netherlands
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	52,400
Other Foreign Tax Authorities
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	102,300
Operating loss carryforwards not set to expire	$ 25,400

Income Taxes - Difference Betwe

Income Taxes - Difference Between Income Taxes Computed at Statutory Rate and Reported Income Taxes and Effective Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Amount
Income taxes at The Netherlands statutory rate	$ (19,444)	$ 56,434	$ 28,594
Taxation of foreign operations, net	(25,720)	(33,994)	(38,635)
Tax impact from intangible property transfer	(21,122)	0	0
Unrecognized tax benefits	10,962	13,570	23,189
Tax impact from nondeductible items	7,986	2,949	2,645
Excess tax benefit related to share-based compensation	(3,989)	(4,740)	(5,237)
Government incentives and other deductions	(7,516)	(2,892)	(6,519)
Changes in tax laws and rates	331	1,907	12,958
Other items, net	1,306	(1,170)	(5,658)
Valuation allowance	20,885	3,293	62,644
Total income tax (benefit) expense	$ (36,321)	$ 35,357	$ 73,981
Percent
Income taxes at The Netherlands statutory rate	25.00%	25.00%	25.00%
Taxation of foreign operations, net	33.10%	(15.10%)	(33.80%)
Tax impact from intangible property transfer	27.20%	0.00%	0.00%
Unrecognized tax benefits	(14.10%)	6.00%	20.30%
Tax impact from nondeductible items	(10.30%)	1.30%	2.30%
Excess tax benefit related to share-based compensation	5.10%	(2.10%)	(4.60%)
Government incentives and other deductions	9.70%	(1.20%)	(5.70%)
Changes in tax laws and rates	(0.40%)	0.80%	11.30%
Other items, net	(1.70%)	(0.50%)	(4.90%)
Valuation allowance	(26.90%)	1.50%	54.80%
Total income tax (benefit) expense	46.70%	15.70%	64.70%
Valuation allowance	$ 87,619	$ 68,651
Interest Carryforward
Percent
Valuation allowance	$ 12,700		$ 60,500

Income Taxes - Changes in Amoun

Income Taxes - Changes in Amounts of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 55,780	$ 44,033	$ 18,294
Additions based on tax positions related to the current year	5,770	3,359	12,212
Additions for tax positions of prior years	14,532	11,984	9,933
Decrease for tax position of prior years	(9,073)	0	0
Decrease related to settlements	(7,605)	0	0
Decrease due to lapse of statute of limitations	(409)	(1,238)	0
(Decrease) increase from currency translation	(993)	(2,358)	3,594
Balance at end of year	$ 58,002	$ 55,780	$ 44,033

Income Taxes - Components of Ne

Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred Tax Asset
Net operating loss and tax credit carryforward	$ 50,274	$ 27,293
Accrued and other liabilities	17,977	15,480
Inventory	4,726	3,978
Unrealized gain (loss) on investments	0	3,280
Property, plant and equipment	5,297	3,604
Intangible assets	1,078	1,721
Share-based compensation	13,787	17,998
Disallowed interest carryforwards	73,690	60,458
Convertible notes	7,104	8,102
Other	5,998	5,854
Deferred tax assets, gross	179,931	147,768
Valuation allowance	(87,619)	(68,651)
Deferred tax assets, total	92,312	79,117
Deferred Tax Liability
Net operating loss and tax credit carryforward	0	0
Accrued and other liabilities	0	0
Inventory	(1,439)	(1,725)
Unrealized gain (loss) on investments	(4,973)	(4,855)
Property, plant and equipment	(20,332)	(25,448)
Intangible assets	(26,294)	(63,990)
Share-based compensation	0	0
Disallowed interest carryforwards	0	0
Convertible notes	0	0
Other	(6,174)	(3,614)
Deferred tax liabilities, total	(59,212)	(99,632)
Net deferred tax assets (liabilities)	$ 33,100
Net deferred tax assets (liabilities)		$ (20,515)

Equity - Shares (Details)

Equity - Shares (Details) - € / shares	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Common shares, shares authorized (in shares)	410,000,000	410,000,000
Preference shares, shares authorized (in shares)	450,000,000	450,000,000
Financing preference shares, shares authorized (in shares)	40,000,000	40,000,000
Common shares, par value (in EUR per share)	€ 0.01	€ 0.01
Preference shares, par value (in EUR per share)	0.01	0.01
Financing preference shares, par value (in EUR per share)	€ 0.01	€ 0.01
Financing preference shares, shares issued (in shares)	0	0
Preference shares, shares issued (in shares)	0	0

Equity - Issuance of Warrants (

Equity - Issuance of Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Nov. 13, 2018	Sep. 13, 2017	Mar. 19, 2014	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Number of share warrants (in shares)					15.2
Proceeds from issuance of warrants, net of issuance costs					$ 0	$ 72,406	$ 45,396
2019 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)			15.2
Exercise price per share (in USD per share)			$ 32.0560
Proceeds from issuance of warrants, net of issuance costs			$ 40,600
2021 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)			10.6
Exercise price per share (in USD per share)			$ 32.0560
Proceeds from issuance of warrants, net of issuance costs			$ 28,300
2023 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)		9.7
Exercise price per share (in USD per share)		$ 50.9664
Proceeds from issuance of warrants, net of issuance costs		$ 45,300
2024 Notes \| Cash Convertible Notes
Class of Stock [Line Items]
Number of share warrants (in shares)	10.9
Exercise price per share (in USD per share)	$ 52.1639
Proceeds from issuance of warrants, net of issuance costs	$ 72,400			$ 72,400

Equity - Issuance of Warrants,

Equity - Issuance of Warrants, Narrative (Details) - USD ($) $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2019	Mar. 19, 2014
Class of Warrant or Right [Line Items]
Common shares issued in connection with the conversion of warrants (in shares)	2.1
Number of warrants converted (in shares)	15.2
Impact due to conversion of warrants	$ 4
Cash payment for fractional shares	4
Treasury Shares
Class of Warrant or Right [Line Items]
Impact due to conversion of warrants	(68,761)
Additional Paid-In Capital
Class of Warrant or Right [Line Items]
Impact due to conversion of warrants	31,067
Retained Earnings
Class of Warrant or Right [Line Items]
Impact due to conversion of warrants	$ 37,698
2019 Notes \| Cash Convertible Notes
Class of Warrant or Right [Line Items]
Number of warrants converted (in shares)		15.2

Equity - Share Repurchase Progr

Equity - Share Repurchase Program (Details) - USD ($)	12 Months Ended			23 Months Ended
Equity - Share Repurchase Program (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	May 06, 2019	Jan. 31, 2018	Apr. 27, 2016
Equity, Class of Treasury Stock [Line Items]
Treasury shares repurchased	$ 74,450,000	$ 104,685,000	$ 60,970,000
Sixth Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Amount authorized to repurchase shares					$ 100,000,000
Treasury shares repurchased (in shares)	0
Fifth Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Amount authorized to repurchase shares						$ 200,000,000
Treasury shares repurchased (in shares)	2,000,000	2,900,000		4,900,000
Treasury shares repurchased	$ 74,500,000	$ 104,700,000		$ 179,100,000
Fourth Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Amount authorized to repurchase shares							$ 100,000,000
Treasury shares repurchased (in shares)			1,900,000
Treasury shares repurchased			$ 61,000,000

Equity - Synthetic Share Repurc

Equity - Synthetic Share Repurchase (Details)	1 Months Ended	12 Months Ended
Equity - Synthetic Share Repurchase (Details)	Jan. 31, 2017USD ($)shares	Dec. 31, 2017USD ($)	Dec. 31, 2019€ / shares	Dec. 31, 2018€ / shares	Oct. 26, 2016€ / sharesshares	Oct. 25, 2016€ / sharesshares	Aug. 31, 2016USD ($)
Class of Stock [Line Items]
Common stock, par value (in EUR per share)			€ 0.01	€ 0.01
Capital repayment \| $		$ 244,429,000
Synthetic Share Repurchase
Class of Stock [Line Items]
Amount authorized to repurchase shares \| $							$ 250,000,000
Common stock, par value (in EUR per share)						€ 0.01
Common stock, shares outstanding \| shares	8,900,000
Capital repayment \| $	$ 243,900,000
Decrease in outstanding number of common shares	3.70%
Capital repayment and share consolidation expense \| $	$ 500,000
Synthetic Share Repurchase, First Amendment
Class of Stock [Line Items]
Common stock, par value (in EUR per share)						€ 1.04
Common stock, shares outstanding \| shares						27
Synthetic Share Repurchase, Second Amendment
Class of Stock [Line Items]
Common stock, par value (in EUR per share)						€ 1.08
Common stock, shares outstanding \| shares					26
Synthetic Share Repurchase, Third Amendment
Class of Stock [Line Items]
Common stock, par value (in EUR per share)					€ 0.01

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Net unrealized loss on hedging contracts, net of tax	$ (2,289)
Net unrealized loss on hedging contracts, net of tax		$ (15,453)
Net unrealized loss on pension, net of tax	(561)	(124)
Foreign currency effects from intercompany long-term investment transactions, net of tax of $9.7 million and $9.3 million in 2019 and 2018, respectively	(22,587)	(21,662)
Foreign currency translation adjustments	(284,182)	(273,405)
Accumulated other comprehensive loss	(309,619)	(310,644)
Foreign currency effects from intercompany long-term investment transactions, tax	$ 9,700	$ 9,300

Earnings per Common Share - Nar

Earnings per Common Share - Narrative (Details) shares in Millions	12 Months Ended
	Dec. 31, 2019shares
Stock Options and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from the computation of diluted net loss (in shares)	3.9
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from the computation of diluted net loss (in shares)	1.7

Earnings per Common Share - (De

Earnings per Common Share - (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net (loss) income	$ (41,455)	$ 190,380	$ 40,394
Weighted average number of common shares used to compute basic net income per common share (in shares)	226,777	226,640	228,074
Dilutive effect of stock options and restrictive stock units (in shares)	0	4,613	4,760
Dilutive effect of outstanding warrant (in shares)	0	2,203	175
Weighted average number of common shares used to compute diluted net income per common share (in shares)	226,777	233,456	233,009
Basic earnings per common share attributable to the owners of QIAGEN N.V. (in USD per share)	$ (0.18)	$ 0.84	$ 0.18
Diluted earnings per common share attributable to the owners of QIAGEN N.V. (in USD per share)	$ (0.18)	$ 0.82	$ 0.17
Stock Options and Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding securities having no dilutive effect, not included in above calculation (in shares)	107	272	52
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding securities having no dilutive effect, not included in above calculation (in shares)	32,938	35,939	30,434

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Percentage of royalty on net product sales range, minimum	0.45%
Percentage of royalty on net product sales range, maximum	25.00%
Accrued royalties	$ 5,481	$ 5,469
Royalty expense related to agreements	13,500	14,000	$ 16,800
Contingent obligation	179,400
Commitment under employment contract agreements	$ 6,200
Standard product warranty term	1 year
Recurring Basis
Loss Contingencies [Line Items]
Contingent obligation	$ 162,160	48,971
Recurring Basis \| Level 3
Loss Contingencies [Line Items]
Contingent obligation	162,160	48,971
Pending Litigation
Loss Contingencies [Line Items]
Legal settlements accrued	800
Payment of legal settlement	5,400
Litigation Settlement
Loss Contingencies [Line Items]
Legal settlements accrued		$ 6,000	4,400
Legal settlement amount awarded			49,200
Legal settlement expense			45,300
License rights recognized			3,900
Payment of legal settlement			$ 44,800
Minimum \| Pending Litigation
Loss Contingencies [Line Items]
Estimated possible litigation loss	300
Maximum \| Pending Litigation
Loss Contingencies [Line Items]
Estimated possible litigation loss	2,200
Accrued and Other Current Liabilities
Loss Contingencies [Line Items]
Future license payments	10,000
Accrued and Other Current Liabilities \| Recurring Basis \| Level 3
Loss Contingencies [Line Items]
Contingent obligation, current	142,600
Other Long-Term Liabilities
Loss Contingencies [Line Items]
Future license payments	14,500
Other Long-Term Liabilities \| Recurring Basis \| Level 3
Loss Contingencies [Line Items]
Contingent obligation, noncurrent	$ 19,600

Commitments and Contingencies_2

Commitments and Contingencies - Commitments to Purchase Goods or Services and for Future License and Royalty Payments (Details) $ in Thousands	Dec. 31, 2019USD ($)
Purchase Commitments [Abstract]
2020	$ 126,121
2021	35,915
2022	26,337
2023	3,223
2024	3,000
Thereafter	0
Total	194,596
License And Royalty Commitments [Abstract]
2020	11,434
2021	9,012
2022	6,507
2023	4,382
2024	1,823
Thereafter	4,297
Total	$ 37,455

Commitments and Contingencies_3

Commitments and Contingencies - Contingent Consideration Commitments (Details) $ in Thousands	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 152,750
2021	11,800
2022	5,900
2024	5,900
Anytime 12-month period from now until 2028	3,000
Total potential contingent consideration commitments	$ 179,350

Commitments and Contingencies_4

Commitments and Contingencies - Changes in the Carrying Amount of Warranty Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Changes in the Carrying Amount of Warranty Obligations
Balance at beginning of year	$ 2,848	$ 3,051
Provision charged to cost of sales	3,229	2,892
Usage	(2,921)	(2,760)
Adjustments to previously provided warranties, net	(1)	(243)
Currency translation	(14)	(92)
Balance at end of year	$ 3,141	$ 2,848

Segment Information - Narrative

Segment Information - Narrative (Details) $ in Thousands	12 Months Ended
Segment Information - Narrative (Details) $ in Thousands	Dec. 31, 2019USD ($)segmentcustomer	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments \| segment	1
Number of customers representing more than ten percent of net sales \| customer	0
Net sales	$ 1,526,424	$ 1,501,848	$ 1,417,536
Long-lived assets	455,243	511,659
Netherlands
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	15,800	15,900	$ 15,000
Long-lived assets	$ 1,300	$ 1,800

Segment Information - Net Sales

Segment Information - Net Sales (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	$ 1,526,424	$ 1,501,848	$ 1,417,536
Total Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	721,990	693,019	653,384
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	663,869	632,660	579,906
Other Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	58,121	60,359	73,478
Total Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	487,476	490,301	462,980
Asia Pacific, Japan and Rest of World
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	$ 316,958	$ 318,528	$ 301,172

Segment Information - Long-Live

Segment Information - Long-Lived Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 455,243	$ 511,659
Total Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	150,534	156,129
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	147,027	152,381
Other Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	3,507	3,748
Total Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	278,229	334,652
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	229,225	284,601
Other Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	49,004	50,051
Asia Pacific, Japan and Rest of World
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 26,480	$ 20,878

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit for the tax deductions from option exercises	$ 500	$ 800	$ 700
Performance achievement rate	120.00%
Share-based compensation expense	$ 65,894	40,113	34,442
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of options exercised	$ 2,000	$ 5,000	$ 3,300
Options excercisable (in shares)	792	900	1,100
Weighted average exercise price of exercisable options (in USD per share)	$ 20.06	$ 20.04	$ 19.54
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-vesting forfeitures percentage	6.20%
Unrecognized share-based compensation expense related to employee stock option awards	$ 60,100
Unrecognized share-based compensation expense recognized weighted average period, years	2 years 6 months 25 days
Weighted-average grant date fair value of restricted stock units granted (in USD per share)	$ 37.28	$ 35.37	$ 31.12
Total fair value of restricted stock units	$ 123,900	$ 54,300	$ 69,200
Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum vesting period	5 years
Restricted Stock \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum vesting period	10 years
The 2005 and 2014 Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved and available for issuance under the plan (in shares)	15,700

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Status of Employee Stock Options (Details) - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Outstanding (in shares)	898
Exercised (in shares)	(104)
Expired (in shares)	(2)
Outstanding (in shares)	792
Vested (in shares)	792	900	1,100
Vested and expected to vest (in shares)	792
Weighted Average Exercise Price
Outstanding (in USD per share)	$ 20.04
Exercised (in USD per share)	19.95
Expired (in USD per share)	17.51
Outstanding (in USD per share)	20.06
Vested (in USD per share)	20.06	$ 20.04	$ 19.54
Vested and expected to vest (in USD per share)	$ 20.06
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Weighted Average Contractual Term [Abstract]
Vested and expected to vest	1 year 9 months 10 days
Vested	1 year 9 months 10 days
Outstanding	1 year 9 months 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Aggregate Intrinsic Value [Abstract]
Outstanding	$ 10,891
Vested	10,891
Vested and expected to vest	$ 10,891

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options (Details) - Restricted Stock shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)shares
Stock Units
Outstanding (in shares)	8,343
Granted (in shares)	1,618
Vested (in shares)	(3,517)
Forfeited (in shares)	(1,261)
Outstanding (in shares)	5,183
Vested and expected to vest (in shares)	3,972
Weighted Average Contractual Term
Outstanding	2 years 6 months 25 days
Vested and expected to vest	2 years 3 months 3 days
Aggregate Intrinsic Value
Outstanding \| $	$ 175,199
Vested and expected to vest \| $	$ 134,254

Share-Based Compensation - Comp

Share-Based Compensation - Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 65,894	$ 40,113	$ 34,442
Less: income tax benefit	12,153	8,277	7,407
Net share-based compensation expense	53,741	31,836	27,035
Excess tax benefit realized for the tax deductions of share-based arrangements	3,989	4,740	5,237
Excess tax benefit realized for the tax deductions of share-based arrangements			5,200
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2,493	2,879	2,641
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	5,810	6,457	6,102
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	7,947	9,372	6,820
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	23,706	21,405	19,614
Restructuring, acquisition, integration and other, net
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 25,938	$ 0	$ (735)

Employee Benefits (Details)

Employee Benefits (Details) $ in Millions	12 Months Ended
Employee Benefits (Details) $ in Millions	Dec. 31, 2019USD ($)plan	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Retirement Benefits, Description [Abstract]
Total expense under employee benefit plans	$ 4	$ 4	$ 3.6
Company matching contributions	$ 0.2	0.2	$ 0.3
Number of defined benefit plans \| plan	5
Liability under the defined benefit plans	$ 8.2	$ 7.4

Related Party Transactions - Su

Related Party Transactions - Summary of Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Related Party Transactions [Abstract]
Net sales	$ 20,002	$ 23,358	$ 3,852
Accounts receivable	7,589	10,109
Prepaid expenses and other current assets	13,697	3,873
Other long-term assets	16,830	24,300
Accounts payable	1,775	4,888
Accrued and other current liabilities	$ 15,404	$ 5,488

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Purchase commitments due to related parties	$ 25.2
Settlement amount	12.8
8% Note Receivable due December 2021
Related Party Transaction [Line Items]
Loans to related parties	$ 16.3	$ 15
Interest rate on loans to related parties		8.00%

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Details) - Allowance for doubtful accounts - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 9,270	$ 8,008	$ 7,614
Provision Charged to Expense	8,701	4,448	3,094
Write-Offs	(5,777)	(2,827)	(3,233)
Foreign Exchange and Other	(79)	(359)	533
Balance at End of Year	$ 12,115	$ 9,270	$ 8,008

Uncategorized Items - a201920-f

Label	Element	Value
Accounting Standards Update 2016-01 [Member] \| AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 942,000